Negative feedback of inflammation of macrophages: transcriptional cross-talk of the LPS and IL-10 signalling pathways by Ridley, Michael Luke
 Negative Feedback of Inflammation of Macrophages: 
 Transcriptional Cross-talk of the LPS and IL-10 Signalling Pathways 
 
Michael Luke Ridley 
 
 
 
A thesis submitted to the University of Birmingham for the degree of  
DOCTOR OF PHILOSOPHY 
 
Institute of Inflammation and Ageing 
College of Medical and Dental Sciences 
University of Birmingham 
June 2016 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
i 
 
Abstract 
The classical picture of interleukin 10 (IL-10) is of a powerful anti-inflammatory cytokine, 
which suppresses many functions of myeloid cells, including antigen presentation and pro-
inflammatory cytokine expression. IL-10 acts via the Janus-activated kinase JAK1 to activate 
the transcription factor Signal transducer and activator of transcription 3 (STAT3). The actions 
of IL-10 are essential for prevention of excessive inflammatory responses, particularly in gut 
tissues that are constantly exposed to potential pathogens. Many of the anti-inflammatory 
effects of IL-10 have been attributed to the inhibition of the transcription factor Nuclear factor 
κ-light-chain-enhancer of activated B cells (NF-κB). However, this simplistic picture of IL-10 is 
becoming increasingly under challenge, with emerging evidence of immune-stimulatory 
properties, and actions that cannot be attributed to NF-κB inhibition. 
In this thesis I used monocyte-derived macrophages from healthy human donors to 
investigate the effects of IL-10 on responses to lipopolysaccharide (LPS), a pathogen 
associated molecule that strongly activates macrophages. Such a transcriptome-wide analysis 
has not been previously reported in primary human macrophages. Microarray analysis 
revealed that of the several hundred genes robustly induced by LPS less than half were 
inhibited by IL-10. Surprisingly, IL-10 cooperated with LPS to enhance the expression of several 
genes. Both the inhibitive and cooperative regulation of gene expression by IL-10 occurred at 
the level of transcription, and were dependent on STAT3. Using a pharmacological inhibitor, 
it was shown that the suppressive effects of IL-10 at the transcriptome level did not correlate 
with inhibition of NF-κB. Many NF-κB dependent genes were either insensitive to IL-10-
mediated inhibition or cooperatively regulated by LPS and IL-10, and many IL-10 inhibited 
genes were not dependent on NF-κB. 
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To investigate cooperative regulation of gene expression by LPS and IL-10 I focused on the 
gene TNF-superfamily member 9 (TNFSF9) which was cooperatively regulated by LPS and IL-
10 at the mRNA and protein level. Although de novo protein synthesis was required for the 
inhibitory effect of IL-10 on TNF expression, it was dispensable for the induction of TNFSF9. 
An evolutionary conserved region (ECR) upstream of the TNFSF9 gene was shown to possess 
potent enhancer activity, and mediate cooperative transcriptional induction by LPS and IL-10. 
Analysis of the ECR identified putative NF-κB and STAT3 binding sites, and its cooperative 
regulation by IL-10 and LPS was dependent on JAKs and NF-κB. Finally a STAT3 reporter 
construct was shown to mediate cooperative transcriptional activation by LPS and IL-10. This 
response was dependent on JAKs and mitogen-activated kinase p38, but independent of NF-
κB. This suggests that a convergence between the JAK and p38 signalling pathways may 
contribute to the cooperative gene regulation by LPS and IL-10. 
 
Together, these findings shed new light on the mechanisms by which IL-10 inhibits pro-
inflammatory gene expression. They also indicate surprisingly broad and powerful gene-
specific cooperative interactions between LPS-induced and IL-10 induced signalling pathways, 
which are likely to contribute to the subtle immune-modulatory properties of IL-10. 
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Chapter 1  – Introduction 
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1.1 – The Immune System 
In order to protect the body from pathogen invasion and infection the immune system has 
evolved both broad and adaptable strategies to detect and remove these organisms. Most 
organisms from bacteria to Homo sapiens have a system of biochemically detecting and 
responding to parasitic or pathogenic attack, varying in complexity; from the specific cleavage 
of DNA sequences in bacteria, to the adaptive and long lasting immune system of vertebrates. 
The vertebrate immune system is a complex multicellular network and can be further 
categorised into two further systems: The adaptive immune system and the innate immune 
system. 
Adaptive immunity is the more recently evolved of the two systems, having arisen after the 
divergence of jawed (Gnathostomes) and jawless vertebrates (Agnathans). The adaptive 
immune response involves the development of antigen-specific lymphocytes through the 
rearrangement and mutation of genetic material, which can then be developed into long 
lasting immunological memory.  
The adaptive immune response is a potent defence against pathogens, it is however a slow 
process to initiate, taking between 4-7 days to initially take effect. Innate immunity is a much 
more rapid and broader response against invasion or damage than the adaptive immune 
system. On contact with pathogens or signals indicating damage, cells of this system release 
cytokine or chemokine factors to recruit more cells to the locality in order to destroy the 
pathogen and initiate the formation or reactivation of the adaptive immune response 
(Murphy, 2007). 
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1.1.1 – Cells of the Immune System 
In humans, the cells which make up the immune system has evolved a number of cell types to 
defend the body in a number of ways. These cells can be broadly categorised into lymphocytes 
and myeloid cells. Lymphocytes include: B cells, T cells and, natural killer (NK) cells, while the 
myeloid lineage consists of a multitude of cell types, including neutrophils, dendritic cells and 
macrophages (Murphy, 2007). 
Both lymphocytes and myeloid cells can be formed from haematopoietic stem cells (HSC) in 
the bone marrow and diverge into distinct lineages early in haematopoiesis (differentiation of 
multiple haematopoietic cell lineages is shown in Figure 1.1). Myeloid cells differentiate from 
the common myeloid progenitor cells (CMPs) and lymphoid cells derive from the common 
lymphoid progenitor cells (CLPs) (Kondo, 2010, Iwasaki and Akashi, 2007). 
 
1.1.1.1 – Lymphoid Cells 
Lymphoid cells are derived exclusively from haematopoietic stem cells in the bone marrow, 
which differentiated into common lymphoid progenitor cells (CLP). From this the three main 
classes of lymphoid cells are derived: B cells and T cells generate antigen specific cell surface 
receptors during maturation, while innate lymphoid cells (ILCs) do not respond to specific 
antigens and instead react to presented cell surface ligands on the target cell (Murphy, 2007). 
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Figure 1.1 – The Differentiation of the Haematopoietic System from HSCs in adult humans 
Long-term HSC (LT-HSC) residing in the bone marrow are able to differentiate into short-term 
HSC (ST-HSC) which can further differentiate into common myeloid progenitor (CMP) or 
common lymphoid progenitor (CLP) cells. These 2 cell types are restricted in the further 
differentiation their daughter cells are able to undergo. CLPs are the progenitor cells of the 
lymphoid lineage are able to differentiate into: B cells, T cells and, innate lymphoid cells (ILCs). 
CMPs can further differentiate into: megakaryocyte-erythroid progenitors (MEP) or 
granulocyte-myeloid progenitors (GMP). MEPs further differentiate into red blood cells (RBC) 
or into megakaryocytes, which produce platelets. GMP cells produce a multitude of innate 
immune cells: such as basophils, monocytes and neutrophils. Taken from Sankaran and Weiss 
(2015).  
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1.1.1.1.1 – B cells 
B cells are generated and mature in the bone marrow. After committing to become a B cell, 
CLP cells begin recombining the gene segments in the Immunoglobulin (Ig) locus, to form an 
antigen receptor. After stimulation, B cells proliferate to form a germinal centre in the lymph 
node follicle. These cells can then differentiate into one of two cell types; plasma cells and 
memory B cells. Plasma cells secrete large concentrations of soluble antibody during the 
course of infection, while memory B cells are less active and persist in the organism, past the 
initial infection, in order to activate specific humoral immunity (Pieper et al., 2013). 
 
1.1.1.1.2 – T cells 
After initial generation in the bone marrow, T cells migrate to the thymus where the rest of 
the stages of maturation occur. In this organ, the immature T cells undergo positive and 
negative selection to reduce the number of self-reactive cells and differentiate into CD4+ 
helper cells or CD8+ cytotoxic T cells. Cytotoxic T cells recognise and kill cells infected with virus 
or intracellular bacteria and CD4+ T helper cells (TH) assist in controlling the adaptive immune 
response. CD4+ T cells are able to interact with antigen presenting cells (APCs) which express 
major histocompatibility complex (MHC) class II proteins (MHC-II). The human version of this 
gene family is known as human leukocyte antigen II and is encoding by 6 paralogues known as: 
HLA-DP/DM/DOA/DOB/DQ/DR depending on the combination of subunits). 
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MHC-II is complex of 2 membrane-bound proteins (MHC-II α and β) that is able to present a 
single molecule of antigen (not larger than 9 amino acids in length) to the antigen receptor on 
a T cell (TCR), as well as bind the molecule CD4 in an antigen-independent manner. The binding 
of the TCR to an antigen bound by MHC-II at the same time as interacting with CD4, allows the 
T cell to become activated, when co-stimulatory receptors on the T cell (such as CD28) are 
bound by ligands on the APC (such as CD80 or CD86) (Murphy, 2007). On activation by TCR and 
co-stimulations, CD4+ T cells, are able to produce a variety of cytokines and the particular 
cytokines these cells produce allow them to be subcategorised into subsets of cells. There are 
several T helper cell subsets including: TH1, TH2, TH17 and Treg (Luckheeram et al., 2012).  
 
TH1 cells assist in activating macrophages that have ingested pathogens which persist in the 
phagocytic vesicles. TH2 cells assist in B cell activation, proliferation and antibody class 
switching (Shinomiya et al., 1989). TH17 are observed in the mucosal barriers (such as intestine) 
and assist in the recruitment of neutrophils and other inflammatory cells in response to 
bacteria or fungus(Ouyang et al., 2008). Treg cells act as key negative regulators of the immune 
response and inhibit potential auto-immune responses, through a number of mechanisms 
including the secretion of anti-inflammatory cytokines and inhibition of co-stimulatory 
molecules (Corthay, 2009). 
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1.1.1.1.3 – Innate Lymphoid Cells 
Unlike the other cells of the lymphoid lineage the innate lymphoid cell (ILC) lineage does not 
express antigen-dependent receptors in order to become activated. Instead this family of cells 
is dependent on myeloid- or epithelial-derived cytokines. These cells have many roles 
including: lymphoid organ development and providing anti-cancer immunity (Artis and Spits, 
2015, Klose and Artis, 2016). These cells can be further sub-classified based on their 
transcription factor expression, as well as whether the cells are able to induce cytotoxicity. The 
natural killer (NK) cell is the sole member of the cytotoxic ILC group. These cells interact with 
the ubiquitous antigen presentation complex MHC class I (MHC-I) and other cell surface 
proteins which suppress the release of inflammatory cytokines, Granzymes and the pore-
forming protein, Perforin (Topham and Hewitt, 2009). The non-cytotoxic compartment of ILCs 
are segregated according to differences in cytokine production and the expression of 
transcription factors. These include: Type 1 ILCs (which are T-bet+ and can produce IFN-y and 
TNF on activation), Type 2 ILCs (which express the transcription factor GATA3 and produce IL-
4/5/9 on stimulation) and, Type 3 ILCs (which can produce IL-17, IL-122 and, GM-CSF). Type 3 
ILCs express the transcription factor RORyt but can also express T-bet, which causes the type 
3 ILCs to produce TNF and IFNy. 
 
1.1.1.2 – Myeloid cells  
After diverging from the lymphoid lineage, the CMP further differentiate into a 
granulocyte/macrophage progenitor cell (GMP), prior to diverging into granulocytes 
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(neutrophils, eosinophils, basophils) or monocytes, dendritic cells and macrophages (Alvarez-
Errico et al., 2015, Murphy, 2007). 
Neutrophils and, eosinophils are short-lived blood circulating immune cells, which have a key 
role clearing infection by bacteria or parasites, respectively. All of these cells remain in the 
blood under normal conditions, but during inflammation and infection these migrate into 
affected tissues. Neutrophils have a potent phagocytic and bactericidal ability and are vital in 
controlling the bacterial load, following bacterial invasion. However, unlike macrophages and 
dendritic cells, they lack the capacity to effectively present antigen to adaptive immune cells 
(Kolaczkowska and Kubes, 2013).  
Eosinophils, while also carrying some bactericidal activity, are thought to mainly target 
parasitic infections due to their increased numbers in circulation, during a parasitic infection 
(Rothenberg and Hogan, 2006). Basophils lack the ability to ingest or kill pathogens and instead 
have histamine granules in their cytoplasm, which (on secretion of the granules) acts to 
increase circulation to inflamed tissue, allowing immune cells to enter into the tissue 
(Voehringer, 2013). 
 
1.1.1.2.1 – Dendritic cells 
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) with an essential role in 
activating and controlling T-cell immune responses. From studies of the mouse immune 
system, it is apparent that DCs are a heterogeneous group of cells with multiple lineage (can 
be derived from both CLP and CMP cells) and functions which are heavily influenced by the 
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tissues in which they are found (Ardavin, 2003, Geissmann et al., 2010). In tissues these cells 
are quiescent until activated by innate immune signals and loaded with antigen. Once 
activated these cells subsequently migrate through the lymphatic system to the draining lymph 
node for the tissue. There they are exposed to naive and memory T-cells and able to stimulate 
the adaptive immune response, on recognising the recognition of the antigen they present to 
a cognate T-cell (Merad et al., 2013). 
 
1.1.1.2.2 – Monocytes 
Monocytes are blood circulating phagocytic myeloid cells. These cells are differentiated in the 
bone marrow from HSC cells which normally circulate the blood, spleen and, bone marrow 
(Yona et al., 2013, Swirski et al., 2009). Under inflammatory conditions, these cells are able to 
migrate into tissue in response to chemokines (Auffray et al., 2009, Zimmermann et al., 2010, 
Geissmann et al., 2010). Once inside the tissue, these cells are able to differentiate into 
macrophages and can assume a similar function to existing tissue macrophages (van de Laar 
et al., 2016).  
In humans blood there are two phenotypic subsets of monocytes segregated on the basis of 
the expression of the cell-surface proteins: CD14 and CD16 (Geissmann et al., 2003). CD14+ 
CD16-/+ monocytes (which in many respects correspond to Ly6C+ monocyte subset in mice) 
are strong producers of pro-inflammatory cytokines in response to bacterial cell products 
whereas, the CD14dimCD16+ subset (corresponding to the LY6C- subset in mice) responds more 
to viruses and nucleic acids (Cros et al., 2010, Ingersoll et al., 2010).  
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As well as having differential preference for stimuli, these cells also have been shown to exhibit 
differences in gene expression and cellular function in different diseases (Geissmann et al., 
2003, Auffray et al., 2009, Zimmermann et al., 2010). 
 
1.1.1.2.3 –Macrophages  
Macrophages are tissue resident cells of the innate immune system. Macrophages have 
important roles in maintaining tissue homeostasis, modulating the adaptive immune response, 
as well as initiating and eventually resolving the inflammatory response (Wynn et al., 2013, 
Murray and Wynn, 2011). In mammals these cells originate from three 3 distinct sources, 
during development: 
1) The Yolk sac during embryogenesis  
2) The foetal liver during initial haematopoiesis 
3) The bone marrow (pre-natally or post-natally depending on the species).  
Initially macrophages originate during embryonic haematopoiesis, from yolk sac blood islands 
at E8.5 (in mice) and colonise the embryo on the establishment of circulation from the yolk sac 
(shown in Figure 1.2) (Gomez Perdiguero and Geissmann, 2013, Schulz et al., 2012). These 
macrophages can persist throughout adult life and have the potential for self-renewal to 
maintain the population of macrophages in that tissue (Hashimoto et al., 2013).  
After mammalian foetal haematopoiesis has been established in the liver, populations of 
monocytes (determined by the expression of the transcription factor MYB) are able to migrate 
into some tissues and differentiate into macrophages (Schulz et al., 2012). This process is then  
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Figure 1.2 – Ontogeny of Tissue macrophages 
Taken from Lavin et al. (2015a). The dissemination of tissue macrophages across an embryo 
occurs in mice between E7 and 7.5 from erythomeyloid progenitor cells (EMPs) in the yolk sac 
into the various developing tissues such as the brain (where they develop in to microglia), the 
lung (where they become alveolar macrophages), the skin (where they differentiate into 
Langerhans cells) and the liver (where they become Kupffer cells). 
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moved to the bone marrow, post-natally in mice, but prenatally in humans (Gordon and Taylor, 
2005). There are several sub-types of macrophages, classified according to their tissue 
localisation, which differ in terms of function and gene expression (Lavin et al., 2015b). These 
subsets include: 
• Microglia, located in the central nervous system (CNS) 
• Osteoclasts, located in and on bones 
• Kupffer cells, located in the liver 
• Alveolar macrophages which reside in the lungs 
• Intestinal macrophages, which are located under the intestinal endothelium. 
 
1.1.1.2.3.1 – Microglia  
Microglia are a highly distinct population of tissue macrophages which inhabit the CNS which 
are derived from the yolk-sac and under homeostatic conditions are not replenished by 
monocytes and instead retain the ability to proliferate (Lawson et al., 1992, Ginhoux et al., 
2013). These cells are responsible for the maintenance of the neuronal network, able to assist 
in the survival of neurons, but also assist in apoptosis and the removal of debris. Microglia also 
sample the local tissue for antigen and are morphologically dendritic in order to survey the 
local tissue. On detection of a pathogen or inflammatory stimulus  they release pro-
inflammatory molecules and initiate antigen presentation (Nayak et al., 2014). The activation 
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of these cells by inflammatory stimuli has been highlighted as a driver of adverse pathology in 
multiple CNS disease, such as Alzheimer’s and Parkinson’s disease (Nayak et al., 2014). 
1.1.1.2.3.2 – Osteoclasts 
Osteoclasts are multi-nucleated cells which are able to resorb mineral bone.  These cells are 
first observed in the developing bones, resorbing bone deposited inside bones by osteoblasts, 
which allows for the growth of the bone during development (Gilbert, 2000). 
These cells are the result of multiple fusions of progenitor cells (Boyle et al., 2003, Miyamoto 
and Suda, 2003). In adults: osteoclast precursors from the bone marrow traffic to sites of bone 
damage or growth and begin to fuse with other osteoclast precursors, in the presence of the 
cytokines M-CSF and RANKL (Yasuda et al., 1998) (Udagawa et al., 1990). These precursor cells 
also arise during embryogenesis where they are detectable after establishment of circulation 
with the yolk sac (Thesingh, 1986). 
 
1.1.1.2.3.3 – Kupffer cells 
Since the liver provides many functions which are vital to the long term health and survival of 
chordates, it stands to reason that maintaining the health and integrity of the organ is also 
critical. Kupffer cells are the resident macrophages of the liver and play a vital role in detecting 
and responding to pathogens that pass through the liver in the blood. These cells also play a 
vital role in clearing apoptotic hepatocytes and recycling of damaged red blood cells (Bilzer et 
al., 2006). These cells are initially derived from yolk sac blood islands and under normal 
conditions do not require supplementation from monocytes. However, under inflammatory 
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conditions (or extensive injury) monocytes are able to extravasate from the blood into the liver 
(David et al., 2016). 
 
1.1.1.2.3.4 – Alveolar macrophages 
Due to the anatomy of the lung, the alveoli would be a chink in the body’s defences, given the 
close proximity of the capillaries to the alveolar space. Alveolar macrophages are therefore 
key in maintaining a front-line defence against pathogen invasion(Morales-Nebreda et al., 
2015). 
Monocytes derived macrophages do not constitute a major population in the lung in healthy 
conditions but are required to control infection and repair damage to tissue  (Hussell and Bell, 
2014). This macrophage compartment originates from the yolk-sac but is able to be 
reconstituted by bone marrow-derived cells (van de Laar et al., 2016). 
 
1.1.1.2.3.5 – Intestinal macrophages 
Unlike many macrophage populations previously mentioned, macrophages which reside in the 
intestinal tract are supplemented and replaced by monocytes from the blood.  
These cells persist in multiple locations throughout the tissue and are almost constantly 
exposed to pathogens, microbial agents and, potential antigens (Bain and Mowat, 2014a, Bain 
and Mowat, 2014b, Smith et al., 2011b). Therefore unlike other macrophage populations, 
these cells are constantly replenished over the course of a lifetime, by circulating monocytes 
(Bain et al., 2014). 
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It was previously thought that tissue resident macrophages constitute a large proportion of 
the total macrophage population after birth and were replenished and eventually replaced by 
circulating monocytes from the blood, which are able to differentiate into macrophages 
through cytokine stimulation (M-CSF and GM-CSF). This replacement of embryonically derived 
macrophage is now only thought to be the case in the presence of inflammatory lesions or 
tissues that are continually exposed to pathogens such as the  intestine (Ginhoux and Jung, 
2014, Varol, 2015).  
Macrophages in different tissues exhibit both differential function and a differential pattern of 
gene expression. These diverse patterns in gene expression are caused predominantly by 
different cytokines and constituents of the tissue in which they reside. These distinctive 
conditions enable recruited macrophage progenitors to assume a phenotype typical of existing 
resident macrophages and enforce cellular responses, appropriate to the tissue (Lavin et al., 
2015b, van de Laar et al., 2016, Gosselin et al., 2014). Whether fully differentiated tissue 
macrophages are able to retain sufficient plasticity for tissue transplantation is a matter of 
debate (Lavin et al., 2015b, van de Laar et al., 2016). Evidence from van de Laar et al. (2016) 
indicates that fully differentiated tissue macrophages are not able to acquire a new tissue 
macrophage phenotype after transplantation, unlike any of the progenitor populations.  
 
1.1.1.2.3.6 – Functional classification of macrophages 
Previous attempts to classify macrophage phenotypic traits in-vitro/vivo lead to a model 
similar to T cell subtypes (Mills et al., 2000). This model proposed that there were two 
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phenotypic extremes of macrophages: M1 (expressing markers such as: IL-12, iNOS and, CD80) 
and M2 macrophages (expressing markers such as CD163, ARG1 and, IL-10) (Edin et al., 2012, 
Kigerl et al., 2009). M1 macrophages were described as an inflammatory macrophage subtype 
analogous to TH1 cells and previously designated as “classically activated” macrophages. At the 
other extreme were the M2 macrophages, described as an anti-inflammatory cell similar to 
TH2 cells and previously described as “alternatively-activated macrophages” (Gordon, 2003).  
However, in recent years this model has proved to be restrictive to its description of 
macrophage responses, otogeny and, heterogeneity (Mosser and Edwards, 2008, Martinez 
and Gordon, 2014, Murray et al., 2014). This paradigm is now being replaced in more recent 
studies by a “spectrum” model of macrophage activation as well as more specific studies on 
tissue macrophage subsets (Mosser and Edwards, 2008, Xue et al., 2014). 
 
1.2 – Inflammation 
Inflammation is a response of vascularised tissue to pathogen invasion, or physical damage. In 
the inflammatory process, blood vessel walls in the vicinity of damage or immune challenge 
become permeable and allow leukocytes, lymphocytes and proteins from the blood stream to 
enter the local tissue to clear the damage or pathogen and repair the tissue. This process leads 
to the classical signs of inflammation; swelling, redness, heat and pain. 
The redness and the heat of an inflamed area, stems from increased blood flow to the area 
due to vascular permeabilisation, while the pain and swelling is caused by fluid from the blood, 
containing leukocytes, lymphocytes and protein leaving the blood stream and accumulating in 
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the area of the tissue damage. Pain also arises from activation of pain receptors by soluble 
factors released at the site of inflammation. 
The egress of leukocytes from the blood stream to the tissue is a tightly controlled process. 
Firstly the leukocytes can only migrate through vascular endothelium that has been activated 
by inflammatory cytokines. This activation causes them to express integrin ligands on their 
vascular facing surfaces, which is consequently bound by leukocytes. This causes them to 
adhere to and roll along the vascular wall, until they reach an endothelial cell-junction. It’s at 
this point the leukocytes are then able to migrate through the cell wall, into the tissue. 
The normal inflammatory response has two distinct stages, the initial inductive phase and the 
resolution phase. The inductive phase involves the production of inflammatory mediators 
(such as TNF and IL-6) to activate and/or recruit other immune cells as well as permeablising 
the local vascular endothelium, to enable the influx of immune cells to the tissue.  
The resolution phase of inflammation involves the release of anti-inflammatory molecules, 
such as glucocorticoid hormones and anti-inflammatory cytokines (Opal and DePalo, 2000, 
Morand and Leech, 2001, Basil and Levy, 2016, Serhan and Savill, 2005). These molecules 
actively inhibit the production and release of pro-inflammatory signals, as well as inhibiting 
the function of adaptive immune cells in the tissue and restore the integrity of the vascular 
endothelium. With the inflammatory process dampened, macrophages and stroma can initiate 
repairing the tissue damage caused by inflammation (Ariel, 2012, Koh and DiPietro, 2011). 
This resolving phase, is a vital part of the normal inflammatory response. Without suppression 
of the inflammatory response, inflammation becomes chronic, damaging or potentially 
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destroying normal tissue function and potentially leading to a systemic alteration in immune 
cell function and generation(Schuettpelz and Link, 2013). 
 
1.3 – Pattern recognition receptors  
Pattern recognition receptors are able to detect molecules known as pathogen associated 
molecular patterns (PAMPs). PAMPs are a diverse array of molecules ranging from cell wall 
constituents to large conserved proteins (flagellum), which usually are required for the life 
cycle or survival of the pathogen and therefore conserved against the evolutionary pressure 
formed by their recognition by the innate immune system (Taylor et al., 2004, Gordon, 2002).  
There are several major classes of PRRs: Toll like receptors (TLRs), retinoid-inducible gene 1-
like receptors (RLRs), nucleotide-binding oligomerization domain-like-receptors (NLRs) and C-
type lectin receptors (CLRs) (Takeuchi and Akira, 2010). These receptors are expressed across 
many cell types, both in professional immune cells and non-immune cells. This range of 
expression allows the detection of pathogens where resident immune cells (such as 
macrophages or DCs) are not present, supressed or, unable to be infected (in the case of viral 
pathogens).  
 
1.3.1 – Toll-like Receptors 
One of the most keenly studied PRR families is the TLR family. These membrane bound 
receptors were initially discovered on the basis of their homology to the D. melanogaster 
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protein Toll (also known as Toll-1), which when knocked out in this insect, fatally compromises 
the immune defence against fungal infection (Lemaitre et al., 1996).  
The two main characteristic features of TLR family are the leucine rich repeat (LRR) domain 
which form the binding surface of the receptor and the cytoplasmic Toll-IL1R (TIR) domain 
which allows the receptor to initiate cell signalling (Medzhitov, 2001). Differences in these 
domains between TLR family members determine which PAMPS the receptors are able to 
recognise as well as the signalling pathways initiated by receptor activation. 
Currently  10 members of the TLR family are recognised in humans of the TLR family in humans, 
6 of which are expressed on the cell surface (TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10), while 
the remainder are localised to the endosome (TLR3, TLR7, TLR8 and, TLR9)(O'Neill and 
Golenbock, 2013). The endosomal TLRs are able to bind to nucleic acid polymers within the 
endosome (such as: dsRNA, ssRNA and CpG rich DNA sequences) and their activation leads to 
the production of type I IFNs through phosphorylation of interferon regulatory factors (IRFs) 3 
or 7(Newton and Dixit, 2012, Uematsu and Akira, 2007).  
The cell surface TLRs are able to bind to microbial cell components (such as flagellin or 
zymosan) as well as viral envelope proteins (RSV) and upregulate multiple inflammatory 
cytokines (Chaturvedi and Pierce, 2009).  
 
1.3.2 – LPS:TLR4 signalling pathway 
Lipopolysaccharide (LPS) is a cell wall component of gram-negative bacteria which has been 
shown to act as a trigger for septic shock, through its initiation of inflammatory signalling 
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through the receptor TLR4 (this signalling pathway is summarised in Figure 1.3 ) However, for 
the interaction to occur LPS must first bind to LPS binding protein (LBP) in order for the LPS to 
be transferred to CD14, which facilitates the binding of LPS to TLR4. After binding to the 
CD14:LPS, TLR4 then binds to myeloid differentiation factor 2 (MD2). MD2 is able to bind two 
TLR4:CD14:LPS complexes, in close enough proximity to initiate the intracellular signalling 
cascade (Park et al., 2009). 
The intracellular signalling pathway utilised by TLR4 on activation is dependent on whether the 
receptor is activated on the cell surface, or in an endosome. When TLR4 is activated on the cell 
surface, an adaptor protein complex of TIRAP and MYD88 binds to the TIR domain, which in 
turn allows the IL-1 receptor associated kinase 4 (IRAK4) to be recruited to the complex. On 
binding to MYD88, IRAK4 is activated and is able to phosphorylate TRAF6. TRAF6 on 
phosphorylation is then able to ubiquitinated with a K67-linked polyubiquitin chain, which 
initiates the formation of a complex of TRAF6 with TAK-1, TAB1, TAB2 and TAB3. This complex 
is then able to phosphorylate 3 notable substrates to effect changes in gene expression; MAPK 
Kinase (MKK) 3, MKK7 and, the IKK complex. The signalling pathways initiated by LPS are 
summarised in  (Andreakos et al., 2004, Lu et al., 2008) 
If activated in the endosome, activated TLR4 recruits the adaptor proteins: TRIF and TRAM. 
This complex is then able to phosphorylate TRAF3 and TRAF6 and TBK1 which activates their 
kinase function (Fitzgerald et al., 2003a). This complex then activates the transcription factors 
NF-κB and IRF3/7 which initiates alterations in gene expression (Fitzgerald et al., 2003b). The 
activation of the of IRF3/7 induces the activation of the type I interferon response due to its 
21 
 
induction of the IFNB1 gene (Ohmori and Hamilton, 2001, Fitzgerald et al., 2003b, Jiang et al., 
2005, Uematsu and Akira, 2007). 
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Figure 1.3 – LPS-induced signalling cascade 
Summary of the LPS activation of the NF-κB, JNK, p38 MAPK and PI3K pathways. Presentation 
of LPS by CD14 (catalysed by LBP) to TLR4 and MD2, causes the dimerization of TLR4 and forms 
a binding surface for the signalling adaptor proteins TIRAP and MYD88 to bind. This association 
allows the binding of IRAK1/4, on binding IRAK1/4 are able to auto-phosphorylate, enabling 
the recruitment of TRAF6. Once TRAF6 binds and is phosphorylated by the receptor complex, 
it is then able to phosphorylate TAK1. TAK1 has 3 main substrates MKK3/6, MKK4/7 and the 
IKK complex. Phosphorylation of MKK3/67 leads to the phosphorylation of p38 MAPK, which 
in turn indirectly activates the transcription factor CREB. Activation of MKK4/7 leads to the 
activation of the kinase JNK, which in turn phosphorylates and enables the activation of the 
transcription factor AP-1. Phosphorylation of IKKα causes the activation of the IKK complex 
kinase activity and initiates the phosphorylation of IκBα.This phosphorylated IκBα is 
recognised by the Cullin-1/Skp-1:β-RTrCP complex and is subsequently poly-ubiquitinated. This 
ubiquitination leads to IκBα being transported to the proteasome and degraded, which allows 
the NF-κB subunits bound to it to be transported into the nucleus and activated transcription. 
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1.3.2.1 – LPS-induced activation of mitogen activated protein kinase 
The MAPK signalling cascade is a multi-layered system of specific serine/threonine kinases, 
which ultimately modulates cellular function at the level of transcription (through the 
modification of transcription factors), mRNA stability (Mahtani et al., 2001, Clement et al., 
2011) as well as altering the function of pre-existing proteins in the cell. These signalling 
cascades are activated under a number of circumstances, including osmotic stress and cytokine 
stimulation. The MAPK pathways consist of a cascade of at least 3 kinases, generally classified 
as a MAP kinase (MAPK), MAP kinase kinase (MKK or MAPK2) and, MAP kinase kinase kinase 
(MKKK or MAPK3) (Cargnello and Roux, 2011). 
The phosphorylation of MKK4/7 by TAK1 causes the protein to subsequently phosphorylate c-
Jun N-terminal kinase (JNK) which in turn phosphorylates the transcription factor AP-1. 
The phosphorylation of MKK3/6 by the TLR4 signalling pathway activates the kinase activity of 
this protein, which is able to directly phosphorylate p38 mitogen activated protein kinase (P38 
MAPK), this protein has a large number of substrates which it can phosphorylate including 
other MAPK proteins. Phosphorylation of the kinases MSK1 and MSK2 leads to the activation 
of the transcription factor CREB (Wiggin et al., 2002, Mayer et al., 2013). 
As well as activating CREB to induce transcription, p38 MAPK also has the ability to influence 
mRNA through its ability to phosphorylate MAPK-activated protein kinases 2 (MK2) , which in 
turn inactivates the mRNA destabilising protein TTP through phosphorylation (Bode et al., 
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2012, Clark and Dean, 2016).  This protein is able to destabilise the mRNA of many genes 
upregulated by LPS, including the inflammatory cytokine TNFα (Brooks and Blackshear, 2013). 
1.3.2.1 – LPS-induced activation of NF-ΚB 
The IKK complex is a large trimeric group of proteins containing two protein kinase subunits 
(IKK-α and β) and one regulatory subunit (IKK-γ or NEMO).  Activation of the IKK allows it to 
phosphorylate IκBα on residues Ser32 and Ser36 (Traenckner et al., 1995, Finco et al., 1994). 
IκBα (the protein transcribed from the NFKBIA gene) is a cytoplasmic protein with multiple 
Ankyrin repeat domains that allow it to bind to the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) family of transcription factors (Viatour et al., 2005). When bound 
to IκBα, NF-κB subunits are sequestered in the cytoplasm due to IκBα masking the nuclear 
localisation signal (NLS) required for the NF-κB dimer to be transported to the nucleus (Tak and 
Firestein, 2001). 
The phosphorylation of IκBα allows the protein to be targeted by a complex of Cullin-
1:Skp1:βTrCP for poly-ubiquitination (Strack et al., 2000). The ubiquitination of IκBα causes the 
protein to be shuttled to the proteasome and broken down, liberating the NF-κB subunits it 
was bound to. This pathway of NF-κB activation is known as the “canonical” NF-κB pathway.  
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1.4 – NF-κB 
The NF-κB family of transcription factor is a highly conserved family with orthologues found in 
a wide range of extant organisms (including Drosophila melanogaster). In humans the NF-κB 
family contains 5 family members (gene names shown in brackets): p65 (RELA), p50/p105 
(NFKB1), p52/p100 (NFKB2), RELB (RELB) and, c-Rel (RELC). 
These 5 proteins, all contain a characteristic N-terminal Rel homology domain (RHD), which 
enables dimerization of members of the family and DNA binding. Three of these family 
members (p65, RelB, c-Rel) contain c terminal transactivation domains, which are required to 
recruit accessory protein complexes such as positive transcription elongation factor b (PTEFb) 
in order to activate transcription (Barboric et al., 2001). The other two members (p50/105 and 
p52/100) lack these transactivation domains and require additional proteins in order to 
activate transcription(Oeckinghaus and Ghosh, 2009). 
p50 and p52 also have distinct precursor and processed forms. The larger precursor forms of 
these proteins, which are translated from the mRNA, can be partially processed by the 
proteasome into smaller forms (p52 and p50 respectively) either immediately following 
translation or in a cell signalling dependent manner(Christian et al., 2016). The precursor forms 
(p105, 100) contain a number of Ankyrin repeat domains, which are degraded after processing. 
These domains act similarly to IκBα, sequestering NF-κB family members and retaining them 
in the cytoplasm, by masking the NLS. The cell-signalling dependent processing of p105 is 
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associated with the activation of a small number of cell-surface receptors (known as the “non-
canonical NF-κB pathway”) and has a key role in lymphoid organogenesis(Matsushima et al., 
2001). 
In order to bind DNA, members of the NF-κB family must first dimerise with each other. The 
constituents of these dimers dictate both the ability of the dimer to induce transcription, as 
well as the consensus motif it is able to bind to on DNA (Siggers et al., 2012, Wong et al., 2011). 
All subunit combinations bind the motif “GGGNNTTTCC” (consensus motifs shown in Figure 
1.4) with some dimer combinations able to bind unorthodox motifs such as the p65 
homodimer motif “AGGAANTTC(T/C)C” (Wong et al., 2011). 
 In LPS:TLR4 signalling, the p65:p50 heterodimer is the predominant combination. Unlike the 
other members of the family, p52 and p50 lack a transactivation domain in the protein and 
dimers of these subunits have little transcriptional activity without accessory proteins (Cao et 
al., 2006, Collins et al., 2014). However these dimers are thought to act competitively for NF-
κB motifs, preventing the binding of more active NF-κB dimers (Lernbecher et al., 1993). 
The activation of NF-κB has also been shown to aggravate pathology or severity in a number 
of diseases, including chronic-inflammatory disease and cancer(Tak and Firestein, 2001, Karin, 
2009). The activation of this pathway upregulates the expression of a number of inflammatory 
mediators such as TNF-α and IL-6. A considerable proportion of the primary response to TLR4 
activation in macrophages has also been shown to be heavily dependent on NF-κB (Tong et al., 
2016, Hargreaves et al., 2009). 
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Figure 1.4 – NF-κB consensus motifs 
Example consensus binding motifs of each NF-κb subunit homodimers taken from Zhao et al 
(2014). 
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1.5 – Control of gene transcription 
In order to adapt protein expression to signals from the tissue environment the transcription 
(or processing) of specific genes have to be modulated. This can include: modifying the 
chromatin architecture surrounding genes and enhancers and modulating the transcriptional 
initiation or elongation. 
 
1.5.1 – Chromatin structure 
Chromatin is the complex of DNA and protein which resides in the nucleus of the eukaryotic 
cell and is amorphous prior to the prophase of cell division (where the chromatin condenses 
into discrete chromosomes). In chromatin, DNA is wound around an octamer complex of 
histone proteins: H2A, H2B, H3 and H4. This complex is able to bind approximately 146 
nucleotide bases pairs of DNA around the exterior surface of the complex, forming a subunit 
known as a nucleosome (Alberts B, 2002). 
Chemical modifications of the histones by enzymes regulate their interaction with the DNA, 
regulating the accessibility of the DNA to other proteins. In the case of the acetylation of 
residues in the histone tails, the acetyl-modification weakens the interaction between DNA 
and the histone complex due to its negative charge which repels the negatively charged 
phosphate groups in the DNA backbone. This looser interaction allows proteins to access the 
DNA backbone and bases in order to bind. Other histone modifications such as methylation 
have been shown not to affect the structure of nucleosomes but instead regulate the 
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interaction of other proteins with the nucleosome (Zentner and Henikoff, 2013, Tessarz and 
Kouzarides, 2014). 
 These modifications are dynamic and are altered during cellular differentiation or as a 
response to stimulus, and are associated with gene regulation. The acetylation of lysine 27 on 
H3 (H3K27ac) is associated with actively transcribed gene transcription start sites (TSS) and 
regulatory regions. Similarly the trimethylation of lysine 4 on the same histone subunit 
(H3K4me3) correlates with promoter elements, both active and poised for signal induced 
activation (Heinz et al., 2015). 
 
1.5.2 – Gene transcription 
The induction and regulation of gene expression in response to cellular signalling, is a highly 
complex multi-staged process. The process of transcribing a gene into mRNA can be split into 
three distinct stages: initiation, elongation and termination (Medzhitov and Horng, 2009). 
Initiation consists of the recruitment of Pol II to the TSS of the gene to be transcribed and the 
assembly of the pre-initiation complex (PIC).  
Once Pol II has been bound to the TSS, Poll II is phosphorylated on the serine 5 of the carboxyl-
terminal domain (CTD) heptapeptide repeat (consisting of the peptide sequence “YSPTSPS”). 
Elongation occurs when Poll II escapes the PIC and moves down the coding strand and 
transcribes the nucleotide sequence to RNA. For this to occur protein complexes capable of 
phosphorylating RNA pol II have to be recruited to the paused Pol II. This mainly accomplished 
by positive transcription elongation factor B (P-TEFb) (Ni et al., 2008, Jonkers and Lis, 2015) 
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but there are some genes whose transcription does not require P-TEFB (Medlin et al., 2005, 
Rahman et al., 2011). This recruitment of elongation factors leads to the liberation of Pol II 
from the PIC and initiates its translocation down the coding strand. P-TEFb‘s recruitment to Pol 
II also leads to the Pol II CTD being phosphorylated on the serine 2 of the heptapeptide repeat 
(Zhou et al., 2012, Komarnitsky et al., 2000). It 
 
1.5.3 – Pioneer transcription factors 
The restriction of these enhancive DNA sequences is vital to produce an appropriate response 
to a stimulus, or to prevent expression by an inappropriate cell type. This is accomplished by 
the function of pioneer transcription factors (such as PU.1) which are able to bind to their 
cognate sequence motif, even when the DNA is bound to nucleosomes (closed) and unable to 
be bound by other sequence specific proteins (Adam et al., 2015, Zaret and Carroll, 2011). This 
interaction is able to cause nucleosomes to “shuffle” to expose a region free of nucleosomes 
(open) and later, the pioneer factor is able to recruit histone-modifying enzymes to the site to 
modify the residues of the histone complexes, to further expose DNA, or to signal a site specific 
function (Chen and Dent, 2014). 
Several transcription factors have gained the specialist function to expose regions of chromatin 
even if the regions lie in normally inaccessible heterochromatin. One of the first described 
families “pioneer” transcription factors is the Forkhead family (Kaestner et al., 2000). The 
structure of this protein includes a winged-helix domain which is highly similar in structure to 
the histone subunit H5. H5 (and its functional relative H1) binds to DNA that is bound to 
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nucleosomes and facilitates its condensation. In Forkhead proteins this enables the binding of 
nucleosome bound DNA. Once bound it can recruit chromatin remodelling complexes to 
expose DNA (Clark et al., 1993).  
 
1.5.4 – Transcriptional Promoters and Enhancers 
In order to specifically control protein expression, cells are able to restrict the regions of DNA 
that are available for transcription factor binding.  These promoters and enhancer regions of 
DNA contain specific sequence motifs bound by specific transcription factors, which facilitate 
the transcriptional activation or repression of gene expression.  
The different activation states of enhancers (whether poised for activation, activated or 
repressed) can be indicated by the post-translational modifications of the histone complexes 
bordering the enhancer (key differences between poised and active enhancers are shown in 
(Figure 1.2). Most active or poised regulatory elements are defined by the presence of mono-
methylation (me) or di-methylation (me2) of lysine 4 residue of H3 (H3K4). H3K4me/me2 is 
often associated with local nucleosome depletion and may act as a foundation step for other 
histone modifications such as, enabling the acetylation of lysine 27 on histone 3 (H3K27ac) 
(Creyghton et al., 2010). The H3K4 methylation may also act as a recruitment platform for 
chromatin remodelling complexes (Nadal-Ribelles et al., 2015). The H3K4me1 can also interact 
to silence transcription, when combined with other histone marks and is thought to help 
demarcate the enhancer from other local sequences (Cheng et al., 2014).  
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The H3K27ac modification is an important link between histone enhancer state and 
transcriptional activation. This modification is able to recruit members of the bromodomain 
protein family (Brd). This family of proteins, as well as recognising acetylated lysine residues, 
act as an intermediary to recruit the P-TEFb complex to that area of chromatin (Jang et al., 
2005, Yang et al., 2005). This recruitment of P-TEFb serves to phosphorylate the CTD of Pol II 
recruited to the enhancer or promoter and initiate transcriptional elongation. Therefore this 
modification is associated with regions of active transcription. In some poised or repressed 
enhancers, the H3K27 residue may be tri-methylated (me3) which will then require de-
methylation before acetylation can occur, thereby blocking or reducing the recruitment of Brd 
and P-TEFb. The H3K27me3 mark also acts to recruit Polycomb Repressive Complex 1 (PRC1) 
to chromatin, which can lead to the compaction of chromatin and the silencing of 
transcriptional activity at that loci (Grau et al., 2011, van Kruijsbergen et al., 2015). 
Enhancers, unlike gene promoters, can affect the expression of genes great distances away 
from their actual chromosomal location. This problem of distance can be resolved by the 
looping of chromatin to bring enhancers into proximity to the promoter and TSS of the gene 
in question. There are many mechanisms by which this can take place, including the use of the 
chromatin structural protein Cohesin, the insulator protein CTCF and the use of enhancer RNAs 
(eRNAs) (Natoli et al., 2011, Ghisletti et al., 2010). This enables not only distal enhancers to 
impact on gene expression, but also allows multiple enhancers and promoters to interact 
(Fanucchi et al., 2013, Chepelev et al., 2012, Hnisz et al., 2013). 
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Figure 1.5 – Markers and function of enhancers  
Taken from Heinz et al. (2015) (81). Enhancers primed by lineage-determining transcription 
factors (LDTF) are able to be bound by signal dependent transcription factor (SDTF) and 
Collaborating transcription factors (CTF), to recruit Pol II and induce the production of eRNAs. 
Locally bound looping factors (such as Cohesin, CTCF, the mediator complex, or eRNAs) allow 
the looping of chromatin to bring it into proximity with the promoters of genes. These 
enhancers typically display H3K4 mono and di-methylation which form the boundary of the 
enhancer and guide the potential binding of transcription factors. Active enhancers display 
H3K27ac mark which occurs through the recruitment of p300 and through the bromodomain 
family of proteins enables the recruitment of P-TEFb and enable transcription.  
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1.5.5 – Gene regulation in macrophages 
There are several key transcription factors that have been described through gene knockout 
studies as being required for macrophage differentiation and function. The transcription factor 
PU.1 is expressed at high levels in B cells and monocyte/macrophages). Without this 
transcription factor macrophages are unable to develop from the yolk sac, fetal liver, or bone 
marrow (Scott et al., 1997, McKercher et al., 1996, Kierdorf et al., 2013). The expression of this 
protein is established early during macrophage differentiation and is able to drive the 
expression of the M-CSF receptor, rendering cells sensitive to this vital macrophage-inducing 
cytokine (Zhang et al., 1994). In B cells the expression of this PU.1 is much lower in comparison 
to myeloid cells and the genomic distribution heavily influenced by other transcriptional co-
factors (Heinz et al., 2010). PU.1 has also been shown to contribute to induction of 
inflammatory gene expression in macrophages, and is bound to genomic regions activated by 
LPS stimulation (Ghisletti et al., 2010). 
The transcription factors C/EBPα/β also has a major role in orchestrating macrophage function. 
Mice lacking these transcription factors lack effective monocyte-macrophage differentiation 
(Zhang et al., 1996, Pham et al., 2007) as well as having defects in cell metabolism and 
bactericidal function (Lee et al., 2014). The enforced expression of C/EBPα/β in B cells with low 
levels of endogenous PU.1 are sufficient to drive these cells towards a macrophage phenotype 
and cause the loss of B cell  surface markers (Xie et al., 2004). 
In tissue macrophages the several other transcription factors have been highlighted as having 
a role in establishing the differential genomic landscape of these cells. Microglia have been 
shown to utilise SMAD family transcription factors which are activated by TGFβ, while 
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peritoneal macrophages require retinoic acid (which is present in the peritoneal cavity) in 
order to establish their phenotype (Gosselin et al., 2014). Other important regulators include: 
MEF2C (for also for microglia), LXRA (for Kupffer cells), PPARγ (for alveolar macrophages) and 
RUNX3 (for intestinal macrophages). The transcriptional networks of these cells is of key 
interest in the field. 
 
1.6 – IL-10 
IL-10 is the founding member of the IL-10 family of cytokines, which include: IL-19, IL-20, IL-22, 
IL-24 and, IL-26 (Sabat, 2010, Zdanov, 2004). These genes display high similarity in gene 
structure, mRNA and protein sequence, as well as sharing receptor subunits (Williams et al., 
2004b). The genes coding for IL-10, 19, 20 and, 24 are also located on the same locus, indicating 
a common ancestral gene origin, although IL-10 appears as a distinct gene (with significant 
homology to other identified orthologues) in species that diverged from our own earlier in 
evolution (such as sharks (Smith et al.). The segregation of IL-19/20/24 into separate genes 
occurred later in evolution  (Wang et al., 2010). 
In humans IL-10 is expressed as a 178 amino acid protein, which also includes a 16 amino acid 
signal peptide, required for its secretion, which is subsequently proteolytically removed. The 
protein structure itself contains 6 amphipathic helices, similar to the structure of IFNγ and is 
normally glycosylated (Josephson et al., 2001). Viral homologues of this protein can vary 
largely in terms of protein sequence, but display high similarity in terms of structure (Zdanov, 
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2004), though the differences in sequence can lead to differential cell signalling (Ding et al., 
2000, Yoon et al., 2012, Liu et al., 1997). 
IL-10 was initially described as a soluble inhibitor of TH1 cytokine production, secreted by TH2 
cells upon antigen stimulation (Fiorentino et al., 1989). Since its initial description, IL-10 has 
been shown to be produced by multiple cells including; Tregs, monocytes, mast cells, 
macrophages and dendritic cells and has shown to be fundamental in the regulation of the 
adaptive and innate immune system (Murray and Smale, 2012). 
 
1.6.1 – Consequences of IL-10 signalling 
1.6.1.1 – On Lymphocytes 
T cells 
IL-10 induced signalling has profound effects on lymphocytes and affects their role in the 
immune response. In T cells, IL-10 signalling is able to inhibit the differentiation of naive CD4+ 
T cells into TH1 or TH17 cells (Huber et al., 2011, Qu et al., 2012). Existing TH1 and TH17 cells are 
also responsive to IL-10 signalling, which causes the inhibition of the inflammatory and 
immune-stimulatory cytokine production (TNF/ IFNγ for TH1 and IL-17/22 for TH17) (Liu et al., 
2011, Fiorentino et al., 1989). This has the effect of shifting the immune response from a cell-
mediated immune response (mediated by recruited neutrophils and macrophages) to a more 
humoral immune response (mediated by B cells). 
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IL-10 signalling is also required by the Treg cell subset for multiple functions. Firstly IL-10 
signalling is required to maintain the expression of the transcription factor FOXP3, which is 
critical for the suppressive function of these cells. Without the ability to respond to IL-10, these 
cells are also unable to efficiently upregulate their own IL-10 expression and are less effective 
at restraining immune reactions. 
CD8+ T cells also express the receptor for IL-10 and are influenced by IL-10 signalling. Exposure 
to IL-10 prior to antigen stimulation, inhibits CD8 T cell activation and cytotoxic activity. 
However after antigen stimulation, IL-10 no longer is able to inhibit cytotoxicity and activation 
and instead acts to increase IL-2 mediated proliferation of these cells (Ebert, 2000). IL-10 
signalling differentially affects memory T cell subsets (delineated by CD4 or CD8 expression), 
IL-10 inhibits CD4+ memory T cell, function and expansion, but is required for optimal 
generation of CD8+ T cell memory cells (Foulds et al., 2006, Emmerich et al., 2012, Laidlaw et 
al., 2015).  
B cells 
Contrary to its inhibitive effect on T cells, IL-10 has a stimulatory effect on B cells (Itoh and 
Hirohata, 1995). On exposure to IL-10 B cells have increased MHC class II antigen presentation 
and survival, which can lead to the initiation of a humoral immune response after encountering 
a cognate TH2 cell (Galbas et al., 2012). In activated B cells, IL-10 is able to enhance the 
proliferation and survival of germinal centre B cells, as well as enhancing the differentiation of 
these cells into circulating plasma cells and is also involved in inducing antibody class-switching 
(Choe and Choi, 1998, Levy and Brouet, 1994, Malisan F, 1996).  
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1.6.1.2 – On Myeloid cells 
Neutrophils 
Circulating neutrophils of healthy humans do not express the components of the IL-10 receptor 
complex on the cell surface and therefore cannot initially be stimulated with IL-10. After a 
short time in ex vivo culture or, after exposure to an inflammatory stimulus (LPS, TNF), 
neutrophils upregulate the IL-10 receptor complex and are then susceptible to IL-10-mediated-
inhibition of pro-inflammatory cytokine expression (Elbim et al., 2001, Cassatella et al., 2005). 
IL-10 has been shown to inhibit the phagocytosis and the killing of phagocytosed bacteria in 
vivo and the neutralisation of IL-10 in models of bacterial infections has been shown to 
increase survival (Dang et al., 2006). 
 
Dendritic cells 
Dendritic cell functions are profoundly altered by IL-10. IL-10 signalling during the 
differentiation of monocytes to myeloid dendritic cells (mDC) prevents the cells from acquiring 
classical dendritic cell traits (such as expression of T cell co-stimulatory molecules, IL-12 
production and MHC class II presentation) and instead causes them to differentiate into 
macrophage like cells (De Smedt et al., 1997, Allavena et al., 1998). After monocytes have 
differentiated to mDCs, they become significantly less sensitive to IL-10s suppressive effects 
on TNF production and antigen presentation, due to a downregulation of IL10R1 expression 
and surface presentation (MacDonald et al., 1999, Corinti et al., 2001). 
40 
 
In contrast to its effect on mDCs, IL-10 signalling is able to regulate plasmacytoid dendritic cells 
(pDC) responses to inflammatory stimuli, inhibiting the secretion of immunogenic cytokines 
IFNα, IFNγ and, IL-12. IL-10 is also able to induce the apoptosis of pDCs, which is countered by 
the production of IFNα (which acts as a survival factor for these cells) (Duramad et al., 2003).  
 
Monocytes and macrophages 
The response of macrophages to IL-10 is an integral part of controlling the inflammatory 
response (Pils et al., 2010). Macrophages devoid of an effective IL10R complex or IL-10 develop 
a hyper-inflammatory phenotype in vitro and in vivo demonstrate a spontaneous gut 
inflammation in response to the organism’s microbiota (Zigmond et al., 2014, Shouval et al., 
2014).  The addition of IL-10 to differentiating monocytes skews the phenotype of the mature 
macrophage. Cells exposed to IL-10 have demonstrated increased viability, increased    M-CSF 
binding and receptor expression and, lower antigen-presentation capacity (Hashimoto et al., 
1997).  This reduced ability to present antigen in response to IL-10 has also been shown in vivo 
in response to infection and this may have a role in the orchestration of the immune response 
(Nguyen et al., 2012, Chadban et al., 1998, de Waal Malefyt et al., 1991). Macrophages 
incapable of responding to IL-10 have also been shown to produce greater amounts of 
inflammatory cytokines and are more susceptible to cytokine induced death from an immune 
challenge such as LPS (Bosmann et al., 2014, Pils et al., 2010). Macrophages exposed to IL-10 
have been previously been described as anti-inflammatory or displaying phenotypic features 
of an “M2” macrophage (Mia et al., 2014, Lang et al., 2002). This immunosuppressive 
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phenotype can inhibit important processes such as tissue reconstruction (Eming et al., 2007) 
as well as inhibiting immune surveillance of tumors (Williams et al., 2016).  
 
1.6.2 – IL-10 signalling 
For IL-10 to initiate changes in cell gene expression, it first needs to bind to the IL-10 receptor 
complex. This extracellular section consists of a tetramer complex containing 2 copies of 
IL10R1 and IL10R2, of which only IL10R1 binds directly to IL-10. The intracellular section of the 
complex is associated with Janus kinases (JAKs); JAK1 and Tyk2. JAK1 associates with a JAK 
binding motif on IL10RA, while Tyk2 interacts with another JAK binding motif on IL10RB. Mouse 
knockout studies have previously shown that while IL10R1, IL10R2 and, JAK1 are essential for 
IL-10 signal transduction (Murai et al., 2009); knocking out Tyk2 does inhibit the IL-10 signalling 
pathway, but may in fact be the target of proteins, which in turn regulate the IL-10 signalling 
pathway  (Pike et al., 2014, Karaghiosoff et al., 2000).  
After the binding of IL-10 to the IL10R complex, JAK1 is phosphorylated and in turn 
phosphorylates two tyrosine residues on IL10R1; Tyr446 and Tyr496 (Lim and Cao, 2006). 
These phosphorylated tyrosine residues are then able to bind with the SH2 domains of signal 
transduced activator of transcription 3 (STAT3). This brings STAT3 in close proximity to the 
active JAK protein and consequently STAT3 is phosphorylated on Y705 (Williams et al., 2004b). 
This causes the dimerization of STAT3 proteins allowing the DNA binding domains to interact 
with the DNA strand and act as a transcription factor (Hutchins et al., 2012). 
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IL-10 has also been shown to promote the phosphorylation of the related proteins STAT1 and 
STAT5 and as well as STAT3 (Finbloom and Winestock, 1995, Wehinger et al., 1996, Zhu et al., 
2014). However, the contribution of STAT1 and 5 in IL-10 signalling, are largely 
uncharacterised. In macrophages, STAT1 phosphorylation by IL-10 is robustly observed after 
IFNγ pre-stimulation (Herrero et al., 2003) or inhibiting the phosphatase PTPN1B (Pike et al., 
2014).  
Mice deficient in STAT1 also show a comparable IL-10 response to wild type littermates (Durbin 
et al., 1996). Indicating that although STAT1 plays a role in IL-10 signalling, the majority of IL-
10’s effects in macrophages can be attributed to STAT3 (Williams et al., 2004a). 
While the JAK/STAT above describes the most well described scheme by which IL-10 alters 
intracellular signalling, there are other pathways with which IL-10 has been shown to interact. 
Several studies have shown a role for the PI3K pathway in IL-10 function. In pro-myeloid cells, 
activation of the IL-10 receptor causes the phosphorylation of insulin receptor substrate 2 (IRS-
2) as well as PI3K and Akt (Zhou et al., 2001). In macrophages, inhibitors of PI3K have also been 
shown to inhibit IL-10 induced or modulated gene expression (Antoniv and Ivashkiv, 2011). 
However, the mechanism by PI3K could be activated by IL-10 is unknown. These signalling 
pathways are summarised in Figure 1.6. 
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Figure 1.6 – Overview of IL-10 signalling pathway 
Schematic of IL-10 activation of JAK1/STAT3 signalling. IL-10 binding to the IL10 receptor  which 
associated kinase JAK1 to phosphorylate one another and tyrosine residues on the cytoplasmic 
domain of IL10R1. Once phosphorylated these residues act as a binding site for the STAT3, 
which binds to IL10R1 and is phosphorylated by JAK1. The tyrosine phosphorylation on STAT3 
allows the protein to homodimerise and move into the nucleus to facilitate transcription. JAK1 
also leads to the phosphorylation of p42 ERK MAPK and the activation of PI3K through unclear 
mechanisms. The activation of p42 ERK MAPK leads to the activation of STAT1 which can also 
induce gene expression. 
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1.6.3 – STAT proteins 
In humans there are seven STAT family members: STAT1, 2, 3, 4, 5A, 5B and, 6 (Darnell, 1997). 
This family of transcription factors share a common set of structural domains: The N-terminal, 
Coiled-coil, DNA binding, Linker, SH2 and, TAD domains (Mitchell and John, 2005, Levy and 
Darnell, 2002).  The N-terminal, coiled-coil and, linker domains act as surfaces for protein-
protein interactions, such as nuclear importins and interactions with cytokine receptors (Zhang 
et al., 2000, Chen et al., 2003, Ota et al., 2004). The DNA binding domain is an immunoglobulin 
fold (Ig-fold) type DNA binding structure, which is also used by other DNA binding proteins 
such as p53 and NF-κB (Chen et al., 1998). The SH2 domain binds to phospho-tyrosine residues 
on receptor activated STAT proteins and facilitates dimerisation (Darnell, 1997). The TAD 
domain is able to recruit p300 transcriptional coactivator. This domain is able to be 
alternatively spliced in many STAT family members and there is a low degree of conservation 
between orthologues (Paulson et al., 1999). 
In order to activate transcription STAT proteins must first dimerise to translocate into the 
nucleus and to bind to DNA. This is accomplished by the phosphorylation of a conserved 
tyrosine residue located in the C-terminal TAD domain. Once phosphorylated the tyrosine is 
then able to be bound by the SH2 domain of another STAT protein forming a dimer (Darnell, 
1997).  This dimer is then able to bind to nuclear import complexes and be shuttled into the 
nucleus(Reich, 2013). Once there the STAT dimer is then able to bind to open chromatin 
containing the STAT consensus motif (selected STAT motifs are shown in Table 1.1).  
There is a great similarity in the consensus binding motifs between members of the STAT family 
(Ehret et al., 2001). Members of the STAT family bind to a palindromic consensus  
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NAME MOTIF 
STAT1 
 
STAT3 
 
STAT4 
 
STAT5 
 
STAT6 
 
 
Table 1.1 – Table of known STAT family binding motifs 
A table of selected STAT family binding motifs derived from ChIP-seq experiments curated by 
the HOMER program (Rozowsky et al., 2009, Chen et al., 2008, Wei et al., 2010, Liao et al., 
2008, Ostuni et al., 2012). 
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sequence: “TTC(N)1-3GAA” where the number of N is dependent on the STAT proteins binding 
to the sequence. In order to fine tune a response additional co-factors may selectively  complex 
with the STAT dimer, or expose other regions of chromatin for the dimer to bind to (Hutchins 
et al., 2013). 
 
1.6.3.1 – STAT3 
It has been well established that STAT3 is required for the suppressive effects of IL-10, 
Macrophages transfected with a constitutively active form of STAT3, produce much lower 
inflammatory cytokines upon LPS stimulation, as well as synthesising more IL-10 inducible 
genes at the basal state(Williams et al., 2007). 
Whole organism deletions of STAT3 are embryonically lethal(Takeda et al., 1997). However, 
macrophages with STAT3 specifically deleted from the genome, display a high sensitivity to 
endotoxin shock and have increased levels of circulating inflammatory cytokines(Takeda et al., 
1999). A similar effect is observed with macrophages in vitro transfected with a dominant 
negative version of the protein (mutating the critical tyrosine residue at position 705 to a 
phenylalanine residue) (Williams et al., 2004a). 
As well as the JAK induced Y705 phosphorylation; there are multiple post-translational 
modifications that can modify STAT3s transcriptional potency and specificity. The best 
characterised is the phosphorylation of serine 727. This phosphorylation alone does not cause, 
dimerization or transcriptional activation of STAT3, but instead modifies its transcriptional 
activity, upregulating a subset of its target genes (Wen and Darnell, 1997, Miyakoshi et al., 
2015, Huang et al., 2014, Chung et al., 1997). 
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Mechanisms of STAT3s suppression of inflammatory gene expression is a contentious point 
within the field, with multiple transcriptional and post transcriptional mechanisms proposed 
for this activity. As highlighted in Hutchins et al. (2013 and 2015) this discrepancy could have 
arisen due to the differences in cell types across these studies. 
STAT3’s actions are not however solely anti-inflammatory. Many other cytokines including: the 
IL-6 superfamily of cytokines (Berishaj et al., 2007), the satiety hormone leptin (Bates et al., 
2003)) and, the inflammatory cytokine GM-CSF (Gu et al., 2007), also induce tyrosine 
phosphorylation of STAT3. The major difference between the effects of signalling between 
these cytokines, is the sustaining of the phosphorylated STAT3 signal. STAT3 is only 
phosphorylated for a short time after IL-6 stimulation compared to IL-10. This is due to the 
production of suppressor of cytokine signalling 3 (SOCS3), which binds to “SOCS box” motif in 
the IL-6 receptor’s intracellular domain and directly inhibits the receptor associated JAK 
proteins (Babon et al., 2003). In the absence of SOCS3 or the “SOCS box”, IL-6 phosphorylation 
is sustained and instead of its pro-inflammatory effect, gains an anti-inflammatory effect 
similar to IL-10 (Niemand et al., 2003, Yasukawa et al., 2003a). 
 
1.6.4 – IL-10 Mediated Suppression of Inflammation 
There is little consensus on the molecular mechanisms by which IL-10 suppresses inflammatory 
signalling. Smale and Murray (2012) summarise that two major hypotheses exist for IL-10’s 
ability to supress inflammation:  
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1) There exists a “master regulator” upregulated by IL-10 signalling which exerts the inhibitive 
effect on inflammation.  
2) That IL-10 induces the expression of a number of different negative regulators which act in 
concert to suppress inflammation in different contexts 
There is general agreement however that STAT3’s transcriptional activity is absolutely required 
for IL-10s inhibitive effects on the expression of inflammatory genes. Cells deficient in STAT3, 
or expressing a dominant negative version of the protein, produce higher levels of 
inflammatory cytokines such as TNF and IL6 on LPS stimulation and this production is 
insensitive to inhibition by IL-10(Williams et al., 2004a, Nakamura et al., 2015). Although there 
have been some studies that hypothesise the existence of a STAT3-independent mechanism 
for some of IL-10’s inhibitive effects (Chan et al., 2012). 
The effect of IL-10 on immune cells is highly variable between cell types even with a common 
stimulus, indicating that IL-10’s suppression of inflammation may be effected by different 
mechanisms in different cell types (Hutchins et al., 2012, Hutchins et al., 2015). Another 
potential confounding factor in identifying IL-10’s effector of inhibition is the difference in 
exposure time of cells to IL-10 before stimulus. Denys et al. (2002)   demonstrated that pre-
treatment with IL-10 initiated a differential mechanism of TNF suppression, compared to IL-10 
stimulus co-stimulation. 
In monocytes and macrophages, IL-10 has been proposed to act through a variety of 
mechanisms on a multitude of inflammatory genes. These can be stratified into primary 
response genes (PRGs) and secondary response genes (SRGs) based on the requirement for 
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nucleosome remodelling or de novo protein synthesis (Smale, 2010, Ramirez-Carrozzi et al., 
2009, Ramirez-Carrozzi et al., 2006). 
PRGs (such as TNF or IL1A) require no new protein synthesis in order for transcription to occur 
and are often rapidly induced on innate immune signalling. The expression of these genes are 
critical to the induction of the inflammatory response and some genes (such as TNF) have been 
shown to be key drivers of inflammatory pathology. The IL-10 mediated inhibition of TNF 
production has been the focus of much of this research (due its role in inflammatory pathology) 
and multiple strata of mechanisms have been proposed to explain IL-10’s inhibition of its 
expression, including; inhibition of translation to protein (Chan et al., 2012), reduction in mRNA 
stability (Schaljo et al., 2009), inhibition of transcription (Murray, 2005, Smallie et al., 2010), 
modulation of transcription factor function(Wang et al., 1995) and, inhibition of upstream 
signalling (Curtale et al., 2013, Weaver et al., 2007, Verstrepen et al., 2008). 
 
The inhibition of SRGs by IL-10 (such as IL-6 or IL-12p40) has in contrast received much less 
attention. Many transcriptional regulators induced by IL-10, have been shown to act on 
promoters of some of these genes, in order to supress their production by macrophages (El 
Kasmi et al., 2007, Kuwata et al., 2003, Smith et al., 2011a). It has also been shown that at the 
IL12p40 loci (Kobayashi et al., 2012), IL-10 is able to inhibit the transcription of these genes, 
through inhibiting the remodelling of chromatin that is required for their initial expression 
under inflammatory conditions (Weinmann et al., 2001). 
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1.6.5 – IL-10 in disease 
IL-10s importance in supressing or modulating immune responses is exemplified by the 
increased susceptibility of individuals with variant sequences in the promoter of IL-10. Single 
nucleotide polymorphisms (SNPs) in proximal regulatory elements to the IL-10 gene are risk 
factors for many diseases, including; inflammatory bowel disease (Jostins et al., 2012), 
Behcet’s disease (Remmers et al., 2010), ulcerative colitis (Anderson et al., 2011) and Crohn’s 
disease (Franke et al., 2010). These alterations in the promoter of IL-10 alter its transcriptional 
induction on stimulation and lead to predisposition to certain diseases (Sakurai et al., 2013).    
SNPs in other genes involved in IL-10 signalling are also associated with inflammatory or 
immune disease incidence and severity. Both the receptor subunits (Moran et al., 2013, Park 
et al., 2013, Jostins et al., 2012, Franke et al., 2010, Barrett et al., 2009), the kinase JAK1 (Hou 
et al., 2013, Silva et al., 2010) and the transcription factor STAT3 (Zhang et al., 2014, Jostins et 
al., 2012, Jakkula et al., 2010). These SNPs are associated with a number of diseases including 
type I diabetes (Plagnol et al., 2011), Bechet’s disease (Remmers et al., 2010), Crohn’s 
disease(Yamazaki et al., 2013) and, ulcerative colitis(Zhang et al., 2014, Moran et al., 2013). 
IL-10’s key role in limiting and dampening inflammation can be seen in in vivo models of 
disease. Mice lacking the IL-10 gene have increased incidence and severity of many 
experimental immune challenges, such as arthritis (Cuzzocrea et al., 2001, Tao et al., 2011), 
sepsis (Latifi et al., 2002) and, asthma (Yang et al., 2000). Mice deficient in IL-10 also 
spontaneously develop an aggressive form colitis (Sellon et al., 1998), in response to gut 
microbiota, which is in part a reflection of local macrophage response to IL-10 produced by Treg 
s (Zigmond et al., 2014, Murai et al., 2009). 
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 Even without disease associated SNPs, IL-10 can still be a driver or aggravator of pathology if 
expressed inappropriately. Expression of IL-10 in the brain prevents microglial macrophages 
from being able to clear Alzheimer plaques leading to aggravation of pathology. In mouse 
models of the disease, blocking the IL-10 pathway or disrupting the gene improves both the 
clearance of plaques and prevents the formation of new ones (Guillot-Sestier et al., 2015, 
Chakrabarty et al., 2015). 
Many viruses such as Epstein-Bar Virus (EBV) and Cytomegalovirus (CMV) produce orthologues 
to IL-10 (vIL-10), to suppress the immune response during infection (Liu et al., 1997, Yoon et 
al., 2012, Kotenko et al., 2000). This capturing of the IL10 gene is believed to have occurred 
multiple times in history (based on position of the gene within the viral genome and divergence 
of viral families), with the latest acquisition of the gene occurring after the evolutionary 
divergence of Old and New world primates (Ouyang et al., 2014, Slobedman et al., 2009, Ding 
et al., 2000). Interestingly, the mutations acquired in evolution by some vIL-10 forms (such as 
that produced by CMV), lack the stimulatory properties on B cells but retain the 
immunosuppressive properties on other cell types (Spencer et al., 2002). 
1.6.6 – IL-10 as therapy 
Since IL-10s discovery, there have been many attempts to derive clinical benefit from its immune 
suppressive abilities and its capacity to regulate the pathologies of several mouse models of 
disease.  
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Initial phase I clinical trials showed that systemic administration of IL-10 was well tolerated by 
healthy volunteers with the only side effects being mild flu symptoms in a fraction of volunteers 
receiving the higher doses of IL-10. In subjects administered with systemic LPS to induce fever, IL-
10 only effectively downregulated inflammatory cytokine production, when administered 
immediately prior or shortly after LPS administration (Pajkrt et al., 1997).  
IL-10 however showed disappointing efficacy in phase II trials, in the treatment of Crohn’s disease 
and psoriasis.  Patients treated with multiple subcutaneous injections of IL-10 at psoriatic lesions 
only developed a modest reduction over 6 weeks, which became indistinguishable from the 
placebo control group at 12 weeks (van Deventer et al., 1997). In patients with Crohn’s disease 
where IL-10 was administered systemically, there was a noticeable reduction in the disease 
activity score, but it did not result in a reduction in disease pathology or significantly alter the rate 
of remission, compared to placebo. The lack of efficacy could have been due to the administered 
IL-10 not reaching the inflamed area of the gut in a sufficient concentration to restrain the 
disease. 
While administration of IL-10 has proved to be an effective treatment in animal models of arthritis 
(Walmsley et al., 1996), trials in humans have only demonstrated a mild effectiveness (Asadullah 
et al., 2003). This is likely due to the immuno-stimulatory effects of IL-10 on B cells, which are able 
to drive the arthritic pathology through autoantibody production. 
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1.7 – Project Aims 
Cytokines and the gene expression changes they initiate are critical for the development, 
maintenance and resolution of an immune or inflammatory response. Dysfunctions in these 
stages are often accompanied or preceded by, aberrant expression of cytokines. IL-10 has been 
shown to be a potent regulator of inflammatory and immune responses but the mechanisms by 
which IL-10 is able to alter inflammatory gene expression remain unclear. Previous work (Smallie., 
et al. (2010)) has shown that IL-10 can alter the ability of NF-κB to be recruited to chromatin and 
therefore reduce its transcriptional activity. I therefore hypothesised that IL-10 is able to alter 
inflammatory gene expression through the activation or modulation of transcription regulators in 
macrophages. 
Initially I investigated the response of macrophages to LPS, IL-10 or co-stimulation using 
microarray analysis of gene expression. Analysis of the microarray lead me to investigate whether 
the effects of IL-10 and LPS in combination as due to an increase rate of gene synthesis using 
primary transcript QPCR. I also undertook to validate the observed patterns of gene expression 
in response to LPS and IL-10 at the mRNA and protein level using QPCR, ELISA, Multiplexed 
cytokine bead assay (Luminex), western blotting and flow cytometry. 
 
In order to interrogate these responses of gene expression to IL-10 signalling I examined the role 
of the transcription factors STAT3 and NF-κB have been described as having prominent roles in 
the response to IL-10 and LPS respectively. I undertook to dissect the role of these transcription 
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factors in the transcriptional response to LPS and IL-10 signalling, utilising siRNA knockdown of 
gene expression as well as the small molecule inhibitor of NF-κB activity MLN-4924. 
After this I investigated in more detail the patterns of gene expression of the gene TNFSF9 (which 
displayed cooperative regulation with LPS/IL-10) and identified and characterised a putative 
regulatory element upstream of the TNFSF9 TSS which was demonstrated responsiveness to LPS 
and IL-10 stimulation.  
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Chapter 2 – Materials and Methods 
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2.1 Materials 
2.1.1 – Cell culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM); Roswell park memorial institute (RPMI) 1640 
culture medium. 
 
2.1.2 – Cytokines and stimuli 
Cytokine Concentration  Source  
LPS 20 µg/mL ENZO 
IL-10 10 µg/mL Peprotech 
M-CSF 10  µg/mL Peprotech 
Table 2.1 – Recombinant cytokines used in this study 
 
2.1.3 – Signalling inhibitors 
Inhibitor  Source  
LY294002 ENZO 
MLN-4924 Peprotech 
Ruxolitinib Selleckchem 
Wortmanin Sigma Aldrich 
SB203580 Sigma Aldrich 
BAY 11-7082 Sigma Aldrich 
JNK Simon Arthur (Glasgow) 
Cycloheximide Sigma Aldrich 
Table 2.2 – Signalling inhibitors and concentrations used in this study 
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2.1.4 – Adenoviruses 
The NF-κB and STAT3 reporter adenoviral constructs were gifted by Dr Tim Smallie and Dr Lynn 
Williams of the Kennedy Institute for rheumatology.  The NF-κB luciferase construct contains a 
firefly luciferase open reading frame (ORF) downstream of a TATA-like promoter (derived from 
Herpes simplex virus thymidine kinase promoter) and 4 concatenated artificial NF-κB binding 
motifs (single binding motif sequence is as follows: “GGAATTTCC”) synthesised based on the 
consensus sequence of p65:p50 dimer (Campbell et al., 2004, Sanlioglu et al., 2001).  
The STAT3 luciferase reporter construct promoter consist of 4 concatenated repeats of a modified 
oligonucleotide probe previously shown to bind to STAT3 (Horvath et al., 1995). The sequence of 
a single the STAT binding unit of this reporter “GGTTCCCGTAAATGCATCA” (STAT binding site is 
underlined). This promoter was previous cloned upstream of a Tata-like promoter (derived from 
Herpes simplex virus thymidine kinase promoter) and a firefly luciferase open reading frame 
(Besser et al., 1999) which was then subsequently cloned into a adenoviral vector (Williams et al., 
2007, Staples et al., 2007). 
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2.1.5 – Plasmid Vectors 
Vector name Application Antibiotic resistance  Other screening Source 
TOPO 2.1 Cloning Ampicillin/Kanamycin 
Blue/white 
screenable 
Invitrogen 
pGL4.26 Luciferase assay Ampicillin None Promega 
rL-TK Luciferase Ampicillin None Promega 
Table 2.3 – Plasmid vectors used in this study 
 
2.1.6 – Bacterial culture reagents 
Lennox L broth 20 g/L  (Invitrogen) 
Lennox L agar  38 g/L  (Invitrogen) 
Ampicillin  100 mg/mL (Sigma Aldrich) 
Kanamycin  50 mg/mL (Sigma Aldrich) 
 
2.1.7 – General buffers and solutions 
Phosphate Buffered Saline (PBS) 137 mM NaCl 
3 mM KCl 
8 mM Na2HPO4 
1.5 mM KH2PO4 
pH 7.3 
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FACS buffer    1% Heat inactivated fetal calf serum 
     0.05% Sodium Azide 
     PBS 
 
Cytoplasmic Lysis Buffer  50 mM Hepes-KOH(pH 7.5) 
140 mM NaCl,  
1 mM EDTA 
 10% (v/v) Glycerol 
 0.5% (v/v) NP40 
 0.25% (v/v) Triton X-100 
 
Nuclear Wash Buffer   10 mM Tris-HCL pH 8 
200 mM NaCl 
1 mM EDTA 
0.5mM EGTA 
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Nuclear Lysis Buffer   10 mM Tris-HCL pH8 
100 mM NaCl, 
1 mM EDTA 
 0.5 mM EGTA 
 0.1% (v/v) Na-Deoxycholate 
0.5% (v/v) N-Lauroylsarcosine 
 
RIPA Buffer    50 mM Hepes-KOH pH 7.6 
500 mM LiCl 
1 mM EDTA 
1% NP40 (IGEPAL) 
10% Na-Deoxycholate 
2.1.8 – Luciferase assay buffers 
Luciferase Lysis Buffer  0.65% (v/v) NP40 (IGEPAL) 
10 mM Tris-HCl pH8 
1 mM EDTA 
150mM NaCl 
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Luciferase Assay Buffer  1% (v/v) Triton-X-100 
25 mM Tris-phosphate pH 7.8 
8 mM MgCl2 
1 mM EDTA 
15% (v/v) Glycerol 
2.1.9 – Western blotting buffers 
Protein lysis buffer   50mM Tris HCL 
 0.25M NaCl 
 3mM EDTA 
 3mM EGTA  
0.5% (v/v) NP-40  
10% (v/v) Glycerol 
Western Sample buffer (5x)  375mM Tris HCL pH 8 
10% (v/v) SDS 
50% (v/v) Glycerol 
12.5% (v/v) β-mercaptoethanol  
0.1% (m/v) Bromophenol blue 
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Running buffer   25 mM Tris 
     192 mM Glycine 
     0.1% SDS 
     pH 8.3 
 
Wash Buffer    1 x Phosphate Buffered Saline 
0.1% Tween 200 
 
Blocking buffer   1 x Phosphate Buffered Saline 
5% (w/v) Milk Powder 
0.1% Tween 200 
2.1.10 – ELISA solutions 
 
ELISA Wash Buffer   1 x Phosphate Buffered Saline 
0.01 % Tween 200 
 
ELISA Blocking Buffer   1 x Phosphate Buffered Saline 
     2% (w/v) BSA 
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2.1.11 – ChIP solutions 
Dynabeads Blocking buffer  0.5% (w/v) BSA  
     1 x Phosphate Buffered Saline 
 
 
Salt wash buffer   1M Tris EDTA 
     50mM NaCl 
 
Bead elution buffer   1M Tris EDTA 
     2% (w/v) SDS 
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2.1.12 – Primers 
Listed here are the oligonucleotide primers used in this study, separated by experiment type. All 
primers were purchased from MWG Eurofins. 
Gene 
Symbol Forward primer sequence (5’-3’)  Reverse primer sequence (5’-3’)  Target 
CCL8 TGTCCCAAGGAAGCTGTGAT TGGAATCCCTGACCCATCTCT Human 
CD274 CCTACTGGCATTTGCTGAACG AGTGCAGCCAGGTCTAATTGT Human 
CH25H CTTTCCGTGGAGGACCACTC GTGAGAGTGATGCAGGTCGT Human 
CXCL10 CCTGCAAGCCAATTTTGTCCA TGTGGTCCATCCTTGGAAGC Human 
DUSP1 ACAACCACAAGGCAGACATCA CAGTGGACAAACACCCTTCCT Human 
FFAR2 GCTACCTGGGAGTGGCTTTC CATAACCCAGGCCACCAGAG Human 
GADD45B ACGAGTCGGCCAAGTTGATG CGCACGATGTTGATGTCGTT Human 
GAPDH GTCAGCCGCATCTTCTTTTGC AATCCGTTGACTCCGACCTTCC Human 
IFNB1 TGGCACAACAGGTAGTAGGC AGTGGAGAAGCACAACAGGAG Human 
IL1A CTCACGGCTGCTGCATTACA CAGCAGCACTGGTTGGTCTT Human 
IL1B CAACAGGCTGCTCTGGGATT CTGGCGAGCTCAGGTACTTC Human 
NFKBIA GAAGTGATCCGCCAGGTGAA CTCACAGGCAAGGTGTAGGG Human 
NFKBID CCGAGACAGGCTGGATTGTG CATGTTGACAAAGGTCCGCAG Human 
NFKBIZ CTCAACCTGAGCTACTTCTACGG CTTGAAAGGGGCCTCTCTGCT Human 
NR4A2 TGAAGAGAGACGCGGAGAAC CAGCCGAGTTACAGGCGTTT Human 
TNF CCCCAGGGACCTCTCTCTAAT TCTCTCAGCTCCACGCCATT Human 
TNFAIP3 CCCTTGGAAGCACCATGTTTG GGTTGGGATGCTGACACTCC Human 
TNFSF9 ACAGTCTTGGGACTCTTCCG ACCCAGGCTGGACGTTATTC Human 
TNIP3 AATTTTGTATACTTGCTCTCACCC TCTTGTTGATGGTTCAGCACA Human 
Tnfsf9 CCTGCTCAGACCCCATAAAA GCATACAGAGACTGGGAGCTG Mouse 
Gapdh CATCATCTCCGCCCCTTCTG CATCACGCCACAGCTTTCC Mouse 
Table 2.4 – Primers used for the detection of mature mRNA transcripts by QPCR 
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GENE SYMBOL 
FORWARD PRIMER SEQUENCE (5’-
3’) 
REVERSE PRIMER SEQUENCE (5’-
3’) 
CD274 ACTTCTCCATGCTGTTCCCA TCCTTTCATTTGGAGGATGTGC 
IL1A CACGCCTCTGGAATCAATGG ACTGCCCAAGATGAAGACCA 
IL1B GGGAACTGGGCAGACTCAAA TCCTGATCATGTGACCTGCT 
NFKBIA TTGCGCTCATAACGTCAGAC TGGGCTATGGAGAATGGAGTC 
TNF GCAGTCAGATCATCTTCTCG AGGTACAGGCCCTCTGATGGCAC 
TNFAIP3 GCCCACACCAGACTGATACT CACAAGGCAGACATCAGCTC 
TNFSF9 CGGGAGTGTAGAACAGGTGT GAGGGTCCCGAGCTTTCG 
TNIP3 CAGGATGCCTTGAATATCAAGTGTTC TTCTCCACAGGATCATGCCACTTC 
Table 2.5 – Primers used to detect mRNA primary transcripts by QPCR 
  
GENE SYMBOL 
FORWARD PRIMER SEQUENCE (5’-
3’) 
REVERSE PRIMER SEQUENCE (5’-
3’) 
IL6 CGAAGCTGCAGGCACAGAACC CAACAACAATCTGAGGTGCCCATG 
NFKBIA TTGCGCTCATAACGTCAGAC TGGGCTATGGAGAATGGAGTC 
TNF GCAGTCAGATCATCTTCTCG AGGTACAGGCCCTCTGATGGCAC 
TNFAIP3 GCCCACACCAGACTGATACT CACAAGGCAGACATCAGCTC 
TNFSF9 CGGGAGTGTAGAACAGGTGT GAGGGTCCCGAGCTTTCG 
Table 2.6 – Primers used to detect enrichment of proteins at downstream gene regions by 
ChIP 
 
GENE 
SYMB
OL FORWARD PRIMER SEQUENCE (5’-3’) REVERSE PRIMER SEQUENCE (5’-3’) 
TNFSF9 TTCTCGAGAGTTTTCACCGCTTCTTGGC TTAGATCTCAGTGGAACCCTGAGTGTCA 
Table 2.7 – Primers used to amplify human genomic regions including restriction sites 
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2.1.13 – Antibodies used in this study 
Target Species Reactivity  Organism  Clone Source 
RELA  Human  Rabbit  C-20 Santa Cruz 
Tubulin  Human  Mouse  DM1A Sigma Aldrich 
STAT3  Human  Mouse  #9132 Cell signalling 
Phospho-Y705 STAT3 Human Mouse D3A7 Cell signalling 
Laminin A/C  Human  Mouse  612163 BD Bioscience 
TNFAIP3 Human Rabbit D13H3 Cell signalling 
TNIP3 Human Rabbit SAB3500087 Sigma Aldrich 
Table 2.8 – Antibodies used for Western blotting 
 
Target Species Reactivity Organism Clone Source 
RNA-polymerase II Human Rabbit H-224x Santa Cruz 
Phospho-serine2 
RNA-polymerase II 
Human Mouse Ab84988 Abcam 
IgG isotype Human Mouse Ab46540 Abcam 
Table 2.9 – Antibodies used in ChIP 
 
Target Species Reactivity  Organism  Clone Source 
TNFSF9-PE Human  Rabbit  5F4 Biolegend 
CD274-Alexafluor450 Human  Mouse  M1H1 eBiocience 
IgG-κ-PE Human Mouse P3.6.2.8.1 Biolegend 
IgG-κ-Alexaflur450 Human  Mouse  MOPC-21 Biolegend 
Table 2.10 – Antibodies used in flow cytometry 
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Target Species Reactivity  Organism  Clone 
/Batch 
Source 
TNF  Human  Rabbit  551220 BD Pharminogen 
TNF Human  Mouse  554511 BD Pharminogen 
Streptavidin-HRP Human  Mouse  PY998 R&D 
Table 2.11 – Antibodies used in TNFα ELISA 
 
2.2 – Methods 
2.2.1 – Cellular methods 
2.2.1.1 – Isolation of monocytes from leukocyte cone 
Leukocyte cones, which are residues of cells leftover from plateletpheresis with heparin, were 
purchased from the National Blood Service, in accordance with the University of Birmingham and 
National Blood Service ethics. 
The blood cells were recovered from the cone by removing the tubing at either end of the cone 
and flushed through with 20 ml of Hanks BSS. The suspended cells were then diluted up to a 
volume of 40 mL and layered on an equal volume of Lympholyte H and centrifugated at 400 x g 
for 20 mins with low acceleration and no braking.  
The density gradient formed in the tube during centrifugation prevents peripheral blood 
mononuclear cells (PBMCs) from moving from the interface between the blood solution and the 
Lympholyte H, while allowing lighter material (including erythrocytes) to sediment at the bottom 
of the tube.  
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After the centrifugation the PBMCs were harvested from the interface and washed 3 times in 
serum free RPMI 1640. Cells were then counted and diluted to a concentration of 20 x 106 cells/ 
mL in 10% heat inactivated fetal calf serum (hiFCS) and layered onto a 0.88 x PBS 46% percoll 
solution. This was then centrifugated for 30 mins at 400 x g with low acceleration no brakes. This 
monocyte-enriched fraction was collected and washed before being resuspended to a 
concentration of 2 x 106 cells/ mL in RPMI 1640. This 10 mL of this solution was then added to a 
10 cm2 cell culture dish and left for 1 hour in the incubator to allow the monocytes to adhere. 
After this time the supernatants containing contaminating cells were removed and the adherent 
cell layer washed with RPMI to further reduce the amount of contaminating T cells. The adherent 
cells were then cultured in 5% HI-FCS RPMI with 50 ng/mL M-CSF over 5 days to differentiate the 
adherent monocytes into macrophages. 
 
2.2.1.2 – siRNA transfection of primary human macrophages 
Macrophages were harvested after 2 days of differentiation in M-CSF supplemented RPMI. These 
cells were then re-plated into 12 well tissue culture plates at a density of 106 cells per well and 
left overnight to adhere in 5% HI-FCS RPMI. The next day the cell culture supernatants was 
siphoned off the cell layer and replaced with serum free RPMI without phenol red. 
The transfection reagent was formed from Dharmafect I, OPTIMEM media and an appropriate 
concentration of STAT3 targeted siRNA or scrambled oligonucleotide control. These 3 reagents 
were mixed together by pipetting and left to stand for 20 minutes at room temperature prior to 
application to the cells. 
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After 20 minutes the transfection reagent was then added to the wells of the cells, drop-wise 
around the plate to allow a consistent concentration of transfection reagent throughout the well. 
The plate was then left in the incubator for 2 hours before being replaced by 5% RPMI (phenol 
red free) with 50 ng/ ml M-CSF. These cells were then left to mature for a further 3 days before 
harvesting to allow knockdown of STAT3 protein. 
 
2.2.1.3 – Adenoviral transfection of primary human macrophages 
Primary human macrophages were harvested using mechanical dissociation and plated at a 
density of 1 x 105 cells per well of 96 well plates and rested overnight in 5% HI-FCS RPMI media. 
The next day cells were infected with 100 MOI of adenovirus in serum free RPMI for 2 hours. After 
this the virus containing media was siphoned off and replaced with 5% HI-FCS RPMI and rested 
overnight prior to stimulation the next day. 
 
2.2.1.4 – Cell culture 
All cell cultures were maintained at 37oC and 5% CO2 atmosphere. Primary human macrophages 
were harvested using cell dissociation buffer. 
 
2.2.1.5 – Cryo-preservation of Cell lines  
Cryo-preservation of RAW 264.7 cells was accomplished by suspending cells in a 10% DMSO 90% 
HI-FCS solution. These cells were then frozen initially at -80oC before being transferred for liquid 
nitrogen. 
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Revival of frozen stocks was accomplished by thawing the cryopreserved cells at 37oC before 
washing the cells in DMEM to remove the DMSO, before seeding at high density overnight, to 
allow viable cells to adhere to the tissue culture flask, before harvesting and reseeding at an 
appropriate density the next day. 
 
2.2.1.6 – Transfection of RAW cells with plasmid DNA 
RAW 264.7 cells were seeded at a density of 25 x 104 cells per well of a 24 well tissue culture in 
0.5 mL of 10% HI-FCS DMEM (with 1% Pen/Strep) plate left overnight to allow the RAW cells to 
adhere. The next day for each well to be transfected: 0.5 μg of reporter plasmid DNA was mixed 
50ng of control rL-TK luciferase plasmid in OptiMEM media to a volume of 25 μL and mixed with 
1.8 μL of FuGENE®HD reagent, this was then pipetted 15 times and left for 10 minutes at room 
temperature. After 25 μL of the transfection mixture was added to each well of the plate and left 
for 18 hours to allow for the transfection to occur. After 18 hours the cell culture supernatants 
with the transfection reagent were removed and replaced with fresh 10% HI-FCS DMEM (with 1% 
Pen/Strep) and stimulated. 
 
2.2.2 – Molecular biology 
2.2.2.1 – Polymerase Chain Reaction (PCR) 
Polymerase chain reaction PCR was used to amplify a target region 276bp of human genomic DNA 
upstream of the gene TNFSF9. For this reaction 1 ng of Human DNA (Sigma Aldrich) was used for 
the template, primers designed to target the desired region and containing restriction digest sites 
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(described in Table 2.7) and  GoTaq® G2 hot start master mix (Promega). The reaction mix was 
prepared to a final volume of 10µL (detailed below). The lid of the PCR machine was heated to 
95oC to prevent condensation in the lid of the reaction tube. The PCR was accomplished with 30 
cycles of the following program: 
1) Initial  Denaturation at 95oC for 30 seconds 
2) Annealing of primers to template temperature at 59.2oC 30 seconds  
3)  Polymerase extension for 30 seconds at 72oC 
After this a final elongation step was p for 5 minutes before being cooled to 4OC. 
REAGENT VOLUME 
DNA  Template (100 ng/µL) 1 µL 
GoTaq® G2 hot start master mix (2x) 5 µL 
Forward Primer (100 pM) 1 µL 
Reverse Primer (100 pM) 1 µL 
H2O (remaining volume) 
Final reaction volume  50 µL 
 
2.2.2.2 – Topo® 2.1 cloning 
To incorporate the amplified PCR fragment into a bacterial plasmid for large scale replication the 
TOPO® 2.1 cloning system was used. This system exploits the property of Taq polymerases to 
polymerise a single adenosine base to the 3’ end of a PCR product. These 3’ adenosines 
“overhang” is then able to hybridise to a single thymidine “overhang” on a linearised vector, 
allowing the PCR to fit into the vector. 
72 
 
 
The protein Topoisomerase I is able to bind DNA duplexes after a specific binding motif (CCCTT) 
and cleave the phosphodiester bond of the DNA backbone before ligating the 5’ hydroxyl group 
to a 3’ phosphate group. 
1 μL of a 50 µL PCR reaction was added to 1μL of master mix, which contained the topoisomerase 
I and vector and diluted salt solution to a volume of 5 μL. This mixture was then left at room 
temperature for 15 minutes to allow the incorporation of the PCR insert to the TOPO II vector. 
After 15 minutes the mix was transferred to TOPO oneshot compotent bacteria and transformed 
according to section 2.2.2.6. 
 
2.2.2.3 – Restriction digestion of plasmid 
For sub-cloning the TNFSF9 ECR from the TOPO II vector to a luciferase containing plasmid 
(PGL4.26), XhoI and BglII restriction enzymes were purchased from New England Biolabs. A 
restriction digest reaction was set up with the following amounts: 
REAGENT AMOUNT 
DNA  3 µg 
NEB 10x restriction buffer (3.1) 5 µL 
Enzyme 1 µL of each enzyme 
H2O (remaining volume) 
Final reaction volume  50 µL 
 
The restriction digest was conducted at 37oC over 2 hours. 
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2.2.2.4 – DNA digest purification 
To resolve the products of a restriction digest reactions by fragment size, completed restriction 
digests were mixed with 10 μL 6x DNA loading buffer. The digest was then loaded onto an 0.7% 
(w/v) agarose TE gel, with SYBR safe DNA dye (Invitrogen), alongside a DNA size ladder. The 
fragments were then electrophoresed across the gel, for 90 minutes at 120 V. After this time, the 
bands were visualised using a bright box and filter and the band corresponding in size to the 
desired fragment was excised from the gel and purified using the QIAGEN Gel purification kit.  
 
2.2.2.5 – Ligation  
To ligate a digested plasmid and insert, 100ng of digest plasmid was mixed with a 3x molar ratio 
of insert. This was then mixed with 1μL of ligase buffer and 1μL of T4 ligase enzyme and made up 
to a volume of 10μL. This reaction mix was left to occur overnight at 4oC, before being used to 
transform chemically competent bacteria the next day. 
 
2.2.2.6 – Transformation of Chemically competent bacteria 
Frozen 20 μL aliquots of Silver competent E. coli (Thermo Scientific) were thawed on ice and 1-4 
μL of ligation product or 1ng of purified plasmid was added and gently mixed with the bacteria. 
The DNA:bacteria mix was then incubated on ice for 30 minutes before being placed in a 42oC 
water bath for 30 seconds and returned to ice for 2 minutes. Cells were then incubated with 500 
μL of SOC media for 30 minutes at 37oC to allow for antibiotic resistance genes to be expressed. 
Pre-warmed LB plates with selective antibiotic (and for TOPO II plasmids 1.6ng of X-gal and 40µL 
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of 100mM IPTG spread on the surface of the plate) were inoculated with 200 μL of transformed 
bacteria and incubated overnight at 37oC. Discrete colonies were then selected for larger liquid 
cultures the next day. In the case of TOPO II plasmids, only white or light blue colonies were 
selected for larger culture and insert confirmation. 
  
2.2.2.7 – Isolation of RNA 
Total RNA was extracted from MDM and RAW 267.4 cells using Qiagen RNeasy kit, typically 1 x 
106 cells were used for QPCR and 2 x 106 cells were used for microarray analysis data points. After 
stimulating the cells, supernatants were removed and the adherent layer was washed with sterile 
PBS. The cells were then lysed in the supplied RLT buffer, supplemented with 0.1% β-
mercaptoethanol. These lysates were then homogenised using QIAShredder spin columns. 
Homogenised lysates were then mixed with an equal volume of 70% ethanol and added to an 
RNA binding column and impurities were washed out with the supplied buffer. 
While bound to the column the RNA was treated with an on-column DNase (QIAGEN), prior to 
the elution step. RNA was then eluted in RNase free water and stored at -80oC. RNA was 
quantified and quality was assessed by nanodrop. 
 
2.2.2.8 – Preparation of samples for Microarray and analysis 
Sample RNA purified from cells was analysed by Nanodrop spectrophotometer for quantification 
and identification of solvent contamination. Solvent contamination was indicated by high 
absorbance at wavelengths of 280nm and 230nm when compared to the peak of absorbance for 
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nucleic acids (260nm). Samples with low or indistinguishable solvent contamination with a 
concentration of >100 ng/µL were taken for further microarray analysis.  
The initial LPS/IL-10 microarray shown in chapter 3 was performed with a Affy HuGene 1_0 st v1 
chip. The MLN4924 microarray in chapter 4 was performed on an Agilent SurePrint G3 GE 
8x60kv2. cDNA labelling, hybridisation and image capture were performed by Dr Tim Smallie (for 
the Affymetrix arrays) and Oxford Gene Technology (for the Agilent array). 
  
In microarray analysis of gene expression; RNA harvested from a cell or a population of cells is 
purified and reverse transcribed into cDNA. This cDNA is then chemically coupled to fluorescent 
dyes, which enables the visualisation of the cDNA under specific wavelengths of light. The 
fluorsenct sample cDNA is then placed on a microarray ChIP which contains many oligonucleotide 
probes of various sequences and lengths between 25nt-60nt. The cDNA is then given time to 
hybridise and then washed to remove cDNA not specifically or weakly bound to a probe. The 
cDNA is then visualised using a laser at a wavelength specific to the fluorophore and the amount 
of cDNA bound to a probe is quantified by the intensity of the fluorescence at that position. 
 
2.2.2.9 – Generation of cDNA from total RNA 
For the generation of cDNA from total RNA, the iScript reverse transcriptate group of reagents 
were used. In a standard reaction 2.5µL of total RNA (typical total quantity of 100ng) was mixed 
with 1 µL iSript reaction mix (5x), 1.25µL of RNase free water and, 0.25µL iScript reverse 
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transcriptase. The reaction mix contains a mixture of random hexamer oligonucleotides and poly-
thymidine primers and will therefore amplify all thypes of RNA not only mature mRNA. 
After the reverse transcriptase reaction was set up, the mixture was placed in a PCR thermocycler 
and heated to 25OC for 5 minutes, before being heated to 42oC for 30 minutes. After this the 
reverse transcriptase was inactivated by heating to 85oC for 5 minutes. 
 
2.2.2.9 – QPCR 
QPCR is a method to quantify the abundance of an mRNA by measuring fluorescence of 
incorporated fluorogenic probe or intercalating dye. The SYBR green dye emits fluorescence when 
intercalated with dsDNA, with the level of fluorescence directly proportional to the amount to 
dsDNA. 
During PCR amplification, dsDNA copies of the amplicon are produced which SYBR green can 
intercalate with. As more amplicons are produced each cycle, the level of fluorescence increases.  
A standard QPCR reaction used in this study is shown in Table 2.12. 
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REAGENT VOLUME 
cDNA   2.4 µL 
SYBR green Master mix (2x) 4 µL 
Forward Primer (100 pM) 0.4 µL 
Reverse Primer (100 pM) 0.4 µL 
H2O 0.8 µL 
Final reaction volume  8 µL 
Table 2.12 – Reaction mix for a standard QPCR reaction 
 
The threshold cycle (Ct) is the number of PCR cycles required for a SYBR green reaction to produce 
fluorescence signal above a background level (an example is shown in ). A relative level of mRNA 
abundance can be then inferred by comparing the Ct of a gene of interest to the Ct of a 
housekeeping gene (in this study GAPDH is used), which is not affected by conditions of the 
experiment. 
ΔCt = Ct (target gene) – Ct (housekeeping gene) 
ΔΔCt = ΔCt (condition 1) – ΔCt (condition 2) 
Fold change = 2-(ΔΔCt) 
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Figure 2.1 – Calculating threshold cycle for QPCR 
A typical QPCR experiment, with fluorescence of a reaction on the Y axis and cycle number on the 
X. Each reaction analyses the abundance of 1 target gene or 1 housekeeping gene. As the number 
of PCR cycles increases the amount of amplicon increases and therefore increases in fluorescence. 
After fitting a curve to the data points acquired the cycle at which the sample fluorescence 
reaches a threshold above background (Ct) 
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This method of quantifying gene expression assumes that the efficiency of the PCR reaction is 
close to 100%. Prior to use in my experiments, the efficiency of the PCR reaction for each primer 
pair was assessed using a standard curve method. In this method, template cDNA was serially 
diluted 1:5 with molecular biology grade water for use as a template for a QPCR reaction. The Ct 
for each dilution was then plotted against the dilution factor and the gradient of this graph was 
used to calculate efficiency using the formula below. Primers were only used for QPCR if the 
efficiency was greater than 80%. 
Efficiency (%) = (-1+10(-1/gradient))*100 
 
2.2.2.10 – Enzyme linked immunosorbent assay (ELISA) 
The concentration of secreted TNF-α was measured by sandwich ELISA. Between each step the 
wells were washed with ELISA wash buffer three times. All antibodies and the HRP:Streptavidin 
conjugate were diluted in 0.5% BSA PBS. 96 well ELISA plates were coated with 100 μL of TNF 
capture antibody overnight at 4oC. The wells were then washed and blocked with 100 μL of ELISA 
Blocking Buffer, for 2 hours at room temperature. After washing; 100ul of cell culture 
supernatants (some supernatants were diluted in 0.5% BSA to adjust the concentration of 
secreted TNF-α into the range of the standard curve) were added to the wells alongside serially 
diluted recombinant human TNF standards (10 ng/mL – 13 pg/mL) and a negative control of PBS 
0.5% BSA in triplicate, for two hours at room temperature. The plate was washed and then 100ul 
of biotin-conjugated secondary anti-TNF antibody for 1 hour at room temperature. After the next 
set of washes 100ul of HRP:Streptavidin conjugate was added to the wells for 1 hour at room 
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temperature. After this final set of washes the samples were developed using 100ul of TMB 
peroxidase substrate system (KPL Inc). The reaction was then stopped using 50 µL of 2M H2SO4 
and read at 450nm on an ELISA plate reader and analysed using GEN5 software. 
 
2.2.2.11 – Flow cytometry 
1 x 106 MDM cells were stimulated for a selected time and were harvested by scraping in 200 μL 
of cell dissociation buffer. The harvested cells were then pipetted gently to remove aggregates of 
cells. The cell suspension was then divided in half for separate staining mixtures and centrifugated 
at 2000 rpm for 3 minutes at 4oC. One aliquot of stimulated cells was then stained with 0.5μg of 
anti TNFSF9-APC antibody and 0.5μg of anti CD274-Alexfluor450 in 50μL of FACS buffer, while the 
other aliquot was stained with the same amount of isotype control antibody. The cells were then 
left for 30 minutes at 4oC in the dark to allow the antibodies to bind to the cell surface antigen. 
Cells were then fixed with FixPerm solution (Biolegend) for 15 minutes in the dark at 4oC and 
washed 3 times prior to being suspended in 100μL of FACS buffer. Fixed cells were then examined 
by using a Cyan flow cytometer (Beckman Coulter) and the Summit software package. The 
strategy for gating on single cells for analysis based on laser scattering is detailed in Figure 2.2. 
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Figure 2.2 – Flow cytometric gating strategy  
Single cell events were gated on by first selecting the population of events of forward scatter (FS) 
between 20K and 50K and a side scatter (SS) of between 15K and 45K, to exclude cellular debris 
from further analysis. This population was then gated further on the pulse width and FS to exclude 
doublet or multiple event acquisitions being further analysed. For each sample roughly 20000 
events for each sample were collected in this second gate for further analysis. 
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2.2.2.12 – Luminex 
Multiplexed cytokine bead assay for: CCL8 and CXCL10 were purchased from R&D and used in 
accordance with the manufacturer’s protocol. 
  
2.2.2.13 – Western blotting 
2.2.2.13.1 – Sample preparation 
2x106 MDM cells were seeded in each well of a 6 well tissue culture plate. After stimulation cell 
culture supernatants were removed and the cells washed twice in PBS. After washing, cells were 
lysed in 80µL of cold protein lysis buffer, supplemented with protease and phosphatase inhibitors. 
These lysates were then centrifuged in QIAshredder spin columns to shear genomic DNA, thereby 
decreasing viscosity of the samples. At this point samples were quantified for protein expression 
using a Bradford assay (BioRad) according to manufacturer’s instructions. 
 
2.2.2.13.2 – Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS is an amphipathic detergent which is able to associate with denatured protein and coat it in 
a charge. Allowing the proteins to be electrophoresis across a gel. 
Lysates were mixed with an appropriate volume of sample loading buffer (section) and boiled for 
10 minutes at 97oC to ensure denaturation of the proteins. After this samples were centrifuged 
at 13,000 rpm for 1 minute to pellet insoluble cell debris and were loaded onto a precast poly 
acrylamide gel (Biorad) and run at 100 V for 90 minutes. 
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2.2.2.13.3 – Protein transfer 
Polyvinylidene difluoride (PVDF) membranes (Bio-Rad) were washed briefly in methanol and placed 
under the gels. The gel/PVDF sandwich was then placed between layers of buffer soaked tissue 
(provided with the PVDF membrane) and placed in the Trans-blot turbo system-cassette. The cassette 
was then loaded into Trans-blot Turbo and proteins transferred to the membrane over 7 minutes at 
a constant of 25V and 2.5 A. 
 
2.2.2.13.4 – Immunoblotting 
PVDF membranes were blocked with blocking buffer (section 2.1.8) for 1 hour at room 
temperature. This coated areas on the membrane where protein had not been transferred from 
the SDS-PAGE gel. The membrane was then washed 3 times in western blotting wash buffer 
(section 2.1.8) for 5 minutes each time. The membrane was then incubated with primary antibody 
suspended in blocking buffer, overnight at 4oC.  Again the membrane was washed in western 
blotting wash buffer 3 times, before being incubated with a secondary HRP-conjugated antibody 
for 1 hour at room temperature. The membrane was then washed again and incubated with the 
chemiluminescent substrate for HRP ECL reagent (Thermo scientific) for 1 minute, before being 
visualised on a chemidoc. 
 
2.2.2.14 – Nuclear Cytoplasmic subcellular fractionation  
After stimulation cells were lifted from tissue culture plates using cell scraper into 1 mL of PBS 
and pelleted at 800g for 1 minute. The cell pellets were then gently resuspended in cold 
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Cytoplasmic Lysis buffer and left on ice for 10 minutes. The cell suspension was then subjected to 
centrifugation at 800g for 1 minute again and the supernatant which comprised the cytoplasmic 
fraction was siphoned off and stored. The pellet was then resuspended in nuclear wash buffer 
and left for 10 minutes at room temperature, after which the nuclear suspension was 
centrifugated at 800g for 1 minute to pellet the nuclei. The supernatant was then removed and 
the pelleted nuclei were lysed in nuclear lysis buffer. 
 
2.2.2.15 – Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation enables the quantification of DNA:protein interactions, by 
chemically joining the DNA and protein molecules in close proximity (cross-linking). These 
complexes can then be precipitated with antibodies specific to a DNA binding protein of interest. 
 
2.2.2.15.1 – Isolation of fixed nuclei 
10x107 of mature MDM were seeded onto 10 cm2 tissue culture dishes and left to adhere 
overnight and stimulated the following day.  After stimulation 1 mL of cell culture supernatant 
was removed for analysis by ELISA and cells were fixed with 1% (final concentration) 
formaldehyde (Sigma) in the remaining cell culture medium for 10 minutes. To quench the 
molecule cross-linking capacity of the formaldehyde 125mM Tris pH 7.5 (final concentration) was 
added to the cell culture medium, which after briefly mixing to ensure a complete quenching of 
formaldehyde was discarded. The cells were then washed 3 times in ice cold PBS, to remove the 
remaining Tris and formaldehyde. Fixed cells were then harvested by scraping in ice cold PBS 
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supplemented with protease and phosphatase inhibitors (Roche) and transferred into 1.5 ml 
lobind tubes (Eppendorf). Cells were then pelleted by centrifugation at 400g for 1 minute at 4oC 
and the supernatant discarded.  
In order to remove the cytoplasmic fraction the cell pellets were gently resuspended in ice cold 
Cytoplasmic Lysis buffer supplemented with protease and phosphatase inhibitors (Roche) and left 
on ice for 10 minutes. The cell suspension was then centrifugated at 800g for 1 minute again and 
the supernatant (the cytoplasmic fraction) was removed. The pellet was then resuspended in 
nuclear wash buffer and left for 10 minutes at room temperature, after which the nuclear 
suspension was centrifugated at 800g for 1 minute to pellet the nuclei. The supernatant was then 
removed and the pelleted nuclei were lysed in nuclear lysis buffer. 
 
2.2.2.15.2 – Chromatin fragmentation 
In order to break down the cross-linked chromatin into fragments that allows efficient QPCR 
reactions (~500bp fragments), nuclear fractions were sonicated at 20% amplitude on a vibracell 
sonicator (Sonics) for 8 x 12 second pulses. Between each round of sonication the fractions were 
incubated on ice for 1 minute to prevent the sample from overheating.  
 
2.2.2.15.3 – Immunopreciptation 
Chemically fixed protein:DNA complexes were isolated by immunoprecipation with Dynabeads 
Protein G (Invitrogen). 1 day prior to the nuclei isolation and sonication steps, Dynabeads were 
washed with ice cold Dynabeads blocking buffer three times. The beads were then suspended in 
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20µg/mL ChIP antibody or isotype control (Table 2.9) and left overnight rotating at 4oC. The 
following day the coated beads were washed 3 more times with dynabead blocking buffer, before 
being resuspended in 500µL of Nuclear lysis buffer and 100µL of sheared sample chromatin and 
left rotating at 4oC overnight. 
Samples were then centrifugated at 16000g for 1 minute and 200µL of the supernatant was 
retained for use as an input DNA control. The beads were then washed 5 times with ice cold RIPA 
buffer, supplemented with protease and phosphatase inhibitors followed by one wash with salt 
wash buffer .Beads were then centrifugated at 400g for 3 minutes and resuspended in 200µL of 
bead elution buffer and incubated at 65oC for 15 minutes, resuspending the beads every 2 
minutes. The beads were then centrifugated again at 400g for 3 minutes and the supernatants 
were extracted and incubated at 65oC overnight in lo-bind tubes (Eppendorf) to reverse the 
chemical cross-linking of the protein:DNA complexes. 
 
2.2.2.15.4 – DNA purification 
After reversing the cross-links DNA was purified using QIAquick PCR purification kit (QIAGEN) 
according to the manufacturer’s protocol and eluted in 200µL of molecular biology grade water. 
The immoprecipitation was then assessed by QPCR (2.2.2.9). 
2.2.2.15 – Luciferase assay 
Cells transfected with plasmid DNA or adenoviral plasmids containing luciferase were stimulated 
and cell culture supernatants removed. The cells were then lysed in 100μL of luciferase assay lysis 
buffer (section). 50μL of this was then removed and added to 120μL of luciferase assay buffer 
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(section) and 30μL of Luciferin (Promega) and luciferase activity assessed using a plate 
luminometer. After 40 minutes of repeated 1 second per well acquisition, Stop-and-Glo 
(Promega) reagent was added to the wells. The addition of this reagent, quenches the firefly 
luciferase activity but also provides a substrate for the control Renilla luciferase plasmid under 
control of a 760bp human thymidine kinase promoter (rL-TK). The Renilla luciferase activity was 
acquired for 1 second per well exposures for a further 40 mins. The Renilla luciferase activity was 
then used to normalise differences in transfections between the different stimulations and 
inhibitor treatments. 
 
2.3 – Bioinformatic and statistical methods 
2.3.1 – Microarray analysis 
Microarray image files were prepared by Oxford Gene Technology LTD (OGT) and analysed by 
Partek Genomic Suite®. Feature extraction file for each array were quantile normalised to account 
for inter array variation, prior to the statistical analysis using a multivariate ANOVA. 
Duplicate probes for genes and transcripts were filtered to a single probe which demonstrated 
the highest level of expression. 
 
2.3.2 – Microarray merging  
2.3.2.1 – Yugene 
Comparison between microarray datasets were done using the Yugene method (Cao et al., 2014). 
In this methods, all probes were ranked in terms of “expression” (fluorescence intensity when 
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probes bind to complementary sequences in fluorescently labelled cDNA)  and assigned a value 
based on the fraction of probes whose expression is less than the probe of interest (low 
expression values tending toward 0 and higher expressing values tending to 1). 
The log2 expression data from the microarray samples was taken from Partek Genomic Suite® and 
transformed by the Yugene function of the Yugene R package.  
 
2.3.2.2 – Z-score 
Log2 expression scores of all the probes were transformed using a Z-score transformation, which 
standardises two sets of values based on the mean of the sets and therefore allows comparisons 
between sets of data that vary greatly in magnitude. The z scoring was performed by the scale 
function in R, with the equation shown below where: x = expression a probe, X = mean expression 
of all probes in that data set and n = number of probes in the dataset. 
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2.3.3 – Principal Component analysis (PCA) 
The PCA method attempts to highlight the largest differences in multivariate datasets. To 
accomplish this the data for each sample is mean centred and then co 
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PCA analysis was accomplished using the PCA function of the “MixOmics” R package, with mean 
centred data, but without scaling (Le Cao et al., 2009, González, 2011). 
 
2.3.4 – Pearson correlation 
Pearson correlation statistics were calculated on the 1000 most variable genes (defined by the 
highest standard deviation between samples) on log2 expression values. The Pearson correlation 
matrix was computed using the “cor” function of R and a heatmap of these data was drawn by 
the “ComplexHeatmap” package. 
 
2.3.5 – Gene ontogeny analysis 
Microarray probe lists for each hierarchical cluster were transformed into the respective 
ENSEMBL gene ID and added as a search query to InnateDB (www.InnateDB.com) (Breuer et al., 
2013, Lynn et al., 2008, Lynn et al., 2010). 
 
2.3.6 – Transcription Factor motif enrichment 
Microarray probe lists for each hierarchical cluster were transformed into the respective 
ENSEMBL gene ID and assessed for transcription factor motif enrichment using HOMER. The 
program assessed the enrichment of transcription factor binding motifs between -2000bp and 
+500 bp from the transcription start site (TSS) of the gene. 
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 2.3.7 – Multiple alignment of syntenic DNA sequences 
Sequences syntenic to regions of human refseq DNA were acquired through the liftover tool in 
the UCSC genome browser. These sequences were then aligned using the Clustal Omega. 
(Goujon et al., 2010, Li et al., 2015, McWilliam et al., 2013, Sievers et al., 2011) 
  
2.3.8 – 3rd party data access-and credits 
PU.1, H3K27ac ChIP-seq tracks from human MDM were retrieved from (Pham et al., 2012) and 
H3K4me3, H3K4me1 ChIP-seq tracks and Dnase-seq data produced by the blueprint consortium 
(Saeed et al., 2014) was accessed through the UCSC browser.  
This study makes use of data generated by the Blueprint Consortium. A full list of the investigators 
who contributed to the generation of the data is available from www.blueprint-epigenome.eu. 
Funding for the project was provided by the European Union's Seventh Framework Programme 
(FP7/2007-2013) under grant agreement no 282510 – BLUEPRINT. 
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Chapter 3 – IL-10 modulation of LPS-induced transcription 
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3.1 – Introduction 
Dissecting the mechanisms macrophage responses to LPS have been most often  studied using 
macrophages derived of bone marrow of inbred mouse strains, using either M-CSF (which 
generates homogenous macrophage populations) or GM-CSF (which produces mixed populations 
of macrophage and dendritic cells (Helft et al., 2015). This approach allows the use of genetically 
modified (e.g. knock out) mouse strains to interrogate the roles of specific factors in the response, 
as well as reducing inter-individual variation. However, there are abundant differences in gene 
expression between mouse and human macrophages. Extrapolation from mouse studies to the 
behaviour of human macrophages in health or disease can therefore be difficult. 
Macrophages constitute an extremely heterogeneous population of cells, in terms of origin, of 
function and, patterns of gene expression. It is therefore naive to think that there exists a single 
archetypal macrophage population, which exists as a model for all subpopulations. Tissue 
resident macrophages from different anatomical sites display clear differences from one another 
and from bone marrow derived macrophages (Lavin et al., 2015b, van de Laar et al., 2016). 
However, certain core responses of macrophages appear to be shared. For practical and ethical 
reasons, large numbers of tissue resident macrophages are extremely difficult to obtain from 
healthy humans. Macrophages derived from patients with chronic inflammatory disease or 
cancer must be treated with caution because of the possible confounding effects of disease and 
treatment. 
In this thesis I wished to investigate the effect of IL-10 on primary human macrophages, because 
of the relevance of these effects to inflammation, resolution, health and, disease. I chose to use 
93 
 
 
macrophages derived from healthy donor monocytes using M-CSF, because these could easily be 
generated in large numbers and as relatively homogenous populations. Monocyte-derived 
macrophages (MDM) differentiated with M-CSF were expected to recapitulate at least some of 
the IL-10 responses of tissue-resident macrophages. Given the variety of methods for 
macrophage isolation, it is important to report the method of isolation and differentiation clearly, 
and to avoid excessive extrapolation of the results (Murray et al., 2014). 
 
3.2– Results 
3.2.1 – IL-10 selectively modulates LPS-induced gene expression 
The ability of IL-10 to inhibit LPS-induced gene expression has been the focus of many studies, 
generating a plethora of hypotheses for a mechanism for this action. In order to establish a 
mechanism for IL-10’s action it was first necessary to characterise the effects of LPS and    IL-10 
induced signalling on the macrophage transcriptional program. 
To investigate whether IL-10 is able to modulate the LPS-induced transcriptome, monocyte 
derived-macrophages (MDM) from 4 independent donors stimulated with LPS, IL-10 or in 
combination for one or four hours were analysed by the Affymetrix HuGene-1_0-ST V1 microarray 
platform (performed by Dr Tim Smallie). This platform contains 33296 oligonucleotide probes 
which have been annotated based on sequence to bind to 24832 unique mRNA transcripts 
corresponding to 24329 genes. 
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Due to the number of samples in the experiment, it was necessary to perform the chip 
hybridisation and image capture in a number of batches. In order to account for batch variation, 
the data from the microarray were pre-processed using quantile normalisation. In this method 
the relative intensity between the majority of microarray probes is assumed not to change over 
an experiment and therefore the distributions between samples are similar and can be 
normalised to one another. Figure 3.1 highlights the variation in probe intensity before and after 
quantile normalisation in the experiment. Although there was some variation in the distribution 
between samples (Figure 3.1A) after quantile normalisation the samples became comparable in 
distribution (Figure 3.1B). 
Once the data had been processed to enable comparison the intensities of the microarray probes 
were extracted. The samples were assessed for the similarity between donors and timepoints to 
ensure robust statistical comparisons later on in the analysis. To accomplish this, I utilised a 
Pearson correlation which analyses the strength of a linear correlation between two samples. All 
samples were compared in a pairwise fashion and the resulting Pearson values (structured as a 
matrix) were then hierarchically clustered (using an average linkage algorithm) to restructure the 
matrix, placing more similar samples adjacent to one another (Figure 3.2). 
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Figure 3.1 – Distribution of microarray probes across multiple chips prior and post quantile 
normalisation 
2x106 primary human macrophages from 4 independent donors were stimulated for 1 or 4 hours 
with 10 ng/mL LPS. Cells were then harvested for RNA and microarray analysis performed on the 
samples (Samples prepared by Dr Tim Smallie). The probe intensities on each microarray chip 
were extracted and the range of intensities are shown above, prior to quantile normalisation (A) 
and after quantile normalisation (B). 
 
96 
 
 
not separate. After 4 hours all samples clustered according to treatment. LPS alone and LPS and 
IL-10 stimulation were highly similar to one another but still segregated according to treatment 
rather than the donor, whereas the IL-10 treated samples were quite closely correlated with 
untreated samples. This correlation analysis did not identify any potential outliers and indicated 
that the data would allow for robust statistical analysis of the dataset. 
 
In order to visualise the differences between the stimulated transcriptomes of the microarray, I 
performed a principal component analysis (PCA) on the whole microarray using the log2 
expression values generated by Partek Genomics Suite and the R package “MixOmics” principal 
component analysis. A principal component analysis is a method of visualising variation between 
samples with large number of measurements per sample and reducing the variation seen into 
principal components (PC) that account for some of the differences in the data. Figure 3.3 shows 
the proportion of the dataset variation explained by each principal component. In these data it 
can be seen that the first three PCs explain over half of the variance of the dataset (0.45, 0.13 and 
0.06 for PC1, 2 and 3 respectively) with remaining components (4-28) each explaining less than 
0.05 of the data each. 
Knowing that the first three principal components explained the majority of the variation in the 
data, I examined the distribution of the data in the first three principal components, as shown in 
Figure 3.4. The most noticeable feature about the data is the clustering of the four donors 
according to treatment, indicating that the major changes to the transcriptome on stimulation 
are consistent between individuals. 
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Figure 3.2 – Pearson correlation of the LPS/IL-10 microarray 
2x106 primary human macrophages from 4 independent donors were stimulated for 1 or 4 hours 
with 10 ng/mL LPS. Cells were then harvested for RNA and microarray analysis performed on the 
samples (Samples prepared by Dr Tim Smallie). Individual samples across the experiment were 
compared using a Pearson correlation and the resulting correlation coefficient matrix was 
hierarchically clustered using an average linkage algorithm. 
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Figure 3.3 – Scree plot of principal components contribution to the variation in the IL-10 
microarray 
2x106 primary human macrophages from 4 independent donors were stimulated for 1 or 4 hours 
with 10 ng/mL LPS, 10 ng/IL-10 or in. Cells were then harvested for RNA and microarray analysis 
performed on the samples (Samples prepared by Dr Tim Smallie). Principal component analysis 
was then performed data and the eigenvalues of each component were plotted as a fraction of 
the variance of the whole dataset. 
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Figure 3.4 – PCA of LPS/IL-10 stimulated macrophage transcriptomes 
2x106 primary human macrophages from 4 independent donors were stimulated for 1 or 4 hours 
with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination. Cells were then harvested for RNA and 
microarray analysis performed on the samples (Done by Dr Tim Smallie). The raw data from the 
chips was quantile normalised and the variation in the dataset visualized by PCA (MixOmics 
package). 
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The first 2 PCs (corresponding to the two largest sources of variation) separated the one and four 
hour LPS-stimulated cells. While I expected the two timepoints to separate in the PCA, the fact 
that they separated in two separate principal components, indicates that the LPS modulated 
program of gene expression, significantly changes between the two timepoints.  
Another interesting feature of the PCA is the much smaller degree of change in the transcriptome, 
when cells were stimulated with IL-10. In the first two PCs there was very little difference between 
unstimulated cells and cells treated with IL-10 for one hour. At four hours there was a more 
pronounced change in both PC1 and PC2 between unstimulated and IL-10 stimulated cells. 
However, this shift was small in comparison to the changes caused by LPS stimulation. Cells 
treated with LPS or LPS and IL-10 in combination separated to some extent at one hour and more 
clearly at four hours. In each case the effect was orthoganol to the effect of LPS. At one hour, LPS 
stimulation caused a shift mostly in PC2, whereas the addition of IL-10 separated samples (albeit 
weakly) in PC1. At four hours the inverse was true; LPS stimulation separated samples in PC1 while  
the addition of IL-10 separated them in PC2. The orthoganol shifts caused by LPS and IL-10 may 
reflect broadly opposing effects on macrophage gene expression. 
The third PC did not describe differences according to time of stimulation or stimulus used, but 
instead separated the donors indicating that despite the identical conditions producing broadly 
similar effects (shown by PC1 and 2), on a genome wide scale the variation between individuals 
was still able to produce a significant effect. However, the level of this variation was much smaller 
than the effect of the stimuli (PC1; 45% variation, PC2; 13% variation, PC3; 6% variation). 
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Both the Pearson correlation analysis and principal component analysis indicated that most 
changes of gene expression in response to LPS and IL-10 were robust and reproducible between 
individuals, although some inter-individual variation was present. The effect of IL-10 on the 
macrophage transcriptome were small in comparison with the effects of LPS. Either in the 
presence or absence of LPS, effects of IL-10 on the macrophage transcriptome were greater at 
four hours than at one hour. 
I then examined how LPS and IL-10 stimulation affected expression of individual genes over time. 
The microarray was analysed by multivariate ANOVA, which took into account: sample 
stimulation, time, donor and, batch. Genes were filtered on significant changes in expression from 
unstimulated samples (>2 fold difference, ANOVA p-value<0.05) and I examined the number of 
shared modulated genes between the two time points. Figure 3.5 and 3.6 show that the 
macrophage transcriptome was more profoundly altered at the four hour timepoint compared to 
one hour time point. After one hour of LPS stimulation 214 genes were induced by LPS and 80 
genes were significantly repressed. After four hours 403 genes were induced by LPS and 833 
genes were repressed.  
IL-10 treatment produced a much smaller change in gene expression compared to LPS. IL-10 alone 
induced only 31 genes after one hour and 139 at four hours. It also repressed the expression of 
only 4 genes at one hour and 49 after four hours of stimulation. These results are not surprising, 
given the high Pearson correlations between unstimulated and IL-10 stimulated samples (Figure 
3.2).  
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Figure 3.5 – Comparison of LPS induced genes at 1 and 4 hours 
Microarray data was filtered on genes that changed expression on LPS stimulation (>2 fold 
change, ANOVA p-value <0.05). Venn diagrams showing the number of probes A) shared by those 
induced by LPS, B) repressed by LPS stimulation. 
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Figure 3.6 – Comparison of IL-10 induced genes at 1 and 4 hours 
Microarray data was filtered on genes that changed expression on IL-10 stimulation (>2 fold 
change, ANOVA p-value <0.05). Venn diagrams showing the number of probes A) shared by those 
induced by IL-10, B) repressed by IL-10 stimulation. 
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I then assessed whether the alterations in gene expression on stimulation were either due to the 
modulation of strongly (or weakly) expressed genes or whether the changes in gene expression 
were confined to genes intermediately expressed. To do this I correlated the Log2 of the gene 
expression for all unique genes from all conditions and plotted them against the unstimulated 
values (Figure 3.7).  From this I observed that the distribution of induced (and repressed genes) 
was spread across a range of levels in unstimulated cells. 
Both Pearson correlation and the principal component analyses indicated a somewhat restricted 
rather than general effect of IL-10 on the macrophage transcriptional response to LP. However, 
IL-10 is very well known to inhibit the LPS-induced expression of many genes. Therefore, I 
undertook a hierarchical clustering approach to examine in more detail the effects of IL-10 on the 
transcriptional response to LPS. I extracted the significantly LPS induced genes at 1 and 4 hours 
(upregulated >2 fold, p value <0.05) and hierarchically clustered according to the gene expression 
behaviour in response to LPS and IL-10. This analysis (Figure 3.8 and ) identified three distinct 
patterns of gene expression: transcripts that were inhibited by IL-10 (labelled as “A”), transcripts 
whose expression was not affected by IL-10 (labelled “B”) and transcripts whose expression was 
cooperatively regulated by LPS and IL-10 (labelled “C”).  
At the one hour timepoint 42% of the LPS induced genes were inhibited by IL-10 while an equal 
number of genes were unaffected by IL-10 signalling, with the remaining 19% being cooperatively 
regulated by LPS and IL-10. At four hours the pattern shifted and almost 3/4 of LPS induced gens 
were unaffected by IL-10 signalling. The proportion of IL-10 inhibited probes dropped to 20% and 
the cooperatively regulated cluster dropped to just over 8% of the total LPS-induced probes. 
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Figure 3.7 – Correlation plots showing changes in gene expression between stimulated and 
unstimulated macrophages 
2x106 primary human macrophages from 4 independent donors were stimulated for 1 or 4 hours with 10 
ng/mL LPS, 10 ng/mL IL-10 or in combination. Cells were then harvested for RNA and microarray analysis 
performed on the samples (Done by Dr Tim Smallie). Genes whose expression was altered greater than 2 
fold compared to unstimulated and whose change was statistically significant (ANOVA p value<0.05) are 
highlighted in red (for those upregulated) and blue (for those downregulated).  
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Figure 3.8 – Hierarchical clustering of LPS/IL-10 1 hour transcriptome. 
2x106 primary human macrophages from 4 independent donors were stimulated for 1 hour with 
LPS, IL-10 or in combination. Cells were then harvested for RNA and microarray analysis 
performed on the samples (Oxford Gene Technology). The raw data from the chips was quantile 
normalised and duplicate probes removed. LPS-induced genes (>2 fold above unstimulated, 
ANOVA p value<0.05) were clustered using average linkage hierarchical clustering. Z-scores of 
genes in each cluster shown in the box and whisker plots. 
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Figure 3.9 – Hierarchical clustering of LPS/IL-10 4 hour transcriptome. 
2x106 primary human macrophages from 4 independent donors were stimulated for 4 hour with 
LPS, IL-10 or in combination. Cells were then harvested for RNA and microarray analysis 
performed on the samples (Oxford Gene Technology). The raw data from the chips was quantile 
normalised and duplicate probes removed. LPS induced genes (>2 fold above unstimulated, 
ANOVA p value<0.05) were clustered using average linkage hierarchical clustering. Z-scores of 
genes in each cluster shown in the box and whisker plots. 
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These results were surprising, given PCA and Pearson correlation of the same data. However, 
given that the PCA and Pearson correlation do not filter on LPS induction, it is possible that the 
differences in this analysis were masked by largely unchanged expression of many genes at the 
global level. 
In order to understand this shift in IL-10 responsiveness to IL-10 I examined genes induced at one 
and four hours after LPS stimulation and assessed the change in proportion of IL-10 responsive 
clusters between these time points (Figures 3.10, 3.11 and 3.12). There was a clear redistribution 
of probes from IL-10 inhibited and cooperatively induced at one hour, to IL-10 insensitive at four 
hours (shown by the blue chords connecting the two sides). About half of the genes inhibited or 
cooperatively regulated by IL-10 at one hour became unaffected by IL-10 at four hours, while the 
majority of 1 IL-10 unaffected genes, remained so at four hours. Interestingly, 6 genes that were 
cooperatively regulated by IL-10 at one hour were inhibited by IL-10 at four hours, while no genes 
inhibited at one hour became cooperatively regulated at four hours. Some example genes are 
shown in Figure 3.12 To illustrate changes in the effect of IL-10  
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Figure 3.10 – Chord diagram of IL-10 clusters of probes induced by LPS at 1 and 4 hours 
Microarray expression data of genes induced by LPS hours (>2 fold induction, ANOVA p value 
<0.05) at both 1 and 4 hours were hierarchically clustered according to their response to IL-10. 
The change in cluster assignment between the two time points is shown by thickness of the 
chords joining the segments. 
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Figure 3.11 – Z-score distribution of 1/4 hours LPS-induced gene expression. 
Microarray expression data of genes induced by LPS hours (>2 fold induction, ANOVA p value 
<0.05) at both 1 and 4 hours were hierarchically clustered according to their response to IL-10.  
genes were then sorted according to their 1 hour and 4 hour clusters and normalised by Z-score. 
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Figure 3.12 – Representative gene expression profiles of 1 and 4 hours LPS-induced genes. 
Microarray expression data of genes induced by LPS hours (>2 fold induction, ANOVA p value 
<0.05) at both 1 and 4 hours were hierarchically clustered according to their response to IL-10.  
genes were then sorted according to their 1 hour and 4 hour clusters and normalised by Z-score. 
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3.2.2 – Validation of microarray data 
To evaluate whether the observations in the microarray were repeatable, I selected 18 genes that 
were induced by LPS at one hour and displayed  different responses to the addition of IL-10. The 
genes selected were: CCL8, CD274, CH25H, CXCL10, DUSP1, FFAR2, GADD45B, IFNB1, IL1A, IL1B, 
NFKBIA, NFKBID, NFKBIZ, NR4A2, TNF, TNFAIP3, TNFSF9 and, TNIP3 (highlighted in Figure 3.13). 
In order to assess the reproducibility of the QPCR assays in this experimental setup, 4 donors were 
assessed for the expression of the genes (mentioned above) compared to the housekeeping gene 
GAPDH (data shown in Figure 3.13). Many of the genes assayed had less than 1% the expression 
of GAPDH in unstimulated cells, with the lowest expression (NFKBIZ) reaching the threshold of 
fluorescence late into the QPCR reaction. On LPS stimulation, these genes consistently rose to a 
detectable level of expression. Since in unstimulated cells the transcripts were weakly expressed 
and difficult to detect, fold inductions compared to unstimulated conditions would be 
inappropriate to use to compare between samples. I therefore normalised the data sets to the 
LPS stimulated sample to allow more consistent comparisons between the data. I then assayed 
the levels of expression the genes by QPCR, on MDM from 4 independent donors stimulated in 
identical manner to those used in the microarray (10 ng/mL LPS, 10 ng/mL or in combination for 
one hour).  
The QPCR values were generated, by normalising to the housekeeping gene GAPDH and the LPS-
stimulated value (due to very low levels of transcripts in the unstimulated samples). These values 
were then analysed by Pearson correlation to the microarray values (also normalised to the LPS 
sample) to assess the similarity of the two methods (side by side comparison shown in Figure 3.14  
113 
 
 
 
Figure 3.13– Selection of genes for microarray validation 
LPS inducible genes were selected from each of the clusters on the basis of differential response 
to IL-10 and on a known role in the immune response, inflammation or, cell signalling. The 
position of each of the selected genes in the hierarchical clustering is indicated. 
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Figure 3.14 – Induction of gene expression on LPS stimulation 
Primary human macrophages of 4 independent donors were stimulated with LPS for one hour or 
left untreated and analysed for the expression of 18 LPS-induced genes and the housekeeping 
gene GAPDH. The expression of each gene was normalised with respect to GAPDH. 
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and a table of the Pearson correlations between the microarray and QPCR values is shown in 
Table 3.1). 
Most of the selected genes had high Pearson correlation coefficients between the microarray and 
QPCR values, with the highest correlation coefficient being NR4A2 with 0.991. The lowest 
correlation coefficient was that of CH25H which had a correlation coefficient of 0.729. The level 
of sensitivity between the two assays, was consistent for most of the genes assayed. However, 
the LPS/IL-10 cooperatively regulated genes TNFSF9, CCL8 and, CXCL8 showed a more 
exaggerated LPS/IL-10 cooperative regulation when measured by QPCR. Overall the genes 
selected demonstrated a high level of concordance with the microarray data set. 
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Figure 3.15 – Comparison of microarray and QPCR data 
Primary human macrophages of 4 independent donors were stimulated with LPS, IL-10 or in 
combination for one hour and analysed for the expression of 18 LPS-induced genes and the 
housekeeping gene GAPDH. The expression of each gene was normalised with respect to GAPDH 
and the LPS-stimulated sample. This was then compared to the LPS normalised expression of 
samples analysed by microarray. 
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Gene Name 
Pearson correlation 
between QPCR and 
microarray values 
NR4A2 0.991 
IFNB1 0.956 
NFKBID 0.992 
IL1A 0.958 
TNF 0.983 
IL1B 0.993 
TNFAIP3 0.987 
NFKBIZ 0.975 
DUSP1 0.962 
NFKBIA 0.996 
CH25H 0.729 
FFAR2 0.840 
TNFSF9 0.972 
TNIP3 0.914 
GADD45B 0.910 
CXCL10 0.876 
CCL8 0.927 
CD274 0.853 
 
Table 3.1 – Pearson correlation statistics between the QPCR and microarray data 
Primary human macrophages of 4 independent donors were stimulated with LPS, IL-10 or in 
combination for one hour and analysed for the expression of 18 LPS-induced genes and the 
housekeeping gene GAPDH. The expression of each gene was normalised with respect to GAPDH 
and the LPS-stimulated sample. This was then compared to the LPS normalised expression of 
samples analysed by microarray. Correlation between the two analyses was assessed by Pearson 
correlation. 
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3.2.3 – IL-10 inhibited genes display differential ontology to those cooperatively regulated by 
LPS/IL-10 
Gene lists from the microarray clusters (IL-10 inhibited, insensitive and cooperatively regulated) 
were assessed for gene ontology enrichment using InnateDB. This web-based program used an 
over-representation analysis, comparing the enrichment of GO terms associated with genes in a 
list to the GO terms in a randomly selected background list of genes. The p-value produced from 
this enrichment analysis was then adjusted with a Benjamini and Hochberg correction to take into 
account multiple testing. The enriched GO terms were then filtered on adjusted p-values lower 
than 0.05 and lists between clusters were compared.  
Of the terms significantly enriched in each of the one hour clusters (Figure 3.15) 4 terms appeared 
in multiple clusters. These terms include: “Cytokine-cytokine receptor signalling”, “TNF signalling” 
and “Toll-like receptor signalling” (full list see Appendix Table 8.1-8.8) All of these terms can be 
attributed to the up regulation of gene expression on LPS I initially filtered on. Interestingly, there 
were a number of enriched GO terms unique to each cluster (6, 28 and 2 for the IL-10 inhibited, 
insensitive and cooperative clusters respectively) indicating a divergence in function between the 
three groups. The GO terms enriched in the IL-10 inhibited cluster include “Epithelial signalling in 
H. pylori infection” and “transcriptional misregulation in cancer”. The IL-10 insensitive cluster 
includes other GO terms related to infection such as: “Leishmaniasis”, “Malaria” and “African 
trypanosomiasis”. However, there were other GO terms of interest in this including: 
“Adipocytokine signalling pathway” and “FoxO” signalling pathway” indicating that the genes 
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Figure 3.16 – Venn diagram of enriched gene ontology terms in the 1 hour clusters 
ENSEMBL IDs of genes induced by LPS (>2 fold increase, ANOVA p<0.05) at 1 hour and separated 
into 3 groups by hierarchal clustering. Each cluster was then assessed for gene ontology (GO) term 
enrichment through over representation analysis (performed by InnateDB) and filtered for a 
multiple-comparison corrected p-value <0.05. Full tables of these GO terms are located in the 
appendix (Tables 8.1-4). 
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 spared IL-10’s inhibitory effect may alter the cell signalling pathways possible in a macrophage 
after exposure to LPS. Between the IL-10 inhibited and unaffected genes, there was considerable 
overlap in enriched GO terms, indicating that there may be some degree of functional o 
ontological overlap. The two terms uniquely enriched in the LPS/IL-10 cooperative cluster were: 
“Hepatitis C” and “Primary bile acid biosynthesis”.  
The four hour enriched GO terms (Figure 3.17) were more distinct in comparison, with only one 
GO term shared between the clusters ("Cytokine-cytokine receptor interaction”) and a much 
lower enrichment of shared GO terms between two clusters. The inhibited IL-10 genes are 
enriched for “Notch signalling pathway” elements as well as those involved in “adherens junction” 
and “salmonella infection”.  
The IL-10 unaffected cluster has a notably higher number of enriched GO terms which is likely due 
to its much larger size compared to the other clusters. Similar to the one hour timepoint this 
includes ontology terms such as “Influenza A” and “Measles” indicating these genes were also 
upregulated in disease. However, there are also a number of GO terms which include cell 
signalling components including: “NF-κB signalling pathway”, “Apoptosis” and, “Prolactin 
signalling pathway”.  
The LPS/IL-10 cooperative cluster has 3 significantly enriched GO terms: “PPAR signalling 
pathway”, “PI3K-Akt signalling pathway” and, “Fatty acid biosynthesis”. This indicates that 
cooperatively regulated genes may be inducing specific signalling pathway components or 
regulators and treated macrophages may have different responses to stimulus after being treated 
with LPS and IL-10. 
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Figure 3.17 – Venn diagram of enriched gene ontology terms in the 4 hour clusters 
ENSEMBL IDs of genes induced by LPS (>2 fold increase, ANOVA p<0.05) at 4 hour and separated 
into 3 groups by hierarchal clustering. Each cluster was then assessed for gene ontology (GO) term 
enrichment through over representation analysis (performed by InnateDB) and filtered for a 
multiple-comparison corrected p-value <0.05. Full tables of these GO terms are located in the 
appendix (Tables 8.5-8) 
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3.2.4 – IL-10 dependent modulation of gene expression occurs at the primary transcript level 
After observing the effect of IL-10 on LPS-induced gene expression, I wanted to examine whether 
these patterns of gene expression represented changes in gene transcription or altered stability 
of mRNA transcripts. To accomplish this I used primary transcript (PT) QPCR to detect unspliced 
mRNA transcripts (Lipson and Baserga, 1989). PT-QPCR is used to quantify the abundance of the 
primary transcript of a gene. A primary transcript (PT) is the first product of gene transcription, 
which contains both the introns and exons of a gene and lacks 3’ polyadenylation, seen in mature 
mRNA (see Figure 3.18)(Lodish H, 2000). 
Due to the inclusion of introns in the PT, it can be distinguished from mature mRNA in QPCR, by 
using a primer that anneals within an intron or exon/intron boundary. However, this technique is 
susceptible to chromatin contamination which can also act as a template for the reaction. To 
reduce the chromatin contamination of the lysates, the RNA was DNase treated during isolation. 
In addition, control cDNA reactions were performed, in the absence of reverse transcriptase to 
assess the extent of chromatin contamination of the samples. These reactions did not have 
detectable or had extremely low levels of amplicon detection demonstrating the specificity of the 
PT reaction. 
Macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination for 30, 60, 
120, 240 or 480 minutes. Cells were then lysed and RNA from the cells was extracted. The 
harvested RNA was treated with DNase to reduce chromatin contamination. The RNA was then  
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Figure 3.18 – mRNA production and maturation schema 
Figure describing the production of mRNA. First RNA Pol II is recruited and released from the 
transcription start site and translocates from 5’ to the 3’ end of a gene. During this translocation 
it replicates the template strand of DNA into a reverse complementary RNA which is capped with 
a 7-methyl-Guanidine base, co-transcriptionally. After RNA Pol II reaches the end of the RNA is 
released (the primary transcript RNA). After release the RNA is then spliced, polyadenylated and 
processed into mature mRNA. 
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reverse transcribed and assessed for primary and mature transcript production by SYBR green 
QPCR. 
Examining the expression of two LPS-induced genes inhibited by IL-10 (TNF and IL1A), there was 
a clear peak of LPS-induced transcription at 60 minutes at both the level of primary and mature 
mRNA transcript levels (Figure 3.19). For TNF mature mRNA this level of expression steadily drops 
from this point till 480 minutes where it has just under a quarter of its maximal expression. IL1A 
retains its high expression after 120 minutes and then begins to lose its expression level, which 
returns to almost unstimulated levels by 480 minutes. At the PT level TNF behaves much the same 
as at the mature transcript level, with only minor differences in the level of expression at each 
timepoint. With IL1A, there is a differential pattern of induction at the PT compared to the mature 
transcript level. The PT expression is induced on LPS stimulation which then peaks at 60 minutes. 
After this the level of expression rapidly falls to 20% of its expression by 120 minutes. The PT then 
remains at this level at 240 minutes before disappearing at 480 minutes. 
In the case of IL1A PT, IL-10 directly inhibits primary transcript production at 30 and 60 minutes, 
before the LPS-induced transcription rapidly disappears at 120 minutes. In contrast to TNF this 
indicates that IL-10s inhibition of IL1A is entirely due to inhibition at the level of transcription. At 
the mature transcript level, both TNF and IL1A were inhibited by IL-10 at the 60, 120 and 240 
minute timepoints. While there appeared to be an IL-10 mediated inhibition at 30 and 480 
minutes, the decrease was not statistically significant. 
After noting the effects of IL-10 on the primary transcript of inhibited genes, I then selected 3 
genes (NFKBIA, IL1B and TNFAIP3) that were induced by LPS but not affected by IL-10 in the 
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Figure 3.19 – Primary and mature transcript mRNA of IL-10 inhibited 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 30, 60, 120, 240 or 480 minutes. The cells were then harvested for RNA and 
assessed for primary transcript and mature transcript mRNA levels of TNF, IL1A and GAPDH SYBR 
green QPCR and normalised to GAPDH between samples and the 60 minute LPS stimulation for 
each gene. Statistical comparisons between the LPS and LPS+IL-10 were conducted using a 
matched 2-way ANOVA, with a Bonferroni-correction for multiple comparisons. * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001. Data represents 3 independent donors and error bars 
represent SEM. 
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specific effect. All three of the genes examined showed high levels of expression at all timepoints 
post LPS stimulation, with NFKBIA and TNFAIP3 mature transcript levels peaking at 60 minutes 
and IL1B peaking at 120 minutes (Figure 3.20). On stimulation with LPS and IL-10 there no 
significant difference between the LPS stimulation at any timepoint for NFKBIA and TNFAIP3 
mature transcript, while IL1B demonstrated a statistically significant inhibition of gene expression 
at 240 minutes, which then returned to no significant difference by 480 minutes. At the PT level 
all three genes microarray, to examine whether the repression of transcription rate was a genome 
wide or gene were rapidly induced by LPS and expression levels peaked at 30 minutes. This level 
of LPS induction then slowly reduced to half the maximal expression (for NFKBIA and TNFAIP3) or 
little over a quarter (for IL1B). The addition of IL-10 did not affect the expression of NFKBIA 
significantly at any timepoint. TNFAIP3 PT was inhibited by IL-10 at   
240 mins although, this inhibition did not persist to the 480 minute timepoint. Interestingly, IL-10 
seemed to act cooperatively with LPS at the IL1B PT, significantly inducing the expression at 60 
minutes. This cooperation also appears at 30 minutes but is not statistically significant. Given the 
difference between the PT and MT of IL1B there is a hint that the IL1B transcripts are actually 
more unstable on IL-10 stimulation compared to LPS alone. 
I then selected 3 genes that were cooperatively regulated by LPS and IL-10 at one hour: TNFSF9, 
TNIP3 and CD274 (Figure 3.21). TNFSF9 MT displayed statistically significant LPS/IL-10 
cooperation at 60 and 120 minutes. At the level of PT there was a significant cooperative effect 
at 30 and 60 minutes, which steadily decreased over the course of 8 hours. In the samples treated 
with LPS alone TNFSF9 PT was induced in a biphasic manner, peaking at 30 and 120 minutes, with  
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Figure 3.20 – Primary and mature transcript mRNA of IL-10 insensitive genes 
106 primary human macrophages from 3 independent donors, were stimulated with 10 ng/mL LPS, 10 
ng/mL IL-10 or in combination for 30, 60, 120, 240 or 480 minutes. The cells were then harvested for RNA 
and assessed for primary transcript and mature transcript mRNA levels of IL1B, TNFAIP3, NFKBIA and 
GAPDH SYBR green QPCR and normalised to GAPDH between samples and the 60 minute LPS stimulation 
for each gene. Statistical comparisons between the LPS and LPS+IL-10 were conducted using a matched 2-
way ANOVA, with a Bonferroni-correction for multiple comparisons. * p<0.05. 
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Figure 3.21 – Primary and mature transcript mRNA of LPS/IL-10 cooperatively regulated genes 
106 primary human macrophages from 3 independent donors, were stimulated with 10 ng/mL LPS, 10 
ng/mL IL-10 or in combination for 30, 60, 120, 240 or 480 minutes. The cells were then harvested for RNA 
and assessed for primary transcript and mature transcript mRNA levels of TNFSF9, TNIP3, CD274 and 
GAPDH SYBR green QPCR and normalised to GAPDH between samples and the 60 minute LPS-stimulated 
for each gene. GAPDH between samples and the 60 minute LPS stimulation for each gene. Statistical 
comparisons between the LPS and LPS+IL-10 were conducted using a matched 2-way ANOVA, with a 
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Bonferroni-correction for multiple comparisons. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Error 
bars represent SEM. 
a reduction in expression at 60 minutes. With the MT LPS induction of the transcript slowly 
increased over four hours, before dropping to the same level as LPS+IL-10 by 8 hours.The levels 
of TNIP3 and CD274 induction were quite different between the donors analysed and therefore 
many timepoints lack statistical significance. However the PT of both TNIP3 and CD274 were 
significantly upregulated by LPS/IL-10 above LPS alone treatment at 60 minutes. In the case of 
CD274 PT the induction by LPS alone significantly overtook the LPS/IL-10 treated samples at 240 
minutes, before falling to the same level at 480 minutes. 
The induction of PT and MT by LPS at both TNIP3 and CD274 peaked at 240 minutes, slowly 
increasing after stimulation, before dropping to levels equal to LPS+IL-10 at 480 minutes. 
 
3.2.5 – IL-10’s effect on LPS-induced gene expression can be observed at the protein level 
In order to determine whether IL-10 mediated regulation of mRNA abundance was reproduced 
at the protein level, the following genes were analysed for protein production: TNF, CCL8, CXCL10, 
TNFAIP3, TNFSF9, CD274, TNIP3. Secreted levels of TNF, CCL8 and, CXCL10 protein were analysed 
by Luminex and ELISA, Intracellular TNFAIP3 and TNIP3 protein levels were assessed by western 
blotting. The cell surface expression of CD274 and TNFSF9 were assessed by flow cytometry. 
CD274, TNFSF9, TNIP3, CCL8 and CXCL10 are genes cooperatively regulated by LPS/IL-10 at the 
early timepoint, though all 4 appear to change pattern of expression later on (microarray values 
for these genes are included in section 8.3). TNFAIP3 is at all timepoints insensitive to IL-10 and 
TNF is well known to be inhibited by IL-10. Biosynthesis of IL1α and β is subject to an additional 
130 
 
 
inflammasome-mediated stage, which operates under a complex regulatory system. I therefore 
elected not to investigate the production of these proteins (Howard et al., 1991, Groß et al., 2012, 
Rathinam et al., 2012). Similarly, I did not assess the production of NFKBIA, as it is heavily modified 
and degraded by LPS signalling and therefore would be difficult to assess its de novo production. 
The protein TNFAIP3 is clearly induced by LPS and LPS+IL-10 by 60 minutes and peaked at 120 
minutes, reducing to close to unstimulated levels by 8 hours (Figure 3.22). LPS+IL-10 does appear 
to subtly inhibit the expression at 8 hours compared to LPS alone. In the IL-10 alone samples, 
TNFAIP3 was not induced at any timepoint compared to unstimulated cells. The cooperation of 
LPS and IL-10 in the expression of TNIP3 is visible at the protein level at 120 minutes. By 240 
minutes this cooperative induction is reduced and by 480 minutes the LPS and LPS+IL-10 
stimulated samples contain roughly equal amounts of TNIP3 expression. IL-10 alone stimulated 
samples do not induce TNIP3 at any of the timepoints tested. 
The secretion of the cytokines CXCL10 and TNF, all were significantly inhibited by IL-10 at 4 and 8 
hours (Figure 3.23).  TNF additionally displayed inhibition at 2 hours significantly. At the remaining 
timepoints, IL-10 appears to inhibit the cytokine production if LPS induces detectable cytokine 
production. These observations (while consistent) are not statistically significant.   
Examining expression of the inhibitory cell surface receptor CD274 (Figure 3.24), there is a clear 
induction on LPS and LPS+IL-10 stimulation between 4 and 8 hours. At 8 hours there is a 
statistically significant increase in mean fluoresce intensity (MFI) (a representation of mean 
surface expression per cell). This increase is not statistically significant in the median fluorescence 
intensity, or the percentage of CD274+ cells.  
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Figure 3.22 – Western blot of TNFAIP3 and β-actin after LPS/IL-10 stimulation 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 30, 60, 120, 240 or 480 minutes. The cells were then lysed and assessed for 
TNFAIP3, TNIP3, β-actin proteins expression by western blot. Representative of two 
independent experiments 
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Figure 3.23 – Secretion of cytokines CCL8, CXCL10, TNFα after LPS/IL-10 stimulation 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for: 60, 120, 240 or 480 minutes. Cell culture supernatants were then analysed by 
multiplex cytokine assay (CCL8, CXCL10) and ELISA (TNF) for cytokine secretion. Statistical 
comparisons between the LPS and LPS+IL-10 were conducted using a matched 2 way ANOVA, 
with a Bonferroni-correction for multiple comparisons (* p<0.05, ** p<0.01). 
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Figure 3.24 – Flow cytometry analysis of CD274 protein expression after LPS/IL-10 stimulation 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for: 60, 120, 240 or 480 minutes. Cells were then harvested and stained for CD274 
or with an isotype control. Cells were then assessed for antibody binding for flow cytometry 
gating on single cell events. Statistical significance between the conditions was computed using a 
matched 2-way ANOVA with Bonferroni correction for multiple comparisons (p<0.05 = *). 
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TNFSF9 on the other hand, is highly expressed and presented on the surface on co-stimulated 
cells as early as 60 minutes (Figure 3.25). This expression peaks (with both MFI and percentage of 
TNFSF9+ cells) at 2 hours before falling back to almost basal expression at 8 hours. LPS alone 
treated cells only begin to show detectable TNFSF9 on the surface at four hours and by eight 
hours this expression has diminished. In both the case of CD274 and TNFSF9, IL-10 alone did not 
induce expression of these proteins. (Representative histogram plots are located in the appendix 
section 8.4).  
Overall, the correlation of gene and protein expression was mixed. Several genes (TNF, TNFAFIP3, 
TNFSF9 and at the earlier timepoints, TNIP3) displayed a good correlation between gene 
expression and later protein expression. However other genes (CD274 and CXCL10) did not seem 
to behave similarly to their initial gene expression. Their expression at later timepoints (CD274 
became unaffected by IL-10 and CXCL10 inhibited by IL-10) did seem to more closely resemble 
their expression pattern. It can also be seen that these proteins became detectable (by flow 
cytometry or Luminex) later than the proteins that do behave similarly to their mRNAs. For 
example, CXCl10 and CD274 do not significantly from unstimulated samples until 240 minutes 
post stimulation. While conversely, TNFSF9 and TNF both are detectable above unstimulated 
levels at 120 minutes or before similar to their mRNA. It can be inferred that the LPS/IL-10 
cooperative proteins, will be the product of those genes which have high early expression, prior 
to autocrine signalling feeding back on gene expression. 
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Figure 3.25 – Flow cytometry analysis of TNFSF9 expression after LPS/IL-10 stimulation 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for: 60, 120, 240 or 480 minutes. Cells were then harvested and stained for TNFSF9 
or with an isotype control. Cells were then assessed for antibody binding for flow cytometry 
Gating on single cell events. Statistical significance between the conditions was computed using 
a matched 2-way ANOVA with Bonferroni correction for multiple comparisons (p<0.05 = *, p<0.01 
= **, p<0.001 = ***, p<0.0001 = ****) 
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3.2.6 – IL-10 is produced by LPS-stimulated macrophages 
Since many of the genes expressed by macrophages stimulated with LPS and LPS+IL-10, had 
similar levels of expression at both the protein and mRNA levels after four hours, I examined the 
production IL-10 by these macrophages, to determine whether IL-10 feedback might be affecting 
gene expression. 
It has previously been shown that IL-10 is itself induced by LPS stimulation in macrophages. Figure 
3.26 shows that there was a significant induction of IL-10 by LPS at 4 and 8 hours, roughly 
equalling 0.5 ng/mL and 2 ng/mL respectively. There was also a small increase of IL-10 production 
after 120 minutes. However, this was not statistically significant above the baseline production 
of IL-10 (50 pg/mL). 
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Figure 3.26 – Quantification of IL-10 secretion of LPS-stimulated macrophages 
106 primary human macrophages were stimulated with 10 ng/mL LPS for:  60, 120, 240 or 480 
minutes. Cell culture supernatants were then analysed by ELISA for cytokine secretion. Statistical 
comparisons between each LPS stimulation and unstimulated cells, was conducted with a Paired 
students t-test. * p<0.05, ** p<0.01. 
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3.3 – Discussion 
In this chapter I described that the IL-10 modulation of LPS-induced gene expression was a gene 
specific effect which can occur at the level of primary transcript. While these gene expression 
patterns have previously been described in (Murray, 2005), (Smallie et al., 2010) and (Dillow et 
al., 2014) these results have demonstrated these patterns of gene expression on a transcriptome 
wide basis. Several of the genes whose expression was inhibited by IL-10 (such as TNF, IL1A and, 
IFNB1) have been previously described as targets of IL-10 (Fiorentino et al., 1991, Varano et al., 
2000). However, NR4A2 has not previously been described as a target of IL-10-mediated inhibition 
of gene expression, this is potentially due to its low expression after long LPS stimulations (Data 
not shown) which are generally selected for gene expression studies. 
Results from Murray (2005) agree with the observation of IL-10 inhibiting gene expression at the 
level of primary transcript and sparing NFKBIA. DIllow et al. (2014) showed also demonstrated an 
LPS/IL-10 synergy of TNIP3 primary transcript mRNA in THP-1 cells stimulated with LPS/IL-10 for 
four hours and indicate that this synergy between stimuli required multiple cell signalling 
pathways including: JAK, PI3K and potentially, JNK. Exactly how these cell signalling pathways 
interact to produce this synergy is left undescribed; however, LPS and IL-10 are known to activate 
these signalling cascades (PI3K and JNK for LPS, JAK and PI3K for IL-10). They also note however 
that a number of cooperatively regulated genes require different signalling cascades, indicating 
that there are multiple mechanisms at work for a similar effect. 
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The majority of early induced LPS transcripts are inhibited by IL-10. However, there are a 
substantial number of transcripts that IL-10 cannot inhibit. GO analysis of each clusters indicates 
that these clusters represent distinct functional groups of genes, modulating macrophage 
phenotype to an anti-inflammatory/pro-homeostatic phenotype shown by lower production of 
inflammatory mediators such as TNFα and IL-6, while at the same time upregulating immune-
modulatory molecules (such as TNFSF9) and inhibitors of intra-cellular signalling (TNIP3). The 
benefit IL-10 exerting these diverse effects as opposed to a global inhibitory effect on LPS-induced 
gene expression is not immediately apparent. However, considering the number of negative 
feedback genes and pro-resolution/wound-healing genes upregulated by LPS, a general inhibition 
of gene expression, could make the return to a homeostasis more difficult. Since the genes 
required to return to homeostasis (such as IKBα to inhibit NF-κB activation) and would also be 
inhibited and lead to a cessation of inflammation, without necessarily dealing with changes to the 
surrounding tissue that would have occurred. 
Many genes described at one hour as displaying cooperative induction by LPS and IL-10 in the 
microarray, later demonstrated an IL-10 insensitivity or were inhibited by IL-10 at four hours. 
While this could indicate a false result with the one hour data, it is more likely that the four hour 
data represents a delayed induction of gene expression (illustrated in Figure 3.27). With this 
behaviour the LPS+IL-10 stimulated cells, reach the peak of gene expression early, which then 
begins to fall towards a steady state level. Meanwhile, the LPS-stimulated cells, remain at a low 
level of induction until the later timepoints, when autocrine signalling of cytokines induces a  
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Figure 3.27 - Comparison of inhibited gene expression and delayed induction of expression 
Illustration explaining the delayed induction behaviour exhibited by some 1 hour cooperatively 
regulated genes at later time points. Inhibited gene expression pattern is given for comparison. 
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similar response to the LPS+IL-10 stimulated samples. Examining two of these timepoints could 
give a misleading impression of the gene expression pattern.  
The data in this chapter demonstrates the differential regulation of the genes IL1A and IL1B by  
IL-10. IL1A/B are two highly related inflammatory cytokines and (in mouse and humans) are 
located adjacent to one another on chromosome 2 (Taylor et al., 2002) and co-expressed by 
macrophages (Mayer-Barber and Yan, 2017, Fenton, 1992). Previous studies have shown the IL-
10-mediated inhibition of IL1A PT expression (Murray, 2005). However, there is no study 
examining IL1B PT expression in response to IL-10 stimulation. The differential response of IL1A/B 
to IL-10 stimulation is interesting, given that both of these genes share a receptor for signalling 
exert a similar inflammatory function. There is some evidence to suggest that these two cytokines 
may differ in their ability to recruit different cell types and are released at different times during 
inflammation (Rider et al., 2011). In contrast to my observations other studies have shown IL1B 
to be inhibited by IL-10 in peripheral blood polymorphic mononuclear cells (Cassatella MA, 1993) 
and demonstrates increased expression in Il10 knockout mouse macrophages (McNab et al., 
2014). This could be in part due to the different experimental models: one using a mixed 
collection of myeloid cells the other using mouse macrophages). It would therefore be interesting 
to see if this finding could be replicated in other human macrophage models. 
The inhibition of secreted CCL8 and CXCL10 by IL-10 is contrary to what was observed at the 
earlier microarray timepoint (Figure 8.1). However, the pattern of expression of these cytokines 
is consistent to what was observed at the level of mRNA expression at the four hour timepoint 
(both inhibited by IL-10). This cannot totally be explained as a delayed induction mechanism, since         
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IL-10’s effect at the protein level is inhibitive and no cooperative regulation of cytokine expression 
was observed in response to LPS and IL-10. From the IL-10 ELISA data, a significant amount of IL-
10 was secreted by macrophages by four hours of LPS stimulation. The amount of IL-10 is roughly 
equal to 1/20 of the stimulating concentration I have used in my stimulation. However, this is an 
average value from a supernatant and does not indicate the concentration of IL-10 in proximity 
to the cells, which will certainly be much higher. This highlights that the four hour dataset in the 
microarray is unlikely to be showing gene expression induced purely from the stimulation. It is 
instead likely to be showing the result of many induced cytokines (such as IL-10 (Pattison et al., 
2012) and IFNβ1 (Chang et al., 2007)), signalling in an autocrine manner back onto the cells. In 
order to avoid this potential confounding factor, I selected to focus on the earlier timepoint to 
dissect the mechanisms of gene expression. 
While the focus of my experiments has been examining the effect of IL-10 on LPS induced genes, 
there are a considerable number of genes whose expression is repressed by LPS stimulation 
(Figure 3.5B). This phenomenon has been observed in other datasets but has not extensively 
studied in the literature (Chen et al., 2012, Sharif et al., 2007). The effect of IL-10 stimulation on 
these genes has not been investigated previously and could prove insightful to the mechanism     
IL-10 employs to alter gene expression. 
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Chapter 4 – The contribution of STAT3 and NF-κB to the regulation of 
gene expression by IL-10 
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4.1 – Introduction 
The mechanism by which IL-10 is able to inhibit gene expression has been a subject of contention 
for many years, with multiple mechanisms being proposed. The major consensus of the field is 
that it requires the activity of the protein STAT3 (Williams et al., 2007, Williams et al., 2004a, 
Niemand et al., 2003).  
There have been many studies which have implicated inhibition of NF-κB transcriptional activity, 
as a mechanism by which IL-10 inhibits inflammatory gene expression (Smallie et al., 2010, 
Driessler et al., 2004, Schottelius et al., 1999, Wang et al., 1995, Hutchins et al., 2015). Therefore, 
I hypothesised that a general repression of NF-κB activity would produce a similar specific 
inhibition of gene expression, as IL-10 stimulation. Depletion of STAT3 was predicted to impair 
both positive and negative effects of IL-10 on LPS-induced gene expression. 
To inhibit NF-κB activity, the inhibitor MLN-4924 was selected. This small molecule inhibitor 
targets the NEDD8 activating enzyme (NAE) complex, preventing the downstream NEDD8 
conjugation (Neddylation) to Cullin-1 (Cul-1). Neddylation of the Skp1: βTrCP: Cul-1 complex is 
required in order for the ubiquitination of phosphorylated IκBα which is generated in response to 
pro-inflammatory stimuli such as TLR agonists. In the absence of ubiquitination, IκBα is unable to 
be targeted by the proteasome and degraded. This leads to NF-κB# subunits being retained within 
the cytoplasm on TLR stimulation and, ablating NF-κB transcriptional activity (Read et al., 2000, 
Milhollen et al., 2010, Chang et al., 2012). The inhibition of Neddylation is known to affect cell 
signalling pathways other than NF-κB. By inhibiting the targeting of Cullin ring ligase to substrates, 
a number of cell processes and signalling pathways are affected such as the JNK (Zhao et al., 
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2011), ERK (Jin et al., 2013)and IRF signalling pathways (Song H, 2016). Therefore, treatment with 
MLN4924 may not specifically inhibit NF-κB activity. 
 
4.2 – Results 
4.2.1 – STAT3 motifs are enriched proximal to transcription start sites of genes cooperatively 
regulated by LPS and IL-10. 
The previous chapter reported that IL-10 modulates the expression of many LPS-induced genes, 
and that this differential modulation is visible at the level of mRNA primary transcript production. 
This indicates that IL-10 is able to modify gene expression at the transcriptional level. I therefore 
hypothesized that these gene expression profiles could be explained by motifs proximal to the 
transcription start site (TSS), which are likely to have low nucleosome occupancy and therefore 
allow for transcription factor binding. To detect transcription factor motif enrichment in the 
different clusters, I extracted the gene lists from each of the clusters and used the software 
Hypergeometric Optimisation of Motif EnRichment (HOMER) to detect the motifs present in the 
region -3000bp to +50bp around the TSS compared to randomly selected gene promoters as a 
background control. 
In all of the clusters examined (Table 4.1 – Table 4.3) there was an enrichment of NF-κB p65 
consensus binding sites above background. This was expected since NF-κB rapidly induces gene 
expression on LPS stimulation and the initial gene list was restricted to genes induced by LPS. Both 
the IL-10 inhibited and IL-10 insensitive clusters also had an enrichment for TATA-box binding. 
Interestingly, there was an enrichment of the STAT4 motif “TTCCNGGAA” in the LPS/IL-10  
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Name Motif 
P-
value 
Benjamini 
Q-value  
% of sequences with motif 
Target 
sequences 
Background 
sequences 
TATA-
Box  0.001 0.038 36.84% 16.07% 
NFkB-
p65   0.001 0.038 8.77% 0.89% 
NFkB-
p65  0.01 0.125 21.05% 7.70% 
Mef2b  0.01 0.191 21.05% 8.38% 
 
Table 4.1 – Enriched transcription factor motifs proximal to transcription start sites of IL-10 
inhibited genes 
Areas surrounding the transcription start sites (-300bp to +50bp) of genes inhibited by IL-10 were 
analysed for transcription factor binding site enrichment using HOMER.  The results were then 
filtered to factors with a p value of less than or equal to 0.01. 
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Name Motif P-value 
Benjamini 
Q-value 
% of sequences with motif 
Target 
sequences 
Background 
sequences 
NFkB-p65 0.00001 0.001 26.56% 7.39% 
HOXD13 
 
0.001 0.043 28.12% 11.62% 
HOXB13 
 
0.001 0.043 28.12% 11.77% 
TATA-Box 0.001 0.070 34.38% 17.49% 
SpiB 0.001 0.070 15.62% 4.81% 
Atf7 0.010 0.070 23.44% 9.70% 
CArG 0.010 0.130 12.50% 3.79% 
C/EBP:AP-1 
 
0.010 0.195 18.75% 8.09% 
Atf1 
 
0.010 0.225 25.00% 12.89% 
Meis1 
 
0.010 0.225 32.81% 19.18% 
ISRE 0.010 0.225 6.25% 1.20% 
RUNX 
 
0.010 0.234 17.19% 7.64% 
IRF2 0.010 0.236 7.81% 2.02% 
Table 4.2 – Enriched transcription factor motifs proximal to transcription start sites of IL-10 
unaffected genes 
Areas surrounding the transcription start sites (-300bp to +50bp) of genes unaffected by IL-10 
were analysed for transcription factor binding site enrichment using HOMER.  The results were 
then filtered to factors with a p value of less than or equal to 0.01. 
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Name Motif P-value 
Benjamini 
Q-value 
% of sequences with motif 
Target 
sequences 
Background 
sequences 
NFkB-p65 
 
0.001 0.082 35.00% 6.89% 
Oct4 
 
0.001 0.086 30.00% 5.47% 
STAT4 
 
0.001 0.086 45.00% 13.31% 
ISRE 
 
0.01 0.187 15.00% 1.34% 
Foxo1 
 
0.01 0.187 50.00% 23.00% 
 
 
Table 4.3 – Enriched transcription factor motifs proximal to transcription start sites of IL-10 
cooperatively regulated genes. 
Areas surrounding the transcription start sites (-300bp to +50bp) of genes cooperatively regulated 
by IL-10 and LPS were analysed for transcription factor binding site enrichment using HOMER.  
The results were then filtered to factors with a p value of less than or equal to 0.01. 
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cooperatively regulated gene cluster (Table 4.3). This binding motif is nearly identical to the STAT3 
binding motif (Table 1.1) This would allow the binding of STAT3 to the promoter to induce gene 
expression. 
Table 4.2 shows that a large number of transcription factor binding motifs were enriched at the 
TSS of the IL-10 unaffected genes. These include another known LPS activated transcription 
factor, AP-1. The variety of transcription factors in these promoters may indicate that this cluster 
is heterogeneously regulated.  
 
4.2.2 – Optimising siRNA knockdown of STAT3 in primary human macrophages 
Since STAT binding motifs were enriched at the promoters of LPS/IL-10 cooperative genes, I 
hypothesised that depleting STAT3 would inhibit cooperative gene regulation by LPS and IL-10. 
To deplete STAT3 in cells, I transfected siRNA oligonucleotides complimentary to the mRNA 
sequence of STAT3. To avoid potential off target or secondary effects, while allowing an efficient 
knockdown of STAT3, I titrated the oligonucleotide concentration transfected into the cells. 2x106 
primary human macrophages were transfected with 100, 200 or 400nM siRNA specific to STAT3 
(siSTAT3) or scrambled control (siControl) on day 3 of differentiation. On day 5 the cells were 
harvested for protein and these lysates were assessed for STAT3 knockdown by Western blotting. 
Figure 4.1 demonstrates that even at 100 nM concentrations, siSTAT3 almost totally depleted the 
STAT3 from the target cells, while there was little effect on the level of the NF-κB subunit p65.  
This indicated that depleting STAT3 with siRNA, would effectively deplete STAT3 without affecting 
the expression of NF-κB and avoid modulating the LPS response. 
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Figure 4.1 – Optimisation of siRNA mediated knockdown of STAT3 protein.  
Primary human macrophages were transfected with varying concentration (100, 200 or 400 nM) 
of oligonucleotides (either specific to the STAT3 mRNA sequence or a scrambled control) 3 days 
into the differentiation protocol and allowed to recover over a further 2 day period. 20 x 106 cells 
from each point were harvested for western blotting. Representative blot of 2 independent 
experiment. 
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4.2.3 – Depletion of STAT3 prevents IL-10 mediated inhibition and cooperative regulation of 
LPS-induced genes 
To reduce off target effects of the siRNA I opted to use the lowest concentration (10 nM) of 
oligonucleotides for transfection, while retaining a high level of knockdown at the protein level.  
After confirming the efficacy of the siRNA depletion, I examined how IL-10 signalling affects LPS-
induced gene expression in cells deficient for STAT3. As Figure 4.2 shows, the knockdown of STAT3 
greatly changed the patterns of gene expression, in response to IL-10. Both cooperative and 
inhibitive effect of IL-10 on gene expression were impaired or lost in cells depleted of STAT3 
(shown in detail Figure 4.3). This indicates that the effects of IL-10 on LPS-induced gene expression 
are strongly dependent on STAT3. In contrast the genes that are insensitive to IL-10’s effects (IL1B, 
, NFKBIZ, DUSP1, NFKBIA) were unaffected by the depletion of STAT3. 
On stimulation with LPS many of the IL-10 inhibited and insensitive genes, exhibited a statistically 
significant increase in expression, when depleted of STAT3 compared to siControl (Figure 4.3). 
This highlights that even at this early timepoint there may be IL-10 autocrine feedback in the LPS-
stimulated samples. However, in the LPS/IL-10 cooperatively regulated genes, there was no 
alteration in expression in LPS-stimulated cells, between the siRNA treatments. If IL-10 feedback 
was occurring significantly, there would have been a downregulation of the LPS response when 
macrophages were depleted of STAT3 and IL-10 insensitive genes would display no significant  
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Figure 4.2 – Expression of key LPS/IL-10 responsive genes in primary human macrophages 
depleted of STAT3. 
Primary human macrophages of 3 independent donors were transfected with 10 nM control 
oligonucleotide or siRNA targeting STAT3, on day 3 of differentiation and left to recover for a 
further 2 days. On day 5 the cells were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 1 hour. Cells were then harvested for RNA and the expression of genes listed 
were assessed by SYBR green QPCR and normalised to GAPDH for each sample and to LPS treated 
siControl.  
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Figure 4.3 – Gene expression in siRNA treated macrophages 
Primary human macrophages of 3 independent donors were transfected with 100 nM control 10 ng/mL LPS, 10 ng/mL IL-10 or in combination 
for 1 hour. Cells were harvested for RNA and the expression of the genes; NR4A2, IFNB1, NFKBID, IL1A, TNF, IL1B, TNFAIP3, NFKBIZ, DUSP1, 
NFKBIA, CH25H, FFAR2, TNFSF9, TNIP3, GADD45B, CXCL10, CCL8, CD274 were assessed by SYBR green QPCR. Normalised to GAPDH for each 
sample and to LPS treated siControl sample. Statistical significance was calculated with Students t-test (*= p<0.05, **=p<0.01, ***=p<0.001, 
****= p<0.0001). 
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upregulation. However, this is not the case, as none of the LPS/IL-10 cooperative genes show a 
statistically significant difference between siRNA treatments after LPS stimulation and of the IL-
10 insensitive genes only TNFAIP3 is significantly upregulated on STAT3 depletion.   
Interestingly, the cooperative induction of CXCL10 mRNA by LPS and IL-10 stimulation remains in 
macrophages depleted of STAT3. On closer examination of the expression data (Figure 4.4) there 
is a large variation in induced gene expression between the donors. Between these 3 donors; two 
display a lesser LPS/IL-10 cooperativity with reduced STAT3, while one donor has an increased 
LPS/IL-10 cooperativity. 
 
4.2.4 – IL-10 inhibits NF-κB activity as detected by luciferase reporter constructs 
Since inhibition of the NF-κB transcription factor activity has been implied by multiple studies to 
be the main mechanism of IL-10’s suppressive activities, I hypothesized that the differential 
effects of IL-10 on LPS-induced gene expression could be explained by the differential 
requirement of NF-κB. If this hypothesis was correct, then inhibiting the NF-κB pathway would be 
able to replicate IL-10’s inhibitory activity on gene expression while simultaneously sparing genes 
that were IL-10 insensitive or demonstrated LPS/IL-10 cooperativity. 
To first assess whether IL-10 is able to inhibit NF-κB activity, I transduced an adenoviral luciferase 
reporter containing 4 artificial NF-κB consensus motifs (“GGGAATTTCC”) upstream of the 
luciferase coding sequence into primary human macrophages. On activation of the NF-κB  
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Figure 4.4 – Expression of CXCL10 in cells depleted of STAT3 
Primary human macrophages of 3 independent donors were transfected with 10 nM control 10 
ng/mL LPS, 10 ng/mL IL-10 or in combination for 1 hour. Cells were harvested for RNA and the 
expression of CXCL10 were assessed by SYBR green QPCR. Normalised to GAPDH for each sample 
and to LPS treated siControl sample. 
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Figure 4.5 – Activity of an NF-κB luciferase reporter construct in response to IL-10 
105 primary human macrophages were transduced with an NF-κB luciferase reporter encoding 
adenovirus on day 5 of differentiation and rested overnight. The following day the cells were 
stimulated with LPS or IL-10 alone or in combination for 120 minutes. Cells were lysed and 
assessed for luciferase activity. Graph represents 3 independent donors. Statistical significance 
was determined by unpaired students t-test (*= p<0.05, **** = p<0.0001). 
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pathway, the transcription factor is able to be recruited to the viral plasmid and induce the 
transcription of luciferase. This production of protein can then be assessed by the production of 
luminescence in the cell lysates, caused by the breakdown of luciferin by luciferase. 
On stimulation with LPS (Figure 4.5) the reporter showed a significant (p<0.0001) 20 fold 
induction in luciferase activity, indicating a strong activation of the NF-κB pathway. Stimulation 
with IL-10 alone did not significantly alter the luciferase activity above unstimulated levels (p = 
0.92). IL-10 significantly (p= 0.02) impaired the activation of the NF-κB reporter by LPS. 
 
4.2.5 – Neddylation inhibitor MLN-4924 can inhibit LPS-induced gene expression on co-
treatment, through inhibiting NF-κB translocation to the nucleus 
After establishing that IL-10 is able to inhibit NF-κB activity, I wanted to examine whether the 
general inhibition of NF-κB using a chemical inhibitor could replicate the effects of IL-10 on LPS-
induced gene expression. For this purpose, I used the compound MLN-4924, which was previously 
shown to potently inhibit NF-κB (Chang et al., 2012, Milhollen et al., 2010). To assess the potency 
of the inhibition, macrophages were transduced with an adenovirus, containing in its genome a 
luciferase gene with an upstream promoter region containing 4 concatenated NF-κB motifs (κB-
luc reporter). Figure 4.6 shows that LPS stimulation caused an increase of the luciferase reporter 
transcription. This upregulation is then significantly diminished on treatment with MLN-4924, in 
a dose dependent manner. At the highest two doses (1 and 2 μM) the luciferase activity was 
almost indistinguishable from the luciferase activity in unstimulated cells. 
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Figure 4.6 – MLN-4924 inhibits an NF-κB luciferase in a dose dependent manner 
105 primary human macrophages were transduced with an NF-κB luciferase reporter encoding 
adenovirus on day 5 of differentiation and rested overnight. The following day the cells were 
stimulated with LPS in the presence of varying doses of MLN-4924 for 120 mins. The cells were 
then lysed and the lysates were assayed for luciferase activity. Graph shows means of 4 technical 
replicates for 3 independent donors. Statistical significance compared to the DMSO+LPS treated 
samples was calculated using 1 way ANOVA (* = p<0.05, ** = p<0.01, *** = p<0.001). 
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It has previously been shown that MLN-4924 treatment is able to block NF-κB induced gene 
expression through stabilising phosphorylated IκBα and therefore restraining NF-κB in the 
cytoplasm  (Chang et al., 2012).  However, these experiments were done with immortalised cell 
lines and with 6 hour preincubation with the inhibitor prior to LPS stimulation. To examine 
whether NF-κB was retained in the cytoplasm in our experimental conditions, I elected to treat 
macrophages with LPS with 2 μM MLN-4924 or a vehicle control for one hour. After stimulation, 
the cells were harvested and fractionated into their nuclear and cytosolic lysates. These lysates 
were then analysed by SDS PAGE and western blotting for the NF-κB subunit p65 and loading 
controls Lamin and Tubulin as indicators of the integrity of nuclear cytosolic fractions. 
On LPS stimulation of macrophages there was a clear translocation of p65 into the nuclear 
fraction, which was heavily abrogated by co-treatment with MLN-4924 (Figure 4.7). In both 
unstimulated macrophages and macrophages treated with LPS and MLN-4924, a small amount of 
p65 was detected in the nuclear fraction.  
To investigate what other effects MLN-4924 could have on LPS signalling cascades, I stimulated 
macrophages with LPS in the presence of 2µM MLN-4924 or DMSO control for 15, 30, 60 or, 120 
minutes and analysed the phosphorylation of JNK, p38 MAPK and IκBα by western blot (Figure 
4.8). The addition of MLN-4924 did not dramatically alter the phosphorylation state of p38 MAPK 
or JNK before the 2 hour timepoint. After two hours the addition of MLN-4924 led to a sustained 
JNK phosphorylation compared to the DMSO treated control. On LPS stimulation there was a 
noticeable loss of IκBα protein in the DMSO treated samples. This loss of IκBα was abrogated by 
the addition of MLN-4924 and was accompanied by the accumulation of phosphorylated-IκBα in  
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Figure 4.7 – MLN-4924 inhibits LPS-induced p65 nuclear translocation 
2x106 primary human macrophages were stimulated with LPS in the presence of 2 μM MLN-4924 
or DMSO control for 1 hour. Cells were then harvested and samples were fractioned into nuclear 
and cytosolic fractions, which were then analysed for the levels of p65, Lamin and Tubulin by SDS 
PAGE and Western blot. Representative blot of 3 experiments 
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Figure 4.8 –The effect of MLN-4924 on LPS induced signalling cascades 
2x106 MDM macrophages were stimulated with LPS and DMSO or 2 μM MLN-4924 for: 15, 30, 60 
or, 120 minutes. Cells were then lysed and the abundance and phosphorylation of MAPK/IKB 
proteins were assessed by western blotting. Blot is representative of two independent 
experiments 
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the cells. These results suggested that prolonged incubation of macrophages with MLN-4924 
could result in off -target effects on the JNK pathway, for example by impairing the expression of 
a negative feedback of this pathway. In order to avoid the effects of sustained JNK signalling (and 
potential other off-target effects) I elected to examine only the one hour timepoint with this 
inhibitor. 
Since MLN-4924 is able to inhibit the translocation of NF-κB in macrophages by 60 minutes post 
LPS stimulation, I wanted to investigate whether MLN-4924 was able to inhibit non-reporter gene 
expression at this time point. To assess this I stimulated macrophages in the presence of DMSO 
or 2µM MLN-4924 for 60 minutes and then measured secreted TNFα and the expression of TNF 
mRNA. TNF has been previously shown to be highly NF-κB dependent for its transcription and the 
secretion of the protein by macrophages is detectable by ELISA by 60 minutes (Andreakos et al. 
(2004), Smallie et al. (2010)). Figure 4.9 shows that on LPS stimulation TNF mRNA and protein 
were potently upregulated. The addition of DMSO did not alter the expression of TNF at the 
protein or mRNA level in unstimulated cells, but significantly diminished the response to LPS 
(reducing TNFα secretion by over 80% and inhibiting TNF mRNA upregulation by 90%).  
 
4.2.6 – MLN-4924 inhibits a significant proportion of the LPS immediate early transcriptome 
After optimizing the concentration of MLN-4924 to maximally inhibit NF-κB pathway at the one 
hour time point, I aimed to determine how much of the LPS response was dependent on the NF-
κB pathway and whether the genes that did require NF-κB corresponded to the genes inhibited 
by IL-10. 
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Figure 4.9 – MLN-4924 inhibits TNF gene expression and protein secretion 
106 primary human macrophages were stimulated with LPS for 60 minutes in the presence of 2 
μM MLN-4924 or vehicle control for 60 minutes. A) Cell culture supernatants and assayed for 
TNF-α production. B) RNA from cells was purified and analysed for TNF gene expression. Graph 
shows the means of 3 independent experiments. Statistical significance was calculated using 
Students t-test (**=p<0.01, ****= p<0.0001).  
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2x106 primary human macrophages from 3 donors were stimulated for 60 minutes with LPS or 
LPS in combination with 0.5 μM or 2 μM MLN-4924, after which cell culture supernatants were 
removed and cells harvested for RNA. The RNA was then processed and analysed by two colour 
microarray by Oxford Gene Technology. The feature extraction files then analysed by Partek 
Genomics Suite. The data was quantile normalised to remove cross microarray chip variation 
(distribution of probes before and after quantile normalisation are shown in Figure 4.10A and B). 
In order to assess the similarity of the samples prior to analysis by ANOVA, I performed a Pearson 
correlation between all samples and hierarchically clustered the results using an average linkage 
algorithm. Figure 4.11 shows that all samples demonstrated a high level of similarity to one 
another with all Pearson correlation values exceeding 0.95. It is also apparent from the 
hierarchical clustering that two of the donors are more similar than the third, which is placed in 
a separate cluster. This difference is particularly observable between the unstimulated Donor #7 
and Donors #5 and #6. However, the variation between all sample conditions was extremely low 
(similar to the microarray in chapter 3) and therefore the differences between donors may be 
exaggerated by the hierarchical clustering. The differences between the sample conditions was 
minimal, but this could be due to a low number of genes being modulated by LPS at this timepoint. 
 To further assess the sources of variation in this dataset I performed a PCA between all samples 
(Figure 4.12). In this analysis the first PC segregated donor #7 from donors #5 and #6, while a 
combination of PC2 and PC3 segregated the unstimulated and the LPS stimulated samples. This 
indicated that the main source of variation in the dataset is due to differences in gene expression 
between donors which would weaken the robustness of any statistical comparisons between  
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Figure 4.10 – Distribution of probe intensities in the LPS/MLN microarray before and after 
quantile normalisation 
2x106 MDM from 3 independent donors were stimulated with LPS and DMSO, 0.5 μM or, 2 μM 
MLN-4924 and RNA extracted for microarray analysis (performed by Oxford Genomic 
Technologies). Differences in probe intensities between the arrays were normalised using 
quantile normalisation. A) The variation the probe intensities across the Agilent dataset before 
quantile normalisation. B) The variation the probe intensities across the Agilent dataset after 
quantile normalisation. 
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Figure 4.11 – Pearson correlation between samples in the LPS/MLN microarray 
2x106 MDM from 3 independent donors were stimulated with LPS and DMSO, 0.5 μM or, 2 μM 
MLN-4924 and RNA extracted for microarray analysis (performed by Oxford Gene Technology). 
Individual samples across the experiment were compared using a Pearson correlation and the 
resulting correlation coefficient matrix was hierarchically clustered. 
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Figure 4.12 – PCA of the LPS/MLN microarray 
2x106 MDM from 3 independent donors were stimulated with LPS and DMSO, 0.5 μM or, 2 μM 
MLN-4924 and RNA extracted for microarray analysis (performed by Oxford Gene Technology). 
Data were background corrected, quantile normalised and, the variation in the dataset visualized 
by PCA (MixOmics package). 
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treatments. However, there is significant differences in gene expression between stimulated and 
unstimulated samples indicating that using a statistical comparison between the two conditions 
would be possible but differences may be masked by donor variation. 
 
To examine the LPS response, probes were selected that had a significant upregulation of gene 
expression by LPS (>2 fold above unstimulated and ANOVA p<0.05), similar to the previous 
microarray.  The probes that passed these criteria (representing 353 unique genes) were then 
organised into clusters using an average linkage hierarchical clustering using the program Genesis.  
Figure 4.13 shows that the results of the hierarchical clustering can be split into 3 major clusters, 
shown as D, E and F (example genes are shown in Figure 4.14). Cluster D shows a clear   dose 
dependent inhibition of LPS-induced gene expression indicating a strong dependency on NF-κB 
transcription factor activity. This behaviour of gene expression is exhibited by the genes IL1A and 
TNFSF9 (shown in Figure 4.14). Cluster E does not show a clear dose dependent sensitivity to 
MLN-4924 treatment but does contain probes that exhibit a decrease in mRNA abundance on 
MLN-4924 treatment. This decrease however is only moderate compared to cluster D and does 
not appear to be dose dependent (highlighted in Figure 4.14 by the genes KFL6 and FOS). Cluster 
F showed an unexpected pattern of gene expression; MLN-4924 upregulating LPS-induced gene 
expression in a dose dependent manner (shown in Figure 4.14 by AREG and TNFSF15). 
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Figure 4.13 – Hierarchical clustering of LPS/MLN microarray 
2x106 primary human macrophages from 3 independent donors were stimulated for 1 hour with 
LPS in the presence of; DMSO, 0.5 μM or 2 μM MLN-4924. Cells were then harvested for RNA and 
microarray analysis performed on the samples (Oxford Gene Technology). The raw data from the 
chips was quantile normalised and the LPS-induced probes (>2 fold above unstimulated, ANOVA 
p value<0.05) were clustered using average linkage hierarchical clustering. 
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Figure 4.14 – Effect of MLN-4924 on gene expression of select LPS-induced genes 
2x106 primary human macrophages from 3 independent donors were stimulated for 1 hour with 
LPS in the presence of; DMSO, 0.5 μM or 2 μM MLN-4924. Cells were then harvested for RNA and 
microarray analysis performed on the samples (Oxford Gene Technology). Select probes from the 
hierarchical clusters: IL1A and TNFSF9 (MLN-4924 sensitive), KFL6 and FOS (MLN-4924 
unaffected), AREG and TNFSF15 (MLN-4924 upregulated). 
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4.2.7 – Comparing the effect of IL-10 and the inhibitor MLN-4924 on the transcriptome of LPS 
activated macrophages 
On observing that MLN-4924 is able to modulate LPS-induced gene expression both positively and 
negatively, I wanted to assess the similarity between the LPS+IL-10 and LPS+MLN-4924 
transcriptomes to determine whether IL-10’s effect on gene expression could be explained by a 
general inhibition of NF-κB. The initial problem with this comparison is that the experiments were 
done with different donors, at different times and on different microarray platforms making 
direct comparisons between the samples inappropriate. To counter this problem; probe IDs of 
the two microarrays were annotated with the corresponding ENSEMBL transcript ID and the 
probes that detected transcripts only in one of the microarrays were removed. This filtered down 
33297 probes in the Affymetrix (IL-10) microarray and 50599 probes in the Agilent (MLN-4924) 
microarray to 21372 probes covering common transcripts.  This allowed me to examine the 
common areas of the microarrays more easily and prevented probes unique to one of the 
platforms from acting as confounding factors in further analysis. 
 Examining the expression frequency of the common probes between the two platforms (shown 
in Figure 4.15 for representative donors unstimulated samples), it becomes apparent that the 
range of expression levels reported by the two platforms, has a strikingly different distribution 
(seen in Figure 4.15). This effect is most likely due to the differences in the method of detection 
of RNA-probe hybridization since there are a number of weakly expressed genes in the Agilent 
array that do not fall in a similar pattern to the Affymetrix array. The data were further filtered to 
remove probes that reported below the detection threshold in all of the samples of one or both 
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of the microarray, which altered the distribution of probe intensities to a more comparable state 
(Figure 4.15 shown as a red line). 
As Figure 4.15 shows, even with the filtering of probes below the detection threshold, the range 
of expression is different between the two platforms (between 5-12 log2 expression in the 
Affymetrix and between 2-15 log2 expressions on the Agilent platform). To account for the 
differences in reported expression the datasets were normalized by two methods: YuGene and Z-
score.  
The “YuGene” transformation ranks the absolute expression of each gene and expresses it as a 
cumulative proportion of the total number of probes, with the lowest expressing transcript being 
close to 0 and the highest expressed transcript approaching 1. Using this method contracts the 
differences in the range of expression onto a comparable scale and reduces the differences in 
absolute expression reported while preserving the pattern. As Figure 4.15 shows, this 
transformation reduces the data from each of the microarrays with different intensities onto a 
similar scale. 
The “Z-score” normalization expresses each transcript expression as a standard deviation of the 
whole sample mean”. This method again contracts the ranges in expression to comparable scale, 
but the transformation requires a near Gaussian distribution to prevent distortion toward the 
extremes edges of the transformation. 
After transforming the data, a principal component analysis was performed on the data to assess 
whether the cross platform variation was reduced to allow a direct comparison between the data  
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Figure 4.15 – Density plot of gene expression between the platforms, in unstimulated 
macrophages, before and after transformation. 
Microarray probes detecting common RNA transcripts between the two microarray platform (Agilent and 
Affymetrix) were selected, the expression values of all probes or all those above detection threshold in 
both microarrays were transformed using either; Yugene or Z-score normalisation. The data was then 
presented as density histograms with fraction of total number of probes on the Y axis and level of gene 
expression on the X axis (shown as either Log2 value, Yugene value, or Z-score). 
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sets. Examining the first 3 principal components of all the data set transformations and filtering 
in Figure 4.16 I observed that over 90% of the variation can be explained by the first principal 
component in all of the transformations. Looking at the resulting plots of the PCA data (Figure 
4.17) this major source of variation is in fact the array these samples were performed on. This 
indicates that none of the transformations removes the effect caused by the different platforms 
and that integrating the datasets together is unsuitable therefore they must be considered in 
future analysis separately.  
Interestingly, the second principal component in this analysis seems to be the stimulus added to 
the samples, with unstimulated and IL-10 alone samples clustering in the same area of the second 
principal component distinct from the LPS+ 0.5 μM MLN-4924, LPS+IL-10 and, LPS alone samples 
with the LPS+ 2 μM MLN-4924 samples clustering between the two groups.  
Since the PCA analysis showed significant variance based on the array platform, I decided not to 
merge the microarrays directly and instead examine the two microarray by comparing the 
contents of the hierarchical clustering analysis done previously to examine the relationship 
between IL-10s transcriptional effect and NF-κB dependency.  
First the probes that hybridized with common transcripts were selected as before and filtered  
further to keep transcripts that displayed significant  induction on LPS stimulation (>2 fold in both 
microarrays, ANOVA p<0.05). Duplicate probes assessing the expression of the same transcript 
were filtered out and the highest value probe retained. The comparison between the two 
microarrays is shown in Figure 4.18. The transcripts were then sorted into groups based on the 
hierarchical clustering results of the Affymetrix and Agilent microarrays (Figures 3.8 and 4.13).  
175 
 
 
 
 
Figure 4.16 – Scree plot showing numbers of principal components in the filtered and 
transformed data 
Microarray probes detecting common RNA transcripts between the two microarray platform 
(Agilent and Affymetrix) were selected, the expression values of all probes or all those above 
detection threshold in both microarrays were transformed using either; Yugene or Z-score 
normalisation. 3 factor Principal component analysis was performed on the data and the 
eigenvalues of each component were plotted as a fraction of the variance in the whole dataset. 
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Figure 4.17 – Principal component analysis of the merged datasets. 
Microarray probes detecting common RNA transcripts between the two microarray platform 
(Agilent and Affymetrix) were selected, the expression values of all probes or all those above 
detection threshold in both microarrays were transformed using either; Yugene or Z-score 
normalisation. 3 factor Principal component analysis was performed on the data and the samples 
were plotted according to calculated eigenvector values in the first two principal components. 
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The clusters in the Affymetrix microarray (IL-10 inhibited, IL-10 unaffected and, LPS/IL-10 
cooperative) were assessed for their sensitivity to MLN-4924 as designated by hierarchical 
clustering (MLN-4924 sensitive, MLN-4924 insensitive and, MLN-4924 upregulated). The clusters 
in the Agilent microarray were similarly assessed for their response to IL-10 the results of these 
analyses are shown in Figure 4.19 and 4.20). 
Between the Affymetrix microarray clustered transcripts there was no significantly different 
pattern of response to MLN-4924. Conversely looking at the clusters from the MLN-4924 
microarray (Figure 4.20), there was no significant pattern to the changes in gene expression 
observed when stimulating with LPS+IL-10. Neither of these showed significantly different 
patterns of MLN-4924 sensitivity or IL-10 responsiveness compared to the whole data set (χ2 
p>0.05). Examining the breakdown of MLN-4924 clustering in the IL-10 inhibited group (Figure 
4.20) shows that just under half of the transcripts inhibited by IL-10 had an LPS response which 
was sensitive to MLN-4924 and that the IL-10 inhibited transcripts account just over 40% of the 
total number of MLN-4924 sensitive genes. This indicated that IL-10’s ability to modulate gene 
expression in a positive or negative manner is not recapitulated by a general inhibition of NF-κB.  
 
4.2.8 – MLN-4924 alters the magnitude of the LPS response but does not alter the effect of IL-
10 on gene expression 
Since many of the LPS/IL-10 cooperative genes were dependent on NF-κB for LPS induction, I 
investigated whether the pattern of response to IL-10 (IL-10 inhibited, unaffected and, LPS/IL-10 
cooperative) was affected by geneal inhibition of NF-ΚB by MLN-4924. To do this I stimulated  
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Figure 4.18 – Comparison of LPS-induced probes between Affymetrix and Agilent microarrays 
Probes significantly induced by LPS (p<0.05, >2 fold induction above unstimulated) for unique 
transcripts common between the Affymetrix and Agilent array samples were compared. 
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Figure 4.19 – Distribution of IL-10 microarray clusters paired with MLN microarray data 
LPS-induced transcripts (>2 fold above unstimulated, ANOVA p value <0.05) common to both 
microarray platforms were selected and separated into previously observed clusters of gene 
expression in response to MLN-4924 and then assessed for the response to  IL-10. 
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Figure 4.20 – Distribution of MLN microarray clusters paired with IL-10 microarray data 
LPS-induced transcripts (>2 fold above unstimulated, ANOVA p value <0.05) common to both 
microarray platforms were selected and separated into previously observed clusters of gene 
expression in response to IL-10 and then assessed for the response to MLN-4924. 
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primary human macrophages with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination for one hour 
in the presence of 2 μM MLN-4924 or DMSO vehicle control and examined the expression of 
select LPS induced genes. 
Figure 4.21 shows that the many of the genes selected were highly sensitive to MLN-4924 
treatment. Out of the select genes only two (NR4A2 and CD274) had an LPS induction which was 
unaffected by MLN-4924 treatment (highlighted in Figure 4.22). To examine whether the gene 
expression pattern of the genes sensitive to MLN-4924 treatment was altered, I normalized the 
data to the LPS stimulated samples. Figure 4.23 clearly shows that despite large scale inhibition 
of gene expression by MLN-4924 many genes retain their gene expression pattern (Shown in 
Figure 4.24). The only exception to this was the gene TNFSF9 which required NF-κB activity in 
order for LPS and IL-10 to cooperatively regulate its expression. 
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Figure 4.21 – Heat map showing the effect of MLN-4924 on LPS/IL-10 gene expression 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 1 hour in the presence of 2 μM MLN-4924, DMSO control or media control. After 
stimulation cells were harvested for RNA and expression of genes listed were assessed by SYBR 
green QPCR and normalised to GAPDH for each sample and to LPS treated media control. 
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Figure 4.22 – Expression of NR4A2, IL1A, TNFAIP3, DUSP1, TNFSF9 and CD274 in MLN-4924 
treated cells 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination 
for 1 hour in the presence of 2 μM MLN-4924, DMSO control or media control. After stimulation cells were 
harvested for RNA and expression of NR4A2, IL1A, TNFAIP3, DUSP1, TNFSF9 and CD274 were assessed by 
SYBR green QPCR and normalised to GAPDH for each sample and the LPS and DMSO treated sample. 
Graphs represent data from 3 independent experiments 
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Figure 4.23 – Heat map showing the effect of MLN-4924 on LPS/IL-10 gene expression 
patterns 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 1 hour in the presence of 2 μM MLN-4924, DMSO control or media control. After 
stimulation cells were harvested for RNA and expression of genes listed were assessed by SYBR 
green QPCR and normalised to GAPDH for each sample and the LPS treated sample of each 
treatment. 
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Figure 4.24– Expression patterns of NR4A2, IL1A, TNFAIP3, DUSP1, TNFSF9 and CD274 in MLN-
4924 treated cells 
106 primary human macrophages were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination 
for 1 hour in the presence of 2 μM MLN-4924, DMSO control or media control. After stimulation cells were 
harvested for RNA and expression of NR4A2, IL1A, TNFAIP3, DUSP1, TNFSF9 and CD274 were assessed by 
SYBR green QPCR and normalised to GAPDH for each sample and the LPS stimulation of DMSO and MLN-
4924 treated samples. Graphs represent data from 3 independent experiments. 
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4.3 – Discussion 
It is well known that NF-κB activity is responsible for the induction of a proportion of gene 
expression by LPS (Sen and Baltimore, 1986). However, given the ability of IL-10 to inhibit NF-κB 
dependent transcription (Smallie et al., 2010, Castellucci et al., 2015) it was unexpected to find 
an enrichment of the NF-κB consensus motifs in all of the clusters. An interesting find was the 
enrichment of a broad range of transcription factor binding motifs in promoters of the IL-10 
unaffected genes. This could potentially be indicative of the broad range of stimuli that induce 
the expression of negative feedback genes (such as TNFAIP3 or NFKBIA) a number of which are in 
this cluster (Murray and Smale, 2012).  
 In this chapter I have shown that the modulation of LPS-induced gene expression by IL-10 can be 
attributed to the activity of the transcription factor STAT3. The requirement of STAT3 for IL-10 to 
inhibit gene expression has been previously described in human macrophages by Williams et al. 
(2004). However, the requirement for STAT3 in LPS/IL-10 cooperative gene expression, has not 
been shown before. Recently (Dillow et al., 2014) demonstrated a requirement for JAK signalling 
in LPS/IL-10 cooperativity in a macrophage like cell-line, but did not show that the signalling 
pathway acted through STAT3 to alter gene expression. 
One hypothesis to explain the IL-10 unaffected gene expression pattern, was that IL-10 could 
generally inhibit the recruitment of transcription factors such as NF-κB to chromatin (Smallie et 
al., 2010), but at specific genes STAT3 could bind to chromatin and induce expression to a similar 
level to LPS stimulation alone. From the STAT3 siRNA data shown in this chapter this hypothesis 
can be rejected since the IL-10 unaffected genes do not change on STAT3 depletion. Furthermore, 
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these genes also lack induction on IL-10 stimulation and are not enriched for enrichment for STAT 
consensus binding motifs in their promoters.  
On closer examination between IL-10-inhibited and cooperative genes, it is apparent that the loss 
of STAT3 from macrophages causes a greater dysregulation in the inhibited genes than the 
cooperative genes, with inhibited genes (such as NR4A2 and IL1A) losing the IL-10 mediated 
inhibition after STAT3 depletion. Meanwhile, LPS/IL-10 cooperatively-regulated genes such as 
TNFSF9 and CD274 lose only a fraction of their LPS/IL-10 cooperative induction. This differential 
sensitivity to STAT3 depletion, could be due to a differential requirement for de novo protein 
synthesis in modulating gene expression(Murray, 2005). 
It is clear from the intersection of the LPS/MLN-4924 and the LPS/IL-10 treated microarrays, that 
the hypothesis that IL-10’s inhibitive actions are solely a result of broad NF-κB inhibition can be 
rejected, since all clusters of gene expression behaviours in response to IL-10 contained 
approximately similar proportions of MLN-4924 sensitive and insensitive genes. Furthermore, the 
spread of the data in the PCA analysis separates the LPS-stimulated samples with the higher dose 
of MLN-4924 form the LPS + IL-10, further indicating that the conditions are not equivalent. 
The luciferase reporter data however does suggest that IL-10 is capable of inhibiting NF-κB 
transcription. This could also be explained however if the protein complexes linking NF-κB to 
increasing transcription, were altered in the presence of IL-10 
Many studies have suggested IL-10’s gene specific inhibition derives from an inhibition of NF-κB 
based transcription (Smallie et al., 2010, Hutchins et al., 2015) and the enrichment of LPS 
activated transcription factors that are not NF-κB (such as AP-1 or c-JUN) at the promoters of 
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genes, not inhibited by IL-10, would have supported this as a potential explanation of the gene 
expression patterns.   
Microarray analysis of the NF-κB dependence of the macrophage LPS response highlighted a 
number of LPS-induced genes which showed a moderate drop in expression when treated with 
MLN-4924. This drop in expression also did not appear to be dependent on MLN-4924 
concentration as increasing the dose of MLN-4924 did not inhibit expression more effectively.  
This moderate reduction in LPS-induced gene expression by MLN-4924 could be explained by one 
of three hypotheses: 
1) NF-κB responsive enhancive elements contribute to the induction of gene expression but other 
LPS-activated transcription factors (such as c-Jun or AP-1) are dominant in the LPS induction of 
these genes. 
2) MLN-4924 blocks the induction of an NF-κB dependent mRNA stabilising protein and this 
reduction in transcript stability could be shown as increased mRNA abundance in the microarray. 
3) MLN-4924 is able alter the activity of transcription factors or mRNA stabilising proteins. 
MLN-4924 has recently been shown to prevent the activity of the transcription factor IRF3 by 
preventing its recruitment to chromatin independently of its inhibition of neddylation manner 
(Song H, 2016). The exact mechanism of this inhibition is yet to be clearly defined but it highlights 
that the inhibitor may have undescribed effects on other transcription factors. However, by using 
multiple MLN-4924 concentrations in the microarray and focusing on the genes that only operate 
in a dose dependent manner, such side effects should be avoided in interpreting the microarray 
results. 
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Chapter 5 – An upstream evolutionarily conserved region mediates 
the cooperative regulation of TNFSF9 by LPS and IL-10 
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5.1 – Introduction 
The requirement for STAT3 in IL-10’s inhibition of gene expression has been long established 
(Williams et al., 2004a, Williams et al., 2007, Bosmann et al., 2014). However few studies have 
attempted to interrogate the mechanisms of LPS/IL-10 cooperative induction of gene expression. 
Work in (Denys et al., 2002) and (Smallie et al., 2010), established that IL-10 is able to inhibit 
luciferase reporters with cloned sections of the TNF locus in MDM. The implication of these 
experiments is that the gene-specific inhibitory effects of IL-10 require the regulatory elements 
for that gene. In the case of TNF, the small size of the locus and highly conserved regions of 
intergenic DNA highlight the local elements required for its transcriptional regulation. 
IL-10’s effect on transcription (as detailed in the previous chapters) is not completely antagonistic 
to inflammatory signalling. Instead, a subset of genes are able to be induced synergistically, which 
is visible at the level of primary transcripts. In the (Dillow et al., 2014) study, these LPS/IL-10 
cooperatively regulated genes were characterised in human and mouse myeloid cell lines. The 
study also cloned a 2.5kb fragment upstream of the human TNIP3 gene (a target of LPS/IL-10 
cooperativity) into a GFP reporter construct. This reporter demonstrated increased expression in 
response to stimulation with LPS and LPS+IL-10, but not IL-10 alone. Therefore I hypothesised 
that other LPS/IL-10 cooperatively-regulated genes, at the level of transcription, are controlled 
by distinct regulatory elements which can operate in isolation. 
The intracellular signalling pathways contributing to LPS/IL-10 cooperativity are largely unknown 
as stimulation of cells with LPS or IL-10 induce a broad range of signalling pathways. Many of 
these signalling pathways are known to activate transcription factors, or modulate the activity of 
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transcription factors, to fine-tune a cellular response to a stimulus. In order to assess the role of 
some of the major LPS and IL-10-activated signalling pathways, I utilised small molecule inhibitors 
to abrogate downstream signalling of pathways. These inhibitors were: MLN-4924 (NF-κB 
transcriptional inhibitor), BAY 11-7082 (inhibitor of IKK), SB2035580 (p38 MAPK inhibitor), JNK-
in8 (JNK inhibitor), Ruxolitinib (JAK1/2 inhibitor), Wortmannin and, LY290002 (inhibitors of PI3K 
activity). The IKK, p38, JNK and, PI3K signalling pathways are activated by LPS in macrophages(Lu 
et al., 2008). This activation of signalling has been shown by previous studies to occur rapidly after 
the addition of stimulus (Sato et al., 2005, Bauerfeld et al., 2012).  JAK1 activation has been 
previously shown as the dominant signalling pathway induced by IL-10 (Pattison et al., 2012, 
Finbloom and Winestock, 1995). However, the PI3K/Akt pathway has been shown to be activated 
by IL-10 stimulation, which contributes to the anti-apoptotic functions of IL-10 (Antoniv and 
Ivashkiv, 2011, Zhou et al., 2001, Crawley et al., 1996). The inhibition of JAK1/2 activity has been 
recently explored as a therapeutic target for inflammatory disease and as such a new generation 
of specific inhibitory compounds for use in the clinics have been synthesised and described.  
 
5.2 – Results  
5.2.1 – IL-10 cooperative regulation, but not inhibition of transcription is a primary event that 
is independent of de novo protein synthesis 
A previous study (Murray 2005) used the protein synthesis inhibitor cycloheximide to try to 
determine whether IL-10’s inhibition of inflammatory genes required new protein. However, 
previous studies have noted that inhibiting protein synthesis has a stabilising effect on the cellular 
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pool of mRNA by preventing mRNA regulator protein production (Han et al., 1991b, Han et al., 
1991a, Beutler et al., 1986). To counteract these effects on mRNA stability, I utilised ChIP to 
investigate RNA polymerase II (Pol II) enrichment at downstream coding regions of genes, to 
assess the transcriptional elongation. 
107 primary human macrophages were pre-treated with DMSO control or 5µg/mL cycloheximide 
to inhibit de novo protein synthesis prior to stimulation with LPS, IL-10 or in combination for 60 
minutes. The cells were then assayed for Pol II enrichment in the downstream regions of the 
genes: TNF, NFKBIA, TNFSF9 and, IL6. 
To assess whether the treatment of cycloheximide was effective at blocking protein synthesis at 
these time points, the cell culture supernatants of stimulated cells were analysed by ELISA for the 
secretion of TNFα. Figure 5.1 shows that TNFα production in macrophages pre-treated with 
cycloheximide was completely abrogated, with all the cycloheximide samples containing less than 
the detection threshold of the ELISA (<13pg/mL). After determining the effectiveness of the 
cycloheximide treatment, I assessed the rate of transcription by examining the downstream 
regions of:  TNF, NFKBIA, TNFSF9 and IL6 (schematic of the QPCR primer locations shown in Figure 
5.2). TNF, NFKBIA, TNFSF9  were selected for analysis by ChIP due to the differential effects of IL-
10 on their LPS-induced gene expression (inhibited, insensitive and cooperatively regulated 
respectively), while IL6 was selected to confirm the effectiveness of the cycloheximide, since the 
transcription of IL6 requires de novo protein to initiate transcription. (Ramirez-Carrozzi et al., 
2009). In the downstream regions of TNF, NFKBIA and IL6 a clear LPS-induced enrichment of Pol 
II was observed. TNFSF9 on the other hand demonstrated no enrichment of Pol II at the  
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Figure 5.1 – Cycloheximide treatment of primary human macrophages blocks TNFα release 
107 primary human macrophages were pre-treated with DMSO or 5μg/mL cycloheximide for 
20mins prior to stimulation with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination for 60 minutes. 
Cell culture supernatants were then removed and analysed for TNFα production by ELISA. N.D, 
No TNF detectable. 
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downstream regions (Figure 5.3).  On cycloheximide treatment, the enrichment of Pol II on LPS 
stimulation was not affected at the downstream regions of TNF and NFKBIA. At the downstream 
region of TNFSF9 there no statistical increase of Pol II enrichment compared to DMSO control. At 
the downstream region of IL6, the LPS-induced enrichment of Pol II was blocked by cycloheximide 
treatment, remaining at the level of Pol II in unstimulated cells. This stands to reason as IL6 is a 
secondary response gene on LPS stimulation and requires de novo protein synthesis to initiate 
transcription.  
On addition of IL-10 in combination with LPS, there was a statistically significant inhibition of Pol 
II enrichment at the TNF downstream region, while simultaneously there was a cooperative 
enrichment of Pol II in the downstream region of TNFSF9, mirroring the effect seen at the mature 
and primary transcript level in chapter 3. Pre-treatment of macrophages with cycloheximide 
completely abolishes the ability of IL-10 to inhibit Pol II enrichment downstream of TNF. This loss 
of IL-10’s inhibitive ability was distinct from its cooperative regulation at TNFSF9, which was 
unaffected by the addition of cycloheximide. 
The inability of IL-10 to inhibit Pol II recruitment to the TNF locus in the presence of cycloheximide 
can be explained in one of two ways. Either the inhibition of TNF by IL-10 requires new protein 
synthesis or the cycloheximide pre-treatment was able to interfere with IL-10 signalling to prevent 
the activation of STAT3, which was required to inhibit TNF. To investigate whether cycloheximide 
interferes with IL-10 signalling, 2x106 primary human macrophages were pre-treated for 20min 
with DMSO or 5µg/mL cycloheximide, prior to stimulation with LPS, IL-10 or in combination for 
30 or 60 minutes. Cells were then harvested for protein and analysed by western blot for STAT3 
tyrosine 705 phosphorylation and total STAT3 levels. 
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Figure 5.2 – Schematic representation of Pol II ChIP assay locations 
Schematic of the intron-exon structure of genes selected for analysis by ChIP. Black bars indicate 
exons, white bars indicate untranslated regions and bent lines denote introns. Arrows show the 
locations of the amplicons. 
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Figure 5.3 – Cyloheximide blocks IL-10 inhibition of RNA polymerase II enrichment at 
downstream regions of TNF but not TNFSF9 and NFKBIA 
107 primary human macrophages from 3 independent donors, were pre-treated with DMSO or 
5μg/mL cycloheximide for 20mins prior to stimulation with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 60 minutes. Cells were analysed by ChIP for RNA polymerase II (Pol II) or Isotype 
control (IgG) at downstream regions of genes. Enrichment of Pol II was normalised to the LPS and 
DMSO treated sample. Graphs represent data from 3 independent experiments. Error bars 
represent SEM and statistical significance calculated by paired Student’s t-test ** p<0.01, *** 
p<0.001, N.S p>0.05 
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Figure 5.4 show that the addition of IL-10 induced a strong phosphorylation of the tyrosine 705 
residue at both 30 and 60 minutes. This phosphorylation is required for SH2-dependent STAT3 
dimerisation, therefore it is an indicator of STAT3 activation. There was also a weak 
phosphorylation of Y705 after 60 minutes of LPS stimulation, possibly indicating that LPS-induced 
IL-10 production was beginning to induce signalling in the macrophages. This was supported by 
the observation that the LPS-induced phosphorylation was blocked on treatment with 
cycloheximide, which would block de novo IL-10 production. 
 
5.2.2 – An evolutionarily conserved region upstream of TNFSF9 is able to cooperatively regulate 
gene expression in response to LPS and IL-10 
Since the cooperative effect of LPS and IL-10 on TNFSF9 expression was observable at the level of 
primary transcript production and was independent of protein synthesis, the elements that 
control the expression of TNSF9 must be readily available to bind signal-activated transcription 
factors in macrophages.  
To first narrow the search around the TNFSF9 locus, I used the mouse macrophage like cell line 
RAW264.7 (RAW) to determine if the cooperative activity of LPS and IL-10 on TNFSF9 was 
conserved. Figure 5.5 shows that similar to IL-10 does not significantly induce Tnfsf9 expression 
on its own, but cooperated with LPS to induce a higher level of Tnfsf9 expression at 60 minutes. 
However the cooperative expression was not sustained and was lost by 120 minutes of 
stimulation. Despite the lower levels of cooperative expression in this cell line, it can be  
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Figure 5.4 – Cycloheximide does not alter STAT3 tyrosine 705 phosphorylation 
2x106 primary human macrophages were pre-treated with DMSO or 5μg/mL cycloheximide for 
20mins prior to stimulation with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination for 30 or 60 
minutes. Cells were harvested and analysed for STAT3 activation by SDS PAGE and western blot. 
Representative blot of 2 independent experiments 
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Figure 5.5 – Tnfsf9 is cooperatively regulated by LPS/IL-10 in RAW 267.4 macrophages. 
0.8x106 RAW 264.7 cells seeded overnight and were then stimulated with 10 ng/mL LPS, 10 ng/mL 
IL-10 or in combination for 30, 60, 120 or 240 minutes. Cells were then harvested for RNA and 
analysed for Gapdh and Tnfsf9 expression by SYBR green QPCR.The expression of Tnfsf9 was first 
normalised to the Gapdh values in each sample, then normalised to the LPS-stimulated sample. 
Statistical significance calculated between LPS and LPS+IL-10 treated samples using students t-
test (*= p<0.05) Graph represents 3 independent experiments. 
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hypothesised that the DNA element or elements controlling the cooperativity are conserved 
between mouse and human. 
Examining the conservation of the TNFSF9 locus between multiple species (Figure 5.6) it is clear 
that the locus only showed one clear evolutionary conserved region (ECR) between mouse and 
human. This ECR was highly conserved between species, even when there was a low conservation 
between the protein coding regions. Due to this level of conservation between species and the 
proximity to TNFSF9 TSS in humans and mouse I hypothesised that this region of DNA had a 
functional role in the transcription of TNFSF9. 
To assess whether this ECR could be accessible for transcription factor binding in human 
macrophages, I used publically available ChIP-seq and Dnase-seq datasets from similarly derived 
macrophages to assess the chromatin accessibility and transcriptional activity of the TNFSF9 
locus. I examined markers of chromatin accessibility (DNase-seq and PU.1 ChIP-seq) and histone 
marks associated with transcriptionally active regions (H3K4 mono and tri methylation 
(H3K4me1/H3K4me3 respectively) and H3K27 acetylation (H3K27ac)). The H3K4me1/3 and 
DNase-seq data was acquired from the BLUEPRINT consortium (Saeed et al. (2014)) 
“macrophage” dataset, while PU.1 and H3K27ac tracks were acquired from Pham et al. (2012) 
“monocyte-derived-macrophage (MAC)” dataset. 
Figure 5.7 shows that in these macrophages there are high levels of H3K27ac and H3K4me3 
around the transcription start site of TNFSF9, indicating a transcriptionally active or poised region.  
There was also H3K27ac enriched regions surrounding a PU.1 binding site, immediately upstream 
of the ECR. Unlike the TSS, this region lacks H3K4me3 marks and instead was enriched for high 
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Figure 5.6 – TNFSF9 gene locus conservation  
Comparison of Mouse, Rat, Cow, Gorilla and Chimp alignments to the Human TNFSF9 locus. Y axis showing % identity to the human 
reference sequence and X axis representing the nucleotide position. The dotted lines bisecting the conservation plots highlights a 
region of high evolutionary conservation. 
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Figure 5.7 – TNFSF9 ECR contains marks of a poised enhancer in macrophages 
ChIP-seq data from Pham et al (2013), the BLUEPRINT consortium and, UCSC, showing histone marks, PU.1 binding ,DNase 
hypersensitivity peaks and, sequence conservation between 100 vertebrate species. X axis showing aligned nucleotide position and Y 
axis represents the number of aligned reads from samples immunoprecipitated for the proteins shown, or the conservation score 
calculated by UCSC. 
204 
 
levels of H3K4me1. The combination of these histone marks has been previously suggested to 
signal an active transcriptional enhancer. The ECR also overlaps with part of a DNase 
hypersensitive region in macrophages indicating there are areas of chromatin that are accessible 
for transcription factors to bind. 
To interrogate potential transcription factor binding sequences in the ECR the human reference 
sequence for the region (hg19) and syntenic sequences from: chimp (PanTro4), gorilla (gorGor3), 
mouse (mm10), rat (rn5) and cow (bosTau7) were downloaded from UCSC genome browser and 
aligned with each other using the ClusterOmega alignment tool. 
Figure 5.8 shows that after the divergence of these species there have been several insertions 
and deletions the ECR upstream of TNFSF9. The Chimp and Gorilla sequences had high similarity 
to the human sequence. The Chimp sequence of this region was identical to the human sequence 
and the Gorilla sequence contained only one base substitution in the region. The sequences for 
the other mammals selected (mouse, rat and cow) all showed lesser degrees of identity compared 
to the human sequences (), with mouse and rat only having roughly 50% identity compared to 
the human sequence due multiple insertions and deletions. The cow sequence on the other hand 
had a higher similarity score to the human and great ape sequences than the rodent sequences. 
This was due to a number of substitutions in the sequence as well as a 9 nucleotide deletion at 
positions 36 to 44 (Figure 5.8).  
The major area of sequence conservation of the ECR is located between bases 112 and 234 of the 
alignment in Figure 5.8. This area contains a very few small indels and had sections of high 
sequence similarity. Analysiis of these sequences through the transcription factor motif finder 
205 
 
JASPAR, identified two NF-κB sites (highlighted in the red boxes) and one STAT motif (highlighted 
in blue). 
The first NF-κB motif (sequence “GGGAATTTCTC” in the human sequence) was highly conserved 
between the selected species, with only the rat genomic sequence varying from the consensus 
sequence. The second detected NF-κB site contains more variation across different species, with 
cow, rat and mouse sequences containing; 1, 3 and 4 nucleotide substitutions respectively. This 
could be because it may not represent a complete NF-κB binding motif and instead resembles 
part of the canonical NF-κB consensus sequence. Similarly, the detected STAT site (positions 184-
194 of ) had multiple nucleotide substitutions between the primate, mouse, rat and cow 
sequences, indicating that there may have been less selective pressure to retain this putative 
STAT binding site. 
In order to examine other potential transcription factor binding sites within the TNFSF9 ECR, I 
utilised the transcription factor binding motif program ALIBABA2 (Figure 5.9). A number of 
transcription factor binding sites were observed including the proposed NF-κB site at position 137 
(which equates to position 128 in Figure 5.8). The second NF-κB site was also detected (positon 
228) as two individual NF-κB motifs overlapping. These two “half-sites” form a less than ideal 
consensus motif and therefore it is unlikely NF-κB may bind directly to the sequence.  
It’s also notable that the STAT3 motif was absent in this analysis and in its place is a motif for 
MPBF (a previous name for STAT5 (Burdon et al., 1994, Hughes and Watson, 2012). The difference 
in motif between STAT3 and 5 is only a few nucleotides occurring in the centre of the motif, which  
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  Human Gorilla Chimp Mouse Rat Cow 
Human   100% 100% 50% 51% 75% 
Gorilla 100%   100% 50% 51% 75% 
Chimp 100% 100%   50% 51% 75% 
Mouse 50% 50% 50%   90% 52% 
Rat 51% 51% 51% 90%   52% 
Cow 75% 75% 75% 52% 52%   
 
 
 
 
Table 5.1 – Percent identity matrix of the TNFSF9 ECR between species 
Syntenic sequences of the human TNFSF9 ECR were extracted from UCSC genome browser and 
aligned according to ClusterOmega algorithm. Percent identity matrix was then computed by 
UGENE with a gap penalty. 
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Figure 5.8 – TNFSF9 ECR contains conserved transcription factor binding sites 
Gorilla, chimp, mouse, rat and cow TNFSF9 conserved region sequences aligned to human reference 
sequence. Computed NF-κB and STAT3 binding sites are highlighted. The binding location of the primers 
used to amplify the human genomic sequence are indicated by the arrows. 
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Figure 5.9 – Motif analysis of the TNFSF9 ECR 
Transcription factor binding motifs present in the conserved TNFSF9 ECR were computed and 
visualised by the program ALIBABA2. Motifs were detected provided the exhibited a minimum 
of 75% sequence conservation with the JASPAR motif position weight matrix. 
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shows greater variability. This difference in nucleotide sequence could be enough to prevent 
binding. 
To assess if the TNFSF9 ECR was responsive to LPS and IL-10 stimulation, I subcloned the ECR from 
human genomic upstream of a luciferase open reading frame in a reporter plasmid containing a 
minimal promoter (pGL4.26). The plasmid containing the ECR or the vector alone was then 
transfected into RAW 264.7 cells overnight, before the cell culture medium was replaced and the 
cells stimulated with LPS and IL-10 for 120, 240 or 480 minutes.  
Figure 5.10 shows a large difference between the luciferase activity of the ECR containing plasmid 
and the minimal promoter control in unstimulated cells. The minimal promoter control had a very 
low basal activity (231 luciferase units) while the ECR plasmid had a basal luciferase activity of 
approximately 3500 units (Two-way ANOVA p value of 0.009). This could indicate that the TNFSF9 
ECR fragment had an innate enhancive effect on the reporter’s transcription. On stimulation with 
LPS and IL-10, the ECR plasmid retained a consistently higher activity than the minimal promoter, 
throughout all time points.  
After LPS+IL-10 the luciferase activity produced by the ECR plasmid increased significantly above 
the basal luciferase activity after 240 minutes and continued to increase until 480 minutes. The 
minimal promoter on the other hand was not able to increase the luciferase activity in a 
consistent manner. There was a slight increase in luciferase activity at 120 and 240, which was 
lost by 480 minutes.  
 
210 
 
 
Figure 5.10- LPS+IL-10 time course of TNFSF9-ECR luciferase reporter 
RAW 264.7 cells were transfected with empty PGL4.26 vector or TNFSF9-ECR luciferase reporter 
construct. The following day these cells were stimulated with 10 ng/mL LPS and 10 ng/mL IL-10 
for; 120, 240 or 480 minutes. Cells were then harvested and analysed for luciferase activity. Data 
shown is a single experiment and error bars represent the standard deviation of 3 technical 
replicates. 
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Since the ECR containing plasmid was responsive to LPS+IL-10 stimulation in transfected RAW 
cells, I aimed to determine whether this responsiveness was a cooperative effect between LPS 
and IL-10 signalling or whether one signalling pathway had a dominant effect on the transcription 
of the reporter. To do this I stimulated plasmid-transfected RAW cells with LPS, IL-10 or in 
combination for 480 minutes and analysed the luciferase activity.  
In Figure 5.11 there was a clear induction of luciferase activity when the ECR reporter-transfected 
RAW cells were stimulated with LPS, which did not occur in cells treated with IL-10 alone sample. 
However, on LPS+IL-10 stimulation there was a statistically significant increase in luciferase 
activity compared to the LPS alone stimulation. While there was a synergistic effect between LPS 
and IL-10 with this reporter, it was to a lesser extent than the maximal amount observed at the 
mRNA level. This could be due to changes to mRNA stability or changes in other areas of 
chromatin which allow Tnfsf9 transcription to be enhanced. 
Earlier in this study, I noted that TNFSF9 expression was strongly impaired by inhibiting NF-κB 
activity with the inhibitor MLN-4924.Therefore I wanted to examine whether NF-κB activity 
contributed to the upregulation of the TNFSF9 ECR reporter by LPS. To inhibit NF-ΚB activity in 
RAW264.7 cells I used the inhibitor MLN-4924 and examined the expression of Tnfsf9 after 
stimulation with LPS/IL-10 at 60, 120 and 240 minutes. 
As can be seen in Figure 5.12, the treatment of RAW 264.7 cells with MLN-4924 leads to an 
inhibited production of Tnfsf9 mRNA on stimulation with LPS and LPS+IL-10 at all timepoints. The 
cooperative induction seen at 60 minutes was heavily reduced in magnitude, after treatment with 
MLN-4924. However, the pattern of gene expression still persisted at this timepoint. 
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Figure 5.11 – Luciferase assay of TNFSF9-ECR reporter 
RAW 264.7 cells were transfected with empty PGL4.26 vector or TNFSF9-ECR luciferase reporter 
construct. The following day these cells were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 480 minutes. Cells were then harvested for and analysed for luciferase activity. 
Statistical significance calculated using two-way ANOVA (* = p <0.05, **** = p<0.0001). Graph 
represents 5 independent experiments. 
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Figure 5.12 – MLN-4924 inhibits LPS induction but not LPS/IL-10 cooperativity of Tnfsf9 
expression in RAW 264.7 cells 
106 RAW 264.7 cells were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in combination for 30, 
60, 120 or 240 minute in the presence of DMSO or 1 μM MLN-4924. Cells were then harvested 
for RNA and analysed for Gapdh and Tnfsf9 expression by SYBR green QPCR. Graph represents 1 
experiment, triplicate measurements. 
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I then examined the effect of MLN-4924 on the TNFSF9 ECR reporter. RAW 264.7 cells were 
transfected with the TNFSF9 ECR reporter or minimal promoter overnight, before the cell culture 
medium being changed. The cells were then stimulated with LPS/IL-10 or in combination in the 
presence of DMSO or 1 μM MLN-4924. Cells were then lysed and analysed for luciferase activity. 
The high basal activity of the ECR reporter appeared to be independent of NF-κB since it was 
unaffected by the addition of MLN-4924 (Figure 5.13). Activation of the ECR reporter by LPS was 
abolished by MLN-4924, as was its cooperative regulation by LPS and IL-10. Both of these 
responses are therefore likely to be dependent on NF-κB. 
Data detailed in chapter 4 also highlighted STAT3 activation as a critical factor induction of TNFSF9 
gene expression by LPS and IL-10 but not by LPS alone. To inhibit STAT3 phosphorylation in these 
cells, I used the JAK1/2 inhibitor Ruxolitinib, which has previously been shown to inhibit 
phosphorylation of STAT3 in response to IL-10 (Pattison et al., 2012). When treated with 
Ruxolitinib the cooperativity between LPS and IL-10 was completely lost while the LPS induction 
of the reporter remained intact (Figure 5.14). 
These experiments indicate that the LPS induction of this ECR reporter absolutely requires NF-κB, 
and when NF-κB transcriptional activity is compromised, cooperative regulation of the reporter 
plasmid is abolished. JAK1/2 activity is also required in order for the cooperative induction of this 
reporter by LPS and IL-10, but is dispensable for the induction by LPS alone. 
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Figure 5.13 – MLN-4924 inhibits TNFSF9 ECR luciferase reporter LPS/IL-10 cooperativity 
RAW 264.7 cells were transfected with empty pGL4.26 vector or TNFSF9-ECR luciferase reporter 
construct. The following day these cells were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 480 minutes in the presence of 1 μM MLN-4924 or DMSO control. Cells were 
then harvested for and analysed for luciferase activity. Two-way ANOVA (**** = p<0.0001, *** = 
p<0.001, ** = p<0.01, *=p<0.05, N.S = p>0.05). Graph represents 3 independent experiments 
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Figure 5.14 – Ruxolitinib inhibits TNFSF9 ECR luciferase reporter LPS/IL-10 cooperativity 
RAW 264.7 cells were transfected with empty PGL4.26 vector or TNFSF9-ECR luciferase reporter 
construct. The following day these cells were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 or in 
combination for 480 minutes in the presence of 1 μM Ruxolitinib or DMSO control. Cells were 
then harvested for and analysed for luciferase activity. Statistical significance calculated by Two-
way ANOVA (**** = p<0.0001, *** = p<0.001, ** = p<0.01, N.S = p>0.05). Error bars represent 
the SEM of 3 independent experiments.  
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5.2.3 – A STAT3 luciferase reporter exhibits LPS/IL-10 cooperativity 
After observing the effect of IL-10 on the NF-κB reporter in chapter 2, I wanted to ascertain 
whether the transcriptional activity of STAT proteins was affected by the co-stimulation of LPS 
and IL-10. To do this I transduced primary human macrophages with an adenoviral STAT3 reporter 
(gifted by Dr Lynn Williams, University of Oxford). This reporter contained 4 repeats of the 
sequence: “GGTTCCCGTAAATGCATCA” (STAT3 binding site underlined) upstream of a TATA-like 
promoter and firefly luciferase coding region. After resting from transduction overnight, the cells 
were stimulated with LPS, IL-10 or in combination for 2 hours, before being lysed and assessed 
for luciferase activity. 
Figure 5.15 demonstrates that after stimulation with LPS or IL-10, there is a statistically significant 
(p value = 0.018 and 0.0091), 2 fold upregulation of luciferase activity. When co-stimulated by LPS 
and IL-10, there is a significant 5.8 fold increase in luciferase (p value = 0.0008) activity compared 
to unstimulated cells. This cooperative effect is significantly more potent than the effect of LPS or 
IL-10 stimulation alone (p = 0.0036 and p = 0.0036 for LPS and IL-10 vs LPS+IL-10 treatments, 
respectively).  
Previous work by Dillow et al. (2014) demonstrated that LPS/IL-10 cooperative regulation was 
sensitive to small molecule inhibitors of multiple cell signalling pathways. Therefore, I undertook 
to examine whether this luciferase reporter cooperativity was dependent on similar cell-signalling 
pathways. I treated the cells with the inhibitors: MLN-4924 (Nedd8/NF-κB pathway inhibitor), 
SB203580 (p38 MAPK inhibitor), JNK-in8 (JNK pathway inhibitor), BAY 11-7082 (IKK inhibitor), 
Ruxolitinib (JAK1/2 inhibitor), Wortmanin and LY294002 (PI3K inhibitors). 
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Figure 5.15 – STAT3 reporter activity on LPS/IL-10 stimulation 
105 primary human macrophages were transduced with 100 M.O.I of a STAT3 luciferase reporter 
construct containing 4 STAT3 consensus motifs for two hours, before the cell culture media was 
changed. The next day the cells were stimulated with 10 ng/mL LPS, 10 ng/mL IL-10 ng/mL or in 
combination for 120 minutes. Cells were then harvested and assessed for reporter activity by 
luciferase assay. Statistical differences between unstimulated and stimulated samples were 
calculated by unpaired t-test for 4 independent donors. * p<0.05, ** p<0.01, *** p<0.001 
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Ruxolitinib completely blocked the activation of the reporter by LPS or IL-10 and its synergistic 
activation by both agonists, as well as slightly decreasing its basal activity (Figures 5.16 and 5.17). 
The involvement of JAK/STAT signalling in reporter responses to IL-10 were expected. The 
inhibition of the LPS response by Ruxolitinib indicates, unexpectedly, that this also depends on 
STAT activation. Neither MLN-4924 nor the IKK inhibitor BAY 11-7082 significantly affected 
reporter activity under any condition, demonstrating a lack of involvement of NF-κB in any of the 
responses tested. A JNK inhibitor (JNK-in8) also failed to influence reporter activity under any 
condition, but the MAPK p38 inhibitor SB203580 inhibited the response to LPS or LPS and IL-10 in 
combination, as well as slightly decreasing the basal activity of the reporter. This result suggests 
a convergence of between the MAPK p38 pathway and STAT3. Two PI3K pathway inhibitors, 
Wortmanin and LY29002 had contradictory effects on the reporter. Whilst LY29002 reduced basal 
LPS-induced and LPS + IL-10 induced activity, Wortmanin significantly reduced only the basal 
activity. The involvement of the PI3K pathway in the activation of the STAT reporter therefore 
remains unclear and requires further investigation. 
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Figure 5.16 – Comparison of cell signalling inhibitors on STAT3 reporter activity 
105 primary human macrophages were transduced with 100 M.O.I of a STAT3 luciferase reporter 
for two hours, before the cell culture media was changed. The next day the cells were stimulated 
with 10 ng/mL LPS, 10 ng/mL IL-10 ng/mL or in combination for 120 minutes with the shown 
concentration of inhibitor or DMSO control. Cells were then harvested and assessed for reporter 
activity by luciferase assay. Luciferase activity was then normalised to the DMSO treated 
unstimulated sample. Statistical differences between DMSO and inhibitor treated samples were 
calculated by unpaired t-test for 3 independent donors. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 5.17 – Effect of chemical inhibitors of signalling pathways on STAT3 reporter activity 
105 primary human macrophages were transduced with 100 M.O.I of a STAT3 luciferase reporter for two 
hours, before the cell culture media was changed. The next day the cells were stimulated with 10 ng/mL 
LPS, 10 ng/mL IL-10 ng/mL or in combination for 120 minutes with the shown concentration of inhibitor 
or DMSO control. Cells were then harvested and assessed for reporter activity by luciferase assay. 
Luciferase activity was then normalised the unstimulated sample for each treatment group. Statistical 
differences between unstimulated and stimulated samples were calculated by unpaired t-test for 3 
independent donors. * p<0.05, ** p<0.01, *** p<0.001. 
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5.3 – Discussion 
5.3.1 – Differential sensitivity of IL-10-modulated gene expression to cycloheximide 
Murray (2005) previously concluded that the inhibitory activity of IL-10 on macrophage gene 
expression required de novo gene expression, based on the production of primary transcript 
mRNA from cells treated with cycloheximide. I show for the first time that the rate of Pol II 
transcriptional elongation is directly affected by protein synthesis inhibition and that IL-10’s 
inhibitory action is un-coupled to its ability to cooperatively regulate gene expression which, in 
the case of TNFSF9, is a direct effect of cell signalling. NFKBIA and TNFAIP3 showed no alteration 
in Pol II enrichment in the downstream coding regions of these genes on stimulation with IL-10 
or treatment with cycloheximide .These observations at TNFSF9, TNF, NFKBIA and TNFAIP3 can 
be interpreted as IL-10 having a gene specific effect on transcriptional elongation, since all three 
patterns of gene expression (IL-10 inhibited, insensitive and cooperatively regulated) of IL-10’s 
effect on LPS-induced genes can be observed. 
The inhibitive effect of IL-10 has been previously described as extremely rapid (Williams et al., 
2004b). It can be therefore, assumed that the gene (or genes) responsible for inhibiting gene 
specific Pol II elongation on stimulation with IL-10 is poised for transcription or translation.  
The cooperative regulation of TNFSF9 at the level of transcriptional elongation by LPS and IL-10 
has not been described previously. Some studies have previously noted cooperative effects of 
LPS/IL-10 on gene expression at other genes, but not in primary human cells. 
There is also slight increase in Pol II enrichment in the downstream region enrichment after 
cycloheximide treatment at the downstream regions of TNF, NFKBIA and, TNFSF9 which could be 
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due to cycloheximide’s described effect of super-inducing NF-κB transcriptional activity by 
preventing the resynthesis of IκBα (Sen and Baltimore, 1986). However, this did not reach the 
level of statistical significance with the number of donors used, but may have with further 
replicates. 
 
5.3.2 – TNFSF9 ECR 
The identification of an enhancer element upstream of TNFSF9 has not previously been described. 
However, the external data sets from Saeed et al. (2014) and Pham et al. (2012) show distinct 
enhancer marks at this location in similarly derived cells. This data combined with the observation 
that the TNFSF9 ECR induces a reporter plasmid in response to LPS indicates that this region can 
act as a transcriptional regulator in macrophages. 
There were a number of other transcription factor binding motifs in this ECR (such as SP1, AP-2 
and, C/EBPα) which are known to regulate transcription in response to LPS stimulation. The 
sensitivity of the reporter to the inhibitor MLN-4924 supports the hypothesis that this reporter is 
driven by NF-κB activity, however MLN-4924 can also affect the activity of transcription factors 
and signalling pathways (Park et al., 2016). MLN-4924 has been previously shown to inhibit the 
expression of C/EBPa (Park et al., 2016). This transcription factor has a known role in macrophage 
function(Zhang et al., 1996, Pham et al., 2007) and its consensous motif is present in the ECR 
reporter. MLN-4924 has also been shown to block the inactivating sumolyation of the 
transcription factor AP-2 (gene name TFAP2A)(Bogachek et al., 2016, Bogachek et al., 2014). The 
consensus motif for this transcription factor does appear in the ALIBABA motif analysis but since 
the addition of MLN-4924 does not increase the activity of the ECR reporter, this protein is 
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unlikely to play a role in the induction of the reporter. In order to establish whether NF-κB is 
responsible for the LPS induction of the reporter NF-κB binding of the ECR must be examined by 
ChIP. 
The low induction of the ECR reporter plasmid by LPS and cooperativity when stimulated with LPS 
and IL-10 in RAW 264.7 cells could be reflective of the lower level TNFSF9 expression generally 
observed in this cell line. This cell line was initially selected due to its ability to respond to both 
LPS and IL-10 and its myeloid cell phenotype, but more importantly it has been previously used 
in similar studies to demonstrate human macrophage enhancer function, since primary human 
macrophages are notoriously difficult to transfect without using viral vectors. 
The identity of which STAT family member is able to induce transcriptional activity at the reporter 
is a key question from my experiments. While the ECR does contain a detectable STAT motif it is 
more similar to a STAT5 motif which has been indicated to be activated by IL-10 signalling 
(Wehinger et al., 1996). Work in the previous chapter has shown that TNFSF9 expression is 
sensitive to STAT3 depletion however, in order to conclusively prove STAT3 is binding to this ECR 
to drive transcription, ChIP of the ECR for both STAT3 and STAT5 should be performed. 
To assess the role of the NF-κB and JAK/STAT3 signalling pathways on the reporter induction, I 
used the inhibitors MLN-4924 and the JAK1/2 inhibitor Ruxolitinib. I observed that the NF-κB 
pathway was highly required for both the LPS induction of the reporter, as well as the cooperative 
induction by LPS and IL-10 co-stimulation, while the JAK1/2 pathways was only responsible for 
the cooperative effect when cells were co-stimulated with LPS and IL-10. 
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This phenomenon can be explained by two potential hypotheses (shown in Figure 5.18 and Figure 
5.19): 
1) Dependent on the reorganization of local chromatin 
2) Independently or chromatin remodelling 
 If chromatin remodelling were required (for example if the STAT3 motif was blocked by histones), 
NF-κB would be required to bind first, to induce the recruitment of chromatin remodelling 
complexes, or histone modifiers, to increase the accessibility of the DNA within the ECR and reveal 
a STAT motif previously masked by chromatin. 
Alternatively STAT3 may not be able to bind to the exposed motif due to its underlying sequence, 
without NF-κB present to stabilize the binding, or recruit more transcriptional machinery.  
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Figure 5.18  – Chromatin remodelling dependent hypothesis of LPS/IL-10 cooperativity at 
TNFSF9 ECR 
Diagram illustrating a hypothesis of how the IL-10 mediated enhancive effect of LPS-induced 
TNFSF9 transcription may occur, through local remodelling of chromatin. The lineage factor PU.1 
is bound proximal to the ECR allowing local unwinding of chromatin to expose the NF-κB motif, 
but not the STAT3 binding site, which remains occluded by surrounding histones. The activation 
of NF-κB by LPS causes the recruitment of NF-κB to chromatin and causes the local remodelling 
or shuffling of nucleosomes, exposing the STAT3 binding site and allowing the enhancer to 
respond to IL-10 signalling. 
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Figure 5.19 – Chromatin remodelling independent hypothesis of LPS/IL-10 cooperativity at 
TNFSF9 ECR 
Diagram illustrating a hypothesis of how the IL-10 mediated enhancive effect of LPS-induced 
TNFSF9 transcription may occur independently of the modification of the local chromatin 
landscape. The lineage factor PU.1 is bound proximal to the ECR allowing local unwinding of 
chromatin to expose the NF-κB motif and STAT3 binding site. The activation of NF-κB by LPS 
causes the recruitment of NF-κB to chromatin and is able to either stabilise the association 
between STAT3 and chromatin, or increase the recruitment of transcriptional machinery. Without 
NF-κB, STAT3 is unable to associate with chromatin or possibly recruit the transcriptional 
machinery to initiate transcription 
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To determine these hypotheses, ChIP could be used to ascertain whether STAT3 is able to bind 
the ECR under IL-10-stimulated and LPS/IL-10-stimulated conditions. If it is unable to bind under 
IL-10 alone stimulation, DNase hypersensitivity assay or formaldehyde-assisted isolation of 
regulatory elements (FAIRE) can be utilized to determine whether the STAT motif is free of 
nucleosomes or occluded. 
 
5.3.3 – STAT3 luciferase reporter 
There are several possible explanations for increased luciferase activity of the STAT3 reporter on 
LPS stimulation. Firstly LPS signalling could be inducing type I interferons which would feedback 
on the cell and activating STAT1, which has been shown to occur previously (Ohmori and 
Hamilton, 2001). An alternate explanation is that the LPS-stimulated macrophages are producing 
IL-6 or IL-10 and that is leading to increased STAT3 activity. However, considering the production 
of IL-6 and IL-10 on LPS stimulation in macrophages has been linked to NF-κB activity and both 
NF-κB inhibitors in the screening experiment (BAY 11-7082 and MLN-4924) do not block the 
synergy or the LPS-induced reporter activity, so are therefore unlikely. TLR4 stimulation has 
previously been shown to phosphorylate STAT1 through a PI3K dependent mechanism (Rhee et 
al., 2003). Since the LPS induction of the reporter is blocked by LY294002, this could be an 
indication of STAT1 phosphorylation activating the reporter. To assess this in future experiments 
IFNγ stimulation could be used as a positive control. 
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The suppression of the STAT3 luciferase reporter by Ruxolitinib, was an expected result. The 
phosphorylation of Y705 of STAT3 by JAK1 (a target of Ruxolitinib) is required for nuclear import 
and DNA binding activity of STAT3. Therefore inhibiting JAK1 kinase activity with Ruxolitinib, will 
prevent any activation of STAT3 and therefore prevent the production of luciferase from the 
reporter. 
The inhibition of reporter activity on stimulation by the inhibitors; SB203580 and LY294002 was 
unexpected.  Inhibition of PI3K has been previously shown to inhibit IL-10 induced gene 
expression in a manner independent of de novo protein synthesis (Antoniv and Ivashkiv, 2011). 
While this phenomenon would explain the loss of activity on IL-10 stimulation, the mechanism by 
which PI3K contributes to IL-10 induced gene expression to examine whether this mechanism also 
explains the inhibition of LPS and LPS+IL-10 induction. In Dillow et al.(2014) the LY294002 
inhibitor did affect the expression of multiple cooperative genes, while SB203580 only affected a 
small subset of LPS/IL-10 cooperatively regulated genes. p38 MAPK has previously been shown 
to phosphorylate STAT3  and modulate its transcriptional activity(Huang et al., 2014, Miyakoshi 
et al., 2014, Darnell, 1997, Decker and Kovarik, 2000). This phosphorylation could explain both 
the synergistic induction of the reporter on LPS and IL-10 co-stimulation and the sensitivity of this 
reporter to p38 MAPK inhibition. 
There is a discrepancy in the inhibition of the reporter by Wortmanin and LY294002, which both 
inhibit the PI3K family. This could be due to Wortmanin needing a different time of treatment to 
establish maximum potency. However LY294002 has recently been described as an inhibitor of 
BET bromodomains (Dittmann et al., 2014). Inhibitors of the BET bromodomain proteins, have 
been shown to antagonize signal-induced gene expression.  
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It should be noted that while the STAT3 reporter has been shown to bind STAT3 by EMSA (Horvath 
et al., 1995) the consensus sequence of the reporter is not an ideal motif for STAT3 (“TTCCCGTAA” 
in the reporter and an ideal STAT3 motif of “TTCCNGGAA”).. The discrepancy between the two 
sequences occur a critical region of the STAT binding motif and would probably affect the affinity 
of the STAT dimer for the reporter. Therefore future work could investigate whether STAT3 is 
binding to the reporter through ChIP or knockdown of STAT3 with siRNA. However, this work 
would be more insightful if the TNFSF9 enhancer region or other cooperatively regulated regions 
were used in an adenoviral construct to investigate the requirement of these cell signalling 
pathways on this phenomenon.  
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Chapter 6 – Discussion  
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6.1 – IL-10-mediated inhibition of LPS-induced gene expression 
The ability of IL-10 to suppress the expression of inflammatory genes has long made it an 
attractive target to mimic therapeutically and multiple hypotheses have been posited on the 
mechanism that this suppression occurs. Several recent studies have highlighted modulation of 
NF-κB activity as a potential method by which IL-10 may exert its inhibitive effects in 
macrophages. Several mechanisms have been proposed including: inhibition NF-κB recruitment 
to chromatin (Smallie et al., 2010), inhibition phosphorylation of the p65 subunit, blocking the 
recruitment of histone acetylases and P-TEFb (Castellucci et al., 2015) , or generally inhibiting the 
expression of NF-κB family members mRNA (Hutchins et al., 2015).The mechanisms hypothesised 
in Smallie et al. (2010) and Hutchins et al. (2015) are not wholly consistent with our observations. 
General inhibition of NF-κB activity using the small molecule inhibitor MLN-4924, did not replicate 
IL-10s effect. Additionally, the expression of a number of genes that were unaffected by IL-10 
stimulation (including the negative regulators of TLR and NF-κB signalling: TNFAIP3 and NFKBIA) 
was heavily inhibited when cells were treated with the compound.  
Castellucci et al. (2015) recently demonstrated in monocytes that IL-10 blocked the 
phosphorylation of serine 276 of NF-κB p65 subunit, as well as the acetylation of lysine 310 on 
the same molecule. The inhibition of these post-translational modifications decreased the 
recruitment of bromodomain protein Brd4 at the CXCL8 and TNF loci but not at the NFKBIA locus. 
Brd4 has been shown previously (Huang et al., 2009) to recruit P-TEFb to acetylated NF-κB to 
stimulate transcriptional elongation and blocking its recruitment prevents production of mRNA 
at specific loci (Nicodeme et al., 2010, Chan et al., 2014). This differential blocking of Brd4 
recruitment to chromatin in gene expression could explain the differences between IL-10 
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inhibited and IL-10 unaffected genes. In order to test this further, ChIP-seq of phosphor-s276 p65 
and Brd4 should be performed in macrophages stimulated with LPS or LPS+IL-10 and compared 
to the gene expression data. 
The results of this thesis are able to shed new light on the expression conditions of the IL-10 
induced suppressor(s) of gene expression. It has previously established that STAT3 was absolutely 
required for the IL-10’s inhibitory activity (Williams et al., 2007, Williams et al., 2004a) which I 
confirmed using siRNA in primary cells. Here I show for the first time in primary human cells, that 
this effect on TNF gene transcription requires de novo protein synthesis from IL-10 signalling to 
inhibit transcriptional elongation. I also show that the IL-10 is still able to inhibit gene expression 
even in the presence of NF-κB inhibitor MLN-4924 and therefore would be contained in the NF-
κB independent section of our datasets.  
Interestingly, while not all NF-κB dependent genes were inhibited by IL-10 there was a decrease 
NF-κB luciferase reporter activity in LPS-stimulated cells co-stimulated with IL-10. This 
phenomenon has two possible explanations. Firstly IL-10 signalling could be acting on this 
reporter, similarly to the TNF locus in Smallie (2010) or Castelucci (2015), or inhibiting the 
recruitment or compromising the ability of NF-ΚB to recruit P-TEFb to initiate transcription. 
Secondly this effect could be in part due to the cooperative induction of the poly-ubiquitin binding 
protein TNIP3, which is able to bind the ubiquitin editing enzyme TNFAIP3 (which is also 
upregulated by LPS). This complex is then able to target and breakdown the polyubiquitin chains 
which act as a scaffold to the TLR4 signalling complex (Wagner et al., 2008, Wullaert et al., 2007). 
TNIP3 is also able to inhibit NF-κB activation independently of its TNFAIP3 binding ability (Weaver 
et al., 2007, Verstrepen et al., 2008). 
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6.2 – IL-10 insensitive genes 
The IL-10 insensitive gene expression pattern has not been well characterised in literature. The 
few studies that have been published mainly focus on NFKBIA (Smallie et al., 2010, Castellucci et 
al., 2015, Murray, 2005) or DUSP1 (Hammer et al., 2005). In this thesis I have expanded this list 
of genes further and shown that these genes are upregulated by multiple pathways from LPS 
signalling (not all controlled by NF-κB) and that STAT3 is not required for their expression. 
Previous work on the NFKBIA locus, in both Smallie et al. (2010) and Casetellucci et al. (2015) has 
shown that IL-10 is unable to inhibit the recruitment of Brd4 and CDK9 to the TSS of NFKBIA, 
unlike what is observed at the TNF locus.  In fact at the NFKBIA locus, Brd4 recruitment to the 
locus is constant between unstimulated and stimulated cells. This signal independent recruitment 
of Brd4, may prove to be a discriminating factor between IL-10 sensitive and IL-10 insensitive 
genes.  
 
6.3 – LPS and IL-10 Cooperative regulation of gene expression 
Previously studies on LPS/IL-10’s cooperative effect on gene expression have focused on a small 
number of key targets (such as SOCS3 and TNIP3). In this thesis, I have examined this gene 
expression behaviour genome wide and dissected some of the mechanisms that control this 
pattern of gene expression. Similar to the other gene expression patterns in response to IL-10 I 
observed, NF-κB was required for the LPS induction of many cooperatively induced genes. On 
further analysis of several select LPS/IL-10 cooperatively regulated genes, most were still able to 
retain their pattern of response to IL-10 despite inhibition of NF-κB. Only one gene (TNFSF9) of 
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the eight I investigated was found to lose all LPS/IL-10 cooperative regulation after treatment 
with the inhibitor MLN-4924. 
Collaboration and cooperative binding of the transcription factors STAT1 and NF-κB have been 
shown previously to cooperatively-regulate CXCL10 expression (Yeruva et al., 2008, Burke et al., 
2013, Qiao et al., 2013). Given the similarities in protein structure between STAT1 and STAT3 
there is the potential that STAT3 might also be act in concert with NF-κB in a similar manner. In 
order to test this theory STAT3 and NF-κB could be immunoprecipitated and assessed for 
cooperative binding or ChIP-seq performed on the samples to assess the level of local binding on 
DNA. 
Due to the opposing signalling effects of LPS and IL-10, the idea that some genes would be 
synergised almost appears counter-intuitive. However, there are many situations these signals 
are likely to co-exist together. Many organs such as the lungs and gut are continually exposed to 
pathogens or microbes but are not in a continuous state of inflammation. One of the mechanisms 
to suppress the potentially harmful inflammatory response in these organ is a constant 
production and secretion of IL-10 into the tissue (Sellon et al., 1998, Hacham et al., 2004, Zigmond 
et al., 2014). IL-10 and pro-inflammatory signals co-exist would also co-exist during inflammation. 
As many studies have shown, after stimulation with cytokines or LPS, macrophages are able to 
produce IL-10 (Pattison et al., 2012, Sellon et al., 1998, Iyer et al., 2010). The induction of IL-10 on 
activation is delayed compared to other cytokines (such as TNFα) and could assist in pushing the 
macrophage to a pro-resolution phenotype. However, if exogenous inflammatory stimuli and      
IL-10 co-exist this may indicate a lack of pathogen clearance and it would be necessary to activate 
or enhance the adaptive immune response to clear the pathogen.  
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Using a STAT3 luciferase reporter, I observed a significant cooperative induction of luciferase 
when cells were co-stimulated with LPS and IL-10, which was sensitive to inhibition of the p38 
MAPK and JAK1/2 cell signalling pathways. The sensitivity of the reporter to PI3K inhibition was 
inconclusive since the inhibitors LY29002 and Wortmanin produced different effects. This 
increase in STAT activity with the two stimuli, has not been reported previously. Physiologically, 
this mechanism may have evolved to increase IL-10’s anti-inflammatory properties, by increasing 
STAT3’s transcriptional ability at the peak of inflammation. If STAT3 activity was broadly enhanced 
by LPS then all IL-10 induced genes would be induced further when co-stimulated with LPS which 
I did not observe in my dataset. 
 
6.4 – TNFSF9 expression 
The protein TNFSF9 (also known as 4-1BBL) is a T cell co-stimulatory molecule which assist in the 
antigen-dependent activation of CD8/4+ T cells (Cannons et al., 2001). Mice which are deficient 
or unable to activate TNFSF9 induced signalling, display a diminished protection from severe viral 
infections due to reduced CD8+ expansion (DeBenedette et al., 1999, Wen et al., 2002).  
In this thesis I have demonstrated that the synergistic expression of this gene in response to 
LPS/IL-10 requires STAT3, but is also heavily dependent on NF-κB and that this pattern of 
expression is mimicked by a luciferase reporter containing an evolutionary conserved element 
upstream of the gene. In order to confirm whether NF-κB and STAT3 bind the ECR in human 
macrophages future experiments should use ChIP to confirm the presence of these factors. 
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The protein itself is only upregulated on the cell surface after co-stimulation, for a short time, 
before returning to basal expression levels. With such a short window of expression, it is difficult 
to grasp, what the result of this upregulation would be physiologically. To test this LPS+IL-10 
stimulated MDM could be cultured in the presence of TNFSF9 blocking antibody and autologous 
T cells. The T cells could then be assessed for phenotypic and gene expression changes due to the 
presence macrophages expressing TNFSF9. 
There are a few potential hypotheses as to how this synergistic regulation might have developed. 
Firstly, if other PRRs cooperate similarly with IL-10 as LPS does, this indicates that viral derived 
PAMPs may cooperate in IL-10 rich tissues, such as the lungs or the gut mucosa. This would cause 
the rapid proliferation and activation of viral specific CD8+ T cells, in tissues where the immune 
response would otherwise be inhibited (so as to not disrupt organ function with an inflammatory 
response). 
Another possible explanation is that IL-10 signalling and sustained activation of STAT3 can act in 
a pathogenic manner. IL-10 has been acquired by multiple extant viral lineages and its production 
by cells can be induced by bacterial species and utilized by tumour cells to evade immune 
surveillance. Therefore, dampening of the immune response by IL-10 would allow the pathogen 
or tumour to replicate or spread, with potentially lethal consequences. Therefore the ability of  
IL-10 to stimulate specific immunity (such as CD8+ T cells) would be advantageous to an organism. 
Viral IL-10 homologues of IL-10 have been shown to signal differently to human IL-10 (Liu et al., 
1997, Ding et al., 2000, Kotenko et al., 2000) and it is not known if these cytokines will induce 
TNFSF9 expression to a similar extent. 
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 IL-10 deficient mice have been previously shown to have compromised CD8+ T cell memory 
generation and survival in response to infection (Foulds et al., 2006) as well as a deficient 
expansion of anti-tumour CD8+ T cells (Emmerich et al., 2012). This phenotype of compromised 
CD8+ immunity is very similar to IL10 knockout mice  (Watts et al., 2011, Humphreys et al., 2010, 
Lin et al., 2009, Mogi et al., 2000, DeBenedette et al., 1999) and therefore could be linked. 
However, for this to be confirmed this would require experiments to confirm whether the 
exogenous addition of IL-10 is able to restore the ability of IL-10 knockout mice to produce CD8+ 
anti-tumour/viral memory cells and whether this restoration of protective memory is dependent 
on TNFSF9. 
Finally, the synergy with IL-10 may only be coincidental. Multiple cell signalling pathways utilise 
STAT3 to effect gene expression changes and the duration of STAT3 activation is key to defining 
that response (Yasukawa et al., 2003b, Braun et al., 2013, Bang et al., 2015). Therefore, the 
upregulation of TNFSF9 by IL-10 and LPS may be unavoidable and therefore downregulated by a 
separate mechanism later. STAT3 is not the only STAT family member reporter to be activated by 
LPS or IL-10. STAT1 has been shown to be activated by LPS and IL-10 (Finbloom and Winestock, 
1995, Ohmori and Hamilton, 2001) and the consensus binding motifs of these proteins are similar. 
To investigate whether STAT1 is driving the cooperative expression of TNFSF9 macrophages could 
be stimulated IFNγ (an activator of STAT1) and LPS and the expression of TNFSF9 could be 
monitored. 
Recent studies on the function of TNFSF9 expressed by macrophages have shown that the 
intracellular domain interacts with TLR4 components to sustain the production of TNF in response 
to LPS (Kang et al., 2007, Ma et al., 2013). TNFSF9 is also able to induce cell signalling cascades on 
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binding to its cognate receptor TNFRSF9. The protein is able to induce the PI3K and Src cell 
signalling pathways to enhance macrophage activation and proliferation. 
 
6.5 – Methodology 
The use of primary human cells in this study makes the observations I have made more relevant 
to assessing the interaction of these signalling pathways in diseased systems. By characterising 
the patterns of gene expression and the mechanisms responsible in healthy cells, aberrant gene 
expression in diseased systems can be more easily identified and potential mechanisms for 
therapeutic intervention can be highlighted.  
Primary cells however are not without drawbacks. For example, primary macrophages are 
notoriously difficult to efficiently transfect without viral vectors. Due to the time constraints of 
engineering an adenoviral construct of the TNFSF9-ECR reporter plasmid, I opted to utilise a 
macrophage like cell line (RAW 267.4), for which a transfection protocol was already optimised. 
This cell line has previously been used to demonstrate similar enhancer effects (Qiao et al., 2013), 
the level of luciferase induction was quite low (similar to the native gene induction), which may 
make further investigation of the mechanism with cell signalling inhibitors or plasmid mutations 
difficult. 
It is clear that the effects of signalling on gene expression at later time points are obscured by the 
autocrine feedback of cytokines such as IL-10. Many of the one hour LPS-induced, IL-10 inhibited 
genes were no longer significantly induced by LPS at four hours or else equal in levels of 
expression to those co-stimulated with LPS and IL-10, potentially hinting that IL-10 autocrine 
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signalling was occurring at this timepoint. Therefore, I focused the bulk of this thesis to the 
dissection of the early induced LPS response. However, there is no guarantee other cytokines or 
chemokines are not also feeding back on the macrophages at this early stage. For instance, I was 
able to detect low levels of STAT3 phosphorylation at 60 minutes post LPS stimulation and this 
was dependent on de novo protein synthesis. To counteract IL-10 autocrine feedback, antibodies 
targeting IL-10 or its receptor complex can be used, but to prevent wider secretion of proteins, 
Brefeldin A or other Golgi transport inhibitors, would have to be used (however this would not 
prevent the shedding of proteins on the cell surface). 
 
The investigation of cooperation between transcription factors is a topic that has garnered much 
interest in recent years. Many of these investigations utilise next-generation sequencing (NGS) to 
investigate the genome wide binding of transcription factors to demonstrate close proximal 
binding of the transcription factors. In future work to assess whether NF-κB cooperate STAT3,   
NF-κB and, the histone modification H3K27ac should be immunoprecipiated and sequenced to 
assess whether cooperative regulation between these two transcription factors occurs generally 
or at specific loci. 
 
The comparison between the two microarray platforms in assessing macrophage gene expression 
is one of the shortcomings of this study. Due to differences in microarray probe structure, as well 
as the variation in the hybridisation procedures carried out by the different companies, made a 
direct integration of the two datasets problematic. A number of the transcripts that contribute to 
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the separation of the two datasets by PCA, are in fact detected by multiple probes. These probes 
also display differential sensitivity to the transcripts and finding a probe specific for a transcript 
that displays similar sensitivity is computationally difficult and intensive. Data integration 
between microarray platforms is a well-known problem in the literature. The decision to use 
Agilent rather than Affymetrix was made for financial and operational reasons, and the difficulties 
of data integration were not fully appreciated at the time. 
More recent studies have overcome these problems of data integration by utilising NGS of RNA 
(RNA-seq). This allows the quantification of RNA transcripts, through assessing the number of 
sequencing reads that map to a sequence. However, at the start of this project the cost of RNA-
seq was prohibitive to the initial experiment (4 donors x 11 conditions) and subsequently 
microarrays were selected to assess the gene expression of these cells.  
 
6.6-Future work 
Much of the work on IL-10’s ability to modulate macrophage responses has been restricted by 
focusing on potent NF-κB activators, such as LPS, IL-1α/β and TNF. In the context of host-
pathogen/ tissue damage response, many more signalling pathways are activated to induce gene 
expression and few studies have examined the effect of IL-10 on other PRR or cytokine induced 
gene expression pathways. Since IL-10 is able to cooperate with LPS to induce the CD8+ T cell co-
stimulatory molecule TNFSF9, there may be other molecules derived from virus (such as dsRNA) 
that may more potently induce or sustain the expression of immunostimulatory molecules. 
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Work on TNFSF9 has highlighted some potential inflammatory mediators being co-operatively 
regulated by LPS and IL-10 which are later down regulated (such as CXCL10 and CCL8). It would 
be interesting to investigate if IL-6 signalling leads to a sustained cooperative regulation of these 
genes. 
Assessing the promoters of the different groups of gene expression did not show a predominant 
occurrence of any single motif, very little of the upstream regions of the genes were used in this 
analysis, (2000 bp from the TSS). These analyses also work on the assumption that these upstream 
regions are permissible to TF binding. In order to ascertain which local regions of DNA to genes 
are available for transcription factor binding, I would employ DNase-seq or ATAC-seq. These 
techniques also allow for the interrogation of which TF’s are binding chromatin and show as a 
unique “footprint” of variably accessible chromatin, in the centre of a nucleosome free region. 
This technique could also be paired with RNA-seq and ChIP-seq (especially for: p65, STAT3 and 
Brd4) to further gain more specific insight into how the macrophage transcriptome is controlled. 
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8.1 – GO analysis 
Gene Ontology term 
Benjimani 
adjusted p-
value 
Epithelial cell signalling in Helicobacter pylori infection 5.16E-03 
Transcriptional misregulation in cancer 1.34E-02 
Neurotrophin signalling pathway 2.41E-02 
Renin secretion 4.35E-02 
Shigellosis 4.35E-02 
Renal cell carcinoma 4.60E-02 
Table 8.1 – 1 hour IL-10 inhibited cluster enriched GO terms 
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Gene Ontology term 
Benjimani 
adjusted 
p-value 
Leishmaniasis 1.10E-06 
Malaria 3.50E-06 
African trypanosomiasis 2.00E-05 
Osteoclast differentiation 3.60E-05 
HTLV-I infection 2.10E-04 
Toxoplasmosis 2.50E-04 
Asthma 4.00E-04 
Allograft rejection 7.60E-04 
T cell receptor signalling pathway 1.60E-03 
Epstein-Barr virus infection 2.70E-03 
Viral myocarditis 2.80E-03 
FoxO signalling pathway 4.00E-03 
Apoptosis 8.20E-03 
Haematopoietic cell lineage 8.70E-03 
Prion diseases 1.30E-02 
Primary immunodeficiency 1.30E-02 
MicroRNAs in cancer 1.40E-02 
Graft-versus-host disease 1.70E-02 
Type I diabetes mellitus 1.90E-02 
Intestinal immune network for IgA production 2.20E-02 
Type II diabetes mellitus 2.30E-02 
Autoimmune thyroid disease 2.70E-02 
Measles 2.80E-02 
Systemic lupus erythaematosus 2.80E-02 
Staphylococcus aureus infection 3.00E-02 
Cell adhesion molecules (CAMs) 3.20E-02 
Adipocytokine signalling pathway 4.60E-02 
B cell receptor signalling pathway 4.90E-02 
Table 8.2 – 1 hour IL-10 insensitive cluster enriched GO terms 
 
 
 
 
 
285 
 
Gene Ontology term 
Benjimani 
adjusted 
p-value 
Hepatitis C 3.28E-02 
Primary bile acid biosynthesis 3.63E-02 
Table 8.3 – 1 hour IL-10 cooperative cluster enriched GO terms
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Gene Ontology term 
Shared terms between IL-10-inhibited and IL-10-insensitive cluster 
MAPK signalling pathway 
NF-kappa B signalling pathway 
NOD-like receptor signalling pathway 
RIG-I-like receptor signalling pathway 
Cytosolic DNA-sensing pathway 
Salmonella infection 
Pertussis 
Legionellosis 
Chagas disease (American trypanosomiasis) 
Amoebiasis 
Tuberculosis 
Hepatitis B 
Influenza A 
Herpes simplex infection 
Inflammatory bowel disease (IBD) 
Rheumatoid arthritis 
 
Shared terms between IL-10-inhibited and LPS/IL-10 cooperative 
cluster 
Chemokine signalling pathway 
 
 
Shared terms between IL-10-insensitive and LPS/IL-10 cooperative 
cluster 
Prolactin signalling pathway  
 
Shared terms between IL-10-inhibited , IL-10-insensitive and, 
LPS/IL-10 cooperative cluster  
Cytokine-cytokine receptor interaction 
TNF signalling pathway 
TNF signalling pathway 
Toll-like receptor signalling pathway 
Toll-like receptor signalling pathway 
Jak-STAT signalling pathway 
Table 8.4 – Shared GO terms between the 1 hour cluster data 
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Gene Ontology term 
Benjimani 
adjusted p-
value 
Notch signalling pathway 6.09E-03 
Adherens junction 1.91E-02 
Salmonella infection 2.84E-02 
Table 8.5 – GO terms enriched in 4 hour IL-10 inhibited cluster 
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Gene Ontology term 
Benjimani 
adjusted p-
value 
Influenza A 2.83E-13 
Measles 1.97E-10 
NF-kappa B signalling pathway 1.19E-09 
Apoptosis 3.25E-08 
Herpes simplex infection 2.71E-07 
Allograft rejection 3.15E-07 
Chagas disease (American trypanosomiasis) 4.41E-07 
Hepatitis B 1.13E-06 
African trypanosomiasis 1.93E-06 
Leishmaniasis 2.22E-06 
Inflammatory bowel disease (IBD) 6.11E-06 
Graft-versus-host disease 8.68E-06 
Toxoplasmosis 1.12E-05 
Prolactin signalling pathway 1.56E-05 
Pertussis 2.25E-05 
Cytosolic DNA-sensing pathway 3.33E-05 
Osteoclast differentiation 3.48E-05 
Hepatitis C 4.09E-05 
Natural killer cell mediated cytotoxicity 4.43E-05 
Tuberculosis 5.63E-05 
RIG-I-like receptor signalling pathway 7.83E-05 
Legionellosis 8.08E-05 
Rheumatoid arthritis 1.01E-04 
MAPK signalling pathway 3.49E-04 
Autoimmune thyroid disease 3.73E-04 
Epstein-Barr virus infection 6.91E-04 
T cell receptor signalling pathway 1.54E-03 
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Malaria 1.63E-03 
HTLV-I infection 3.05E-03 
Acute myeloid leukemia 3.57E-03 
Intestinal immune network for IgA production 7.35E-03 
Pathways in cancer 7.69E-03 
Adipocytokine signalling pathway 9.75E-03 
Prion diseases 1.27E-02 
Non-alcoholic fatty liver disease (NAFLD) 1.48E-02 
RNA degradation 1.52E-02 
Viral myocarditis 1.75E-02 
HIF-1 signalling pathway 1.81E-02 
ErbB signalling pathway 2.61E-02 
Signalling pathways regulating pluripotency of stem cells 3.26E-02 
Type II diabetes mellitus 3.63E-02 
B cell receptor signalling pathway 3.99E-02 
Proteoglycans in cancer 4.02E-02 
Chronic myeloid leukemia 4.19E-02 
Asthma 4.28E-02 
Table 8.6 – GO terms enriched in 4 hour IL-10 insensitive cluster 
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Gene Ontology term 
Benjimani 
adjusted p-
value 
PPAR signalling pathway 1.66E-03 
PI3K-Akt signalling pathway 2.97E-02 
Fatty acid biosynthesis 4.43E-02 
Table 8.7 – GO terms enriched in 4 hour LPS/IL-10 cooperative cluster 
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Gene Ontology term 
Shared terms between IL-10-inhibited and IL-10-insensitive cluster 
Toll-like receptor signalling pathway 
Jak-STAT signalling pathway 
TNF signalling pathway 
Type I diabetes mellitus 
Epithelial cell signalling in Helicobacter pylori infection 
Amoebiasis 
Transcriptional misregulation in cancer 
 
Shared terms between IL-10-insensitive and LPS/IL-10 cooperative 
cluster 
Chemokine signalling pathway 
NOD-like receptor signalling pathway 
Shared terms between IL-10-inhibited , IL-10-insensitive and, 
LPS/IL-10 cooperative cluster 
Cytokine-cytokine receptor interaction 
 
Table 8.8– Shared GO terms between the 4 hour cluster data 
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8.2 – CXCL10 and CCL8 expression in macrophages 
 
 
 
 
Figure 8.1 – Microarray expression profiles of CXCL10 and CCL8 
Expression of CXCL10 and CCL8 expression in macrophages stimulated with LPS (red), IL-10 (blue) 
or in combination (green) extracted from the microarray data. 
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8.3 – Flow cytometry 
 
Figure 8.2 – Representative LPS/IL-10 time course of TNFSF9 expression 
Macrophages stimulated with LPS, IL-10 or in combination for 60, 120, 240 or 480 minutes were 
assessed for surface expression of TNFSF9 expression by flow cytometry. Histograms of the 
surface expression show a representative experiment. 
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Figure 8.3 – Representative LPS/IL-10 time course of CD274 expression 
Macrophages stimulated with LPS, IL-10 or in combination for 60, 120, 240 or 480 minutes were 
assessed for surface expression of CD274 expression by flow cytometry. Histograms of the surface 
expression show a representative experiment. 
